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ABSTRACT 
 
Non-alcoholic fatty liver disease (NAFLD) has been recognised as a growing public 
health problem worldwide. NAFLD is a spectrum ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH) and cirrhosis. Simple steatosis is generally benign 
condition whereas NASH can potentially progress to serious liver complications, 
including liver cancer. Genetic factors have been shown to play a significant role in the 
pathogenesis of NAFLD and may be responsible for the different phenotypes among 
individuals, including predisposition to severe liver disease. Genomic variability may 
present in various forms such as single nucleotide polymorphisms (SNPs), structural 
alterations (deletion, duplication and inversion), variable number of tandem repeats 
(VNTRs) and presence or absence of transportable element. Of all these variations, the 
commonest is the SNP. Copy number variation (CNV) is another type of mutation that 
could serve as a genetic marker for the NAFLD spectrum, and to date, there is no 
published report on CNV in NAFLD. This study aimed to investigate the association 
between SNPs of candidate genes with susceptibilty to NAFLD and the severity of the 
underlying liver disease. This study further identified genomic amplifications and 
deletions (CNVs) in the spectrum of NAFLD. A total of 144 biopsy-proven NAFLD 
patients and 198 controls without NAFLD were genotyped for polymorphisms of 
various candidate genes. Whole-genome array comparative genomic hybridization 
(aCGH) method was used to detect CNVs in a total of 40 patients with NASH and 40 
age, gender, and ethnicity-matched controls. The polymorphisms of PNPLA3, LEPR¸ 
and GCKR render susceptibility to NAFLD (OR 2.23, 95% CI  1.60-3.11, P < 0.0001; 
OR 1.64, 95% CI  1.18-2.28, P = 0.003; and OR 1.49, 95% CI  1.09-2.05, P = 0.012, 
respectively) while SNPs of AGTR1 render protection against the condition (OR 0.40, 
95% CI  0.20-0.81, P = 0.01). The G allele of both the PNPLA3 rs738409 and the 
AGTR1 rs3772622 were associated with increased fibrosis score (P < 0.05). For LEPR 
v 
rs1137100, the G allele was associated with lower fibrosis score (P < 0.05). Analysis of 
gene-gene interaction revealed a strong interaction between the AGTR1, LEPR and 
GCKR genes with the PNPLA3 gene (empirical P = 0.007, empirical P = 0.001 and 
empirical P = 0.003, respectively). Genome wide profiling identified five most 
frequently amplified CNVs located on the chromosome 14q11.2 (62.5%), 12p13.31 
(50.0%), 11p15.4 (45.0%), 5p15.33 (42.5%), and 12p13.2 (40.0%). The most frequently 
deleted CNVs were located on chromosome 11q11 (35.0%), 12p13.2 (32.5%), 16q12.2 
(32.5%), 4q13.2 (32.5%), 1q21.3 (32.5%), and 14q24.3 (32.5%). It can be hypothesised 
that these CNVs may be implicated in mechanisms that lead to progression to NASH. 
Of particular note was a 0.02 Mb deletion on chromosome 16q12.2. This region is rich 
in carboxylesterase 1 gene (CES1) that is important in cholesterol transportation leading 
to fatty liver. Downstream studies to validate findings are being pursued. Overall, this 
study showed the complex nature of NAFLD involving multiple gene interactions. The 
copy number findings are novel and could serve as potential genetic marker for the 
identification of the potentially progressive form of NAFLD. 
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ABSTRAK 
 
Penyakit hati berlemak tanpa kehadiran alkohol (NAFLD) telah diiktiraf sebagai satu 
masalah kesihatan yang semakin meningkat di seluruh dunia. NAFLD merupakan satu 
spektrum yang bermula daripada steatosis biasa kepada steatohepatitis tanpa kehadiran 
alkohol (NASH) dan sirosis. Steatosis biasa, umumnya adalah keadaan benigna 
manakala NASH berpotensi berkembang menjadi komplikasi hati yang serius, termasuk 
kanser hati. Faktor genetik telah didapati memainkan peranan penting dalam 
patogenesis NAFLD dan mungkin bertanggungjawab terhadap perbezaan fenotaip-
fenotaip di kalangan individu, termasuk kecenderungan terhadap penyakit hati yang 
lebih serius. Kebolehubahan genom boleh hadir dalam pelbagai bentuk seperti 
polimorfisme-polimorfisme nukleotid tunggal (SNPs), pengubahan struktur 
(penghapusan, salinan dan penyongsangan), pelbagai nombor pengulangan seiring 
(VNTRs) dan kehadiran atau ketiadaan elemen boleh angkut. Daripada semua variasi 
ini, yang paling lazim adalah SNP. Salinan variasi nombor (CNV) adalah satu lagi jenis 
mutasi yang boleh berperanan sebagai penanda genetik untuk spektrum NAFLD, dan 
sehingga kini, masih lagi tiada laporan penerbitan CNV untuk NAFLD. Tujuan kajian 
ini adalah untuk menyiasat perkaitan antara SNP calon gen-gen dengan kecenderungan 
terhadap NAFLD dan juga terhadap keterukan penyakit hati. Kajian ini seterusnya 
mengenalpasti amplifikasi dan penghapusan genom di dalam spektrum NAFLD. 
Sejumlah 144 pesakit NAFLD yang disahkan melalui biopsi dan 198 subjek kawalan 
tanpa NAFLD digenotaip untuk polimorfisme-polimorfisme pelbagai calon gen. Kaedah 
seluruh genom susunan perbandingan genomik penghibridan (aCGH) digunakan untuk 
mengesan CNV pada 40 pesakit NASH dan 40 subjek kawalan yang dipadankan dari 
segi umur, jantina dan bangsa. Polimorfisme-polimorfisme PNPLA3, LEPR dan GCKR 
menyebabkan kecenderungan terhadap NAFLD (OR 2.23, 95% CI  1.60-3.11, P < 
0.0001; OR 1.64, 95% CI  1.18-2.28, P = 0.003; and OR 1.49, 95% CI  1.09-2.05, P = 
vii 
0.012, masing-masing) manakala SNPs bagi AGTR1 menyebabkan perlindungan 
daripada keadaan ini (OR 0.40, 95% CI  0.20-0.81, P = 0.01). Alel G untuk kedua-dua 
PNPLA3 rs738409 dan AGTR1 rs3772622 dikaitkan dengan kenaikan skor fibrosis (P < 
0.05). Bagi LEPR rs1137100, alel G dikaitkan dengan penurunan skor fibrosis (P < 
0.05). Analisis interaksi gen-gen mendedahkan perkaitan kuat antara gen-gen AGTR1, 
LEPR dan GCKR dengan gen PNPLA3 (empirik P = 0.007, empirik P = 0.001 and 
empirik P = 0.003, masing-masing). Pemprofilan genom luas telah mengenalpasti lima 
CNV yang sering digandakan terletak di kromosom 14q11.2 (62.5%), 12p13.31 
(50.0%), 11p15.4 (45.0%), 5p15.33 (42.5%), dan 12p13.2 (40.0%). CNVs yang sering 
dipadamkan terletak di kromosom 11q11 (35.0%), 12p13.2 (32.5%), 16q12.2 (32.5%), 
4q13.2 (32.5%), 1q21.3 (32.5%), and 14q24.3 (32.5%). Boleh dihipotesiskan bahawa 
CNV ini mungkin diimplikasikan di dalam mekanisma yang menjurus kepada 
perkembangan NASH. Turut diberi perhatian adalah penghapusan 0.02 Mb pada 
kromosom 16q12.2. Kawasan ini kaya dengan gen carboxylesterase 1 (CES1) yang 
penting dalam pengangkutan kolesterol yang membawa kepada hati berlemak. Kajian 
berterusan untuk mengesahkan penemuan ini akan dilaksanakan. Pada keseluruhannya, 
kajian ini menunjukkan sifat kompleks NAFLD yang melibatkan interaksi gen 
berganda. Penemuan dari segi bilangan salinan merupakan penemuan baru dan 
berpotensi menjadi penanda genetik untuk mengenalpasti jenis NAFLD yang berpotensi 
untuk menjadi bertambah teruk. 
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CHAPTER ONE 
INTRODUCTION 
 
Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of 
chronic liver disease and has emerged as an important global health problem (L. Adams, 
Angulo, & Lindor, 2005; Angulo, 2002). The reported prevalence of NAFLD in the 
general population is as high as 35% (Cheung & Sanyal, 2010). NAFLD comprises a 
spectrum of diseases ranging from simple steatosis, which is benign fatty infiltration of 
the liver to its inflammatory counterpart non-alcoholic steatohepatitis (NASH−with or 
without fibrosis), cirrhosis (scarring and hardening of the liver), and hepatocellular 
carcinoma (Charlton, 2004; Malaguarnera, Di Rosa, Nicoletti, & Malaguarnera, 2009). 
Unlike simple steatosis which is usually benign, NASH can potentially progress, 
leading to liver-related mortality. 
NAFLD represents the hepatic component of the metabolic syndrome and is 
strongly associated with obesity and insulin resistance (L. A. Adams, Waters, Knuiman, 
Elliott, & Olynyk, 2009; Bertrand, Lefevre, Prevot, & Perlemuter, 2011; Fatani, Itua, 
Clark, Wong, & Naderali, 2011; Vanni et al., 2010). The interplay between 
environmental and genetic factors promotes the development and progression of 
NAFLD. Life style modification has been shown to improve liver histology in NAFLD 
patients (Bhat, Baba, Pandey, Kumari, & Choudhuri, 2012; Suzuki et al., 2005). A 
familial aggregation study comparing overweight children with NAFLD, and 
overweight children without NAFLD reported that fatty liver was more significant in 
siblings of children with NAFLD (Schwimmer et al., 2009). 
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Figure 1.1   Spectrum of NAFLD  
Adapted and modified from Trauner, Arrese, and Wagner (2010) 
 
Genetic variations are responsible for different phenotype among individuals. 
This genetic makeup also determines the tendency of certain individuals to develop a 
disease. Genomic variability may present in various forms such as single nucleotide 
polymorphisms (SNPs), structural alterations (deletion, duplication and inversion), 
variable number of tandem repeats (VNTRs) and presence or absence of transportable 
element (Freeman et al., 2006). Of all these variations, SNPs are the commonest and 
preferred over others due to their high abundance along the human genome (SNPs with 
minor allele frequency > 0.1 occur once every ~600 kb), low mutation rate and the high 
accessibility of high-throughput genotyping (D. G. Wang et al., 1998). SNPs have been 
associated with many diseases including NAFLD.  
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Other than the more commonly studied SNPs, copy number variation (CNV) is 
another type of mutation that gives more insight into the human genome and may 
explain the missing heritability. To date there is no published report on CNV of NAFLD 
due to the nature of the study which is expensive and the characteristics of CNV with 
the likes of total number, genomic positions, gene content, frequency spectrum and 
patterns of linkage disequilibrium (LD) with one another remain unknown, which make 
the study capacity limited (K. K. Wong et al., 2007). 
Linkage disequilibrium (LD) occurs when alleles at a given locus are not 
independent of alleles at a second locus. The alleles that pass from one generation to 
another are therefore as a result of non-random sampling. LD decays at each generation 
at a rate determined by the degree of recombination. There are five factors that 
contribute to linkage disequilibrium which are mutation, random drift, natural selection, 
inbreeding, and gene flow. Mutation leads to non-random associations between alleles 
at different loci, thus contributing to LD. However the effect of mutation is rather weak 
due to its weak effect on allele frequency change. Furthermore, the rate of 
recombination is typically higher than mutation and it will overtake the non-random 
associations. Random genetic drift from a gene pool of one generation to another affects  
the allele frequency change by random sampling variation. Thus, the smaller the 
population, the larger the effect of genetic drift. The expected value of disequilibrium 
among replicate populations is zero. Natural selection promotes LD by favoring a 
specific combination of alleles at different loci. This combination may function better as 
a group. Natural selection may lead to the evolution of supergenes. The recombination 
between individual genes in the supergene is reduced to maintain this strong linkage. 
Inbreeding affects the LD by reducing the rate of decay of LD through the reduction of 
the proportion of double heterozygotes formed by recombination. Gene flow or gene 
migration which is the transfer of alleles or genes from one population to another  
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affects the allele frequency change and therefore affects the LD. The rate of decay is 
determined by recombination when the gene flow is extensive. On the other hand, when 
the gene flow is small, the rate of decay is determined by the proportion of migrants.  
It is increasingly important to learn that our biological process including 
susceptibility to disease and  response to drugs depend not just on the genotypes, but 
also on the specific haplotypes. Haplotype is a combination of markers (alleles) at 
multiple locations on a single chromosome. Haplotyping is much more powerful than 
allele-by-allele analysis due to the application of multi markers rather than single 
marker only. Human genome can be divided into haplotypes block . A small fraction of 
SNPs in the block, referred as “tagSNP” is used to capture most haplotypes. However, 
different frequency of SNPs and haplotypes across populations generate different 
haplotype block structure and tagSNP. Different population therefore may have 
different haplotype block structure and tagSNP (Zhang, Calabrese, Nordborg, & Sun, 
2002).   
The main outcomes of the study were to assess, in the same set of study 
population, whether the genetic polymorphisms and copy numbers are associated with 
severity of NAFLD, and to evaluate the effects of these genetic variations on 
histological features of NAFLD. The Malaysian population comprises of three major 
ethnic subgroups, namely the Malays, Chinese and Indians, each of which are 
presumably of different genetic pool, hence presenting a good opportunity to study the 
ethnic difference of NAFLD susceptibility with regard to genetic polymorphisms. 
Meanwhile, the copy number study is novel and the new finding should serve as a 
potential new genetic marker for the progressive form of NAFLD. 
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1.1 Objectives 
 
The aims of this study are: 
1. To investigate the association between single nucleotide polymorphisms with 
NAFLD and with severity of NAFLD in the three major ethnic groups of 
Malaysian patients.  
2. To study the association between candidate SNPs with parameters and 
histological features of NAFLD, namely steatosis, lobular inflammation, 
hepatocellular ballooning and fibrosis.  
3. To evaluate the gene-gene interaction between the SNPs of interest. 
4. To determine the profile of copy number variations in the spectrum of NAFLD. 
 
1.2 Justification of study 
 
The study of non-alcoholic fatty liver disease is relatively new. Eventhough the 
condition was first introduced in the 1930s, named in the 1960s and characterised 
histologically in 1980, the major breakthrough on the genetic association studies of 
NAFLD only started in 2000s. In 2008, a single variant of the PNPLA3 gene rs738409 
was found to be associated with hepatic fat content in a genome-wide association of the 
Dallas Heart Study. It then served as the starting point for more genetic association 
studies of NAFLD in various populations. Intriguingly, all yielded a postive association 
finding. Although most of the case-control association studies of PNPLA3 rs738409 and 
its susceptibility to NAFLD have been reported in various populations, only few have 
reported on NAFLD disease severity and no data is available on its association with 
severity of non-alcoholic steatohepatitis (NASH). Published genetic reports were 
centered on the most common pathway of NAFLD; lipid metabolism and insulin 
resistance. Keeping in mind that NAFLD is a hepatic manifestation of metabolic 
syndrome that includes obesity and type 2 diabetes, investigation was also focused on 
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the association of SNPs that were previously reported in obesity and type 2 diabetes. 
This study reports the finding in a Malaysian population which comprises of three major 
ethnic groups, namely the Malays, Chinese and Indians. Each of the ethnic subgroups 
are presumably of different genetic pool, thus providing a good setting to study ethnic 
differences in their susceptibility to NAFLD. Interaction of genes that share the same 
pathway or function is another important aspect to study in order to understand the 
underlying pathway of NAFLD disease progression. This study is also the first attempt 
to identify CNVs associated with NAFLD. The identification of novel CNV markers 
especially in the NAFLD spectrum may provide hints towards NAFLD progression. 
Genetic tests may provide early insights into an individual’s susceptibility to this 
disease despite life style modification. These NAFLD genetic studies may aid 
researchers or even clinicians to better understand the nature of the disease. 
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1.3 Research hypothesis 
 
Hypothesis for this study is: 
 
The null hypotheses (Ho): 
1. There is no association between investigated SNPs with NAFLD and with 
severity of NAFLD in the three major ethnic groups of the Malaysian patients. 
2. There is no association between investigated SNPs with parameters and 
histological features of NAFLD. 
3. There is no gene-gene interaction between the investigared SNPs. 
4. There is no difference between copy number variations at the different NAFLD 
spectrum. 
 
The research hypotheses (H1): 
1. There is an association between investigated SNPs with NAFLD and with 
severity of NAFLD in the three major ethnic groups of the Malaysian patients. 
2. There is an association between investigated SNPs with parameters and 
histological features of NAFLD. 
3. There is a gene-gene interaction between investigated SNPs. 
4. There is a difference between copy number variations at the different NAFLD 
spectrum 
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CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 Background of NAFLD 
 
Non-alcoholic fatty liver disease (NAFLD) took its name only in 1960s although it has 
been recognised as early as 1930s. However, research on NAFLD comes to peak after it 
was histopathologically charaterised in 1980. NAFLD has now becoming a growing 
global disease and a major concern on individuals health (Godlee, 2011). NAFLD 
cannot be explained by a single gene inheritance, such that occurs in Mendelian 
inheritance. It is rather a complex disease that involves multiple genes and their 
interactions with environmental factors (Hernaez, 2012). 
The prevalence of NAFLD varies accross populations. Majority of patients with 
NAFLD possess metabolic disturbances such as obesity, diabetes mellitus and 
dyslipidemia (Chalasani et al., 2012). The prevalence of NAFLD therefore is not 
assessed in patients with NAFLD per se, but rather morbid obese patients undergoing 
bariatic surgery, patients with diabetes and patients with dyslipidemia. It was reported 
that the prevalence of NAFLD can reach up to 90% in morbidly obese patients 
undergoing bariatric surgery, of which 5% were at risk of developing cirrhosis (Boza et 
al., 2005; Haentjens et al., 2009; Machado, Marques-Vidal, & Cortez-Pinto, 2006). 
More than half of the diabetic patients showed faty infiltration on ultrasound, and from 
those who consented for liver biopsy, 87% confirmed NAFLD (Prashanth et al., 2009). 
Prevalence of NAFLD was reported to be 50% in individuals with dyslipidemia (Assy 
et al., 2000). NAFLD does not only affect adults but also children and adolescents. Data 
from a United States study documented that children and adolescents had 10% risk of 
NAFLD (Schwimmer et al., 2006). In the Asia-Pacific region, the prevalence is at least 
10% while in some regions, one out of every three individuals appear to be at risk 
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(Amarapurkar et al., 2007; Fan et al., 2007). Even after applying a strict body mass 
index (BMI) cut-off points for Asians, as high as 15-21% of NAFLD subjects were 
revealed to be non-obese: normal body mass index (BMI 17.5-22.4 kg/m
2
) or 
overweight (BMI 22.5–24.9 kg/m2) (C. J. Liu, 2012). 
The pathogenesis of NAFLD is based on the “two hits hypothesis”. The “first 
hit” which is the development of steatosis, involves the accumulation of triglycerides in 
the liver due to insulin resistance. Insulin’s role in this insult is by (i) promoting the 
adipocytes to secrete potentially harmful adipocytokines (ii) altering the rates of 
synthesis and transport of hepatic triglycerides (iii) increasing lipolysis (Bugianesi, 
McCullough, & Marchesini, 2005). Lipid accummulation, particularly diacylglycerol, 
together with mitochondrial dysfunction, endoplasmic reticulum stress and 
inflammation, could contributes to insulin resistance (Gariani, Philippe, & Jornayvaz, 
2012). The triglycerides accummulation occurs when the rate of fatty acid uptake 
(hepatic fatty acid uptake and de novo synthesis) is greater than secretion (fatty acid 
oxidation and transport in the form of VLDL−very low density lipoprotein) (Fabbrini, 
Sullivan, & Klein, 2010).  
Insulin resistance prepares the hepatocytes for the second insult. In type 2 
diabetes mellitus-induced hyperglycemia patients with NAFLD, it was shown that 
parameters for oxidative stress such as hydrogen peroxide, malondialdehyde, 
interleukin-6  and tumor necrosis factor-alpha were found to be increased. Their levels 
were positively correlated with plasma glucose level (Shams, Al-Gayyar, & Barakat, 
2011). The “second hit” event is particularly due to adipocytokines and oxidative stress, 
that further damages the liver and promotes the progression to steatohepatitis and 
fibrosis. The degree of hepatic inflammation and fibrosis is associated with the presence 
of metabolic traits (Rector, Thyfault, Wei, & Ibdah, 2008).  Most of the NAFLD study 
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designs to date, including candidate gene studies, applied this hypothesis (Day, 2002; 
Day & James, 1998).  
 
 
 
 
Figure 2.1   Physiological interrelationships among fatty acid metabolism, insulin 
resistance, dyslipidemia and intra-hepatic triglycerides content in NAFLD  
 
Adapted from Fabrini et al. (2010) 
 
Patients with NASH have a greater tendency to develop advanced fibrosis than 
those with simple steatosis (Jiang & Torok, 2008; Z. Li et al., 2003). NASH will 
subsequently lead to complications such as cirrhosis, hepatocellular carcinoma and liver 
failure (Matteoni et al., 1999). Powel et al. (1990) was the first to highlight the 
relationship between NASH and cirrhosis, and to report the association between 
NAFLD-associated cirrhosis with hepatocellular carcinoma (HCC). Studies have also 
documented the association between NAFLD and HCC in the absence of cirrhosis 
(Baffy, Brunt, & Caldwell, 2012). Patients with NAFLD-associated HCC displayed 
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more metabolic features than those with non-complicated by HCC (Ertle et al., 2011). A 
retrospective study that investigated patients that had undergone transplant due to 
NASH-associated cirrhosis, found that 24 out of the 40 patients has died while those 
with metabolic syndrome had a 1-year mortality rate of 42% (Heuer et al., 2012). Liver 
transplantation cases due to NASH have been rapidly growing from 3% to 19% for over 
a 10-year period (Agopian et al., 2012). Another underlying disease associated with 
NAFLD that is of major concern is cardiovascular disease (CVD). CVD has emerged as 
a highly death-related disease due to NAFLD. The prevalence of CVD is higher in 
patients with NAFLD than those without, and this finding is independent of the 
metabolic components (Targher et al., 2007). Several studies have conlcuded that CVD 
is the most common causes of death in patients with NAFLD and the prevalence ranges 
from 12.7% to 38% (Dam-Larsen et al., 2009; Ekstedt et al., 2006; N. Rafiq et al., 2009; 
Soderberg et al., 2010).  
 
2.2 NAFLD and metabolic syndrome 
 
NAFLD is closely associated with metabolic syndrome. Liver fat content was found to 
be significantly greater in subjects with  metabolic syndrome than those without. Liver 
Hounsfield units (HU) which will decrease with every miligram of fat deposited in the 
liver, were negatively correlated with BMI, waist circumference and percent body fat 
(Dick, Lesser, Leipsic, Mancini, & Lear, 2013). It was reported that almost 90% 
patients with NAFLD presented with more than one criteria of metabolic syndrome and 
33% with three or more criteria (Almeda-Valdes, Cuevas-Ramos, & Aguilar-Salinas, 
2009). In a study of 1365 subjects in which the World Health Organisation (WHO) 
criteria was applied, the prevalence of metabolic syndrome was 49.8% in the pre-
diabetic and 58.9% in the diabetic (Seo et al., 2012). In the adults study, NASH cases 
were reported to be from 40% to 100% in obese patients (Tarantino, Saldalamacchia, 
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Conca, & Arena, 2007). While in the children, it is about 15% to 25% (Povel, Boer, 
Reiling, & Feskens, 2011).  
A Korean study revealed that BMI 28.9 kg/m
2
 was useful to distinguish NASH 
from simple steatosis (J. W. Park, Jeong, Kim, Kim, & Park, 2007). Newly diagnosed 
diabetes patients have a greater prevalence of NAFLD (62%) compared to those with 
impaired glucose tolerance (43%) (Jimba et al., 2005). It was reported that in a Korean 
study, the risk of abnormal glucose metabolism is greater in NAFLD than in control 
group, with those assessed by impaired fasting glucose at 2.13 times risk, HOMA-IR 
3.25 times risk, type 2 diabetes 7.63 times risk, BMI 3.35 times risk, triglyceride 3.05 
times risk and fasting blood glucose 2.18 times risk (Chon et al., 2012). In the same 
year a Korean study revealed that the degree of NAFLD significantly affects the 
incidence rate of type 2 diabetes, in which normal at 7.0%, mild 9.8%, moderate to 
severe 17.8% (S. K. Park, Seo, Shin, & Ryoo, 2012). A group of newly diagnosed type 
2 diabetes exhibited abnormal alanine aminotransferase (ALT) levels (Saligram, 
Williams, & Masding, 2012). Treatment with glucagon-like peptide receptor agonist in 
a well-defined obese, type 2 diabetes patients with fatty liver showed a reduction in 
hepatic fat content and this was correlated with HbA1c but not with the total body 
weight (Cuthbertson et al., 2012). About 20% to 80% of NAFLD cases were associated 
with dyslipidemia (Souza, Diniz Mde, Medeiros-Filho, & Araujo, 2012) which is 
characterized by increased triglyceride and low density lipoprotein (LDL) cholesterol 
levels, and decreased high density lipoprotein (HDL) cholesterol levels (Chatrath, 
Vuppalanchi, & Chalasani, 2012). Marchesini et al reported as high as 64% of patients 
with steatosis presented with hypertriglyceridemia (Marchesini et al., 2003). 
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Table 2.1   Criteria for clinical diagnosis of metabolic syndrome 
National Cholesterol 
Education Program’s Adult 
Treatment Panel III report 
(ATP III) 
World Health Organization 
(WHO) 
American Association of 
Clinical Endocrinologists 
(AACE) 
  Abdominal obesity, waist 
 circumference 
 Men > 102 cm (> 40 in) 
 Women > 88 cm (> 35in) 
  Triglycerides 
  ≥ 150mg/dL 
  HDL cholesterol 
 Men < 40 mg/dL 
 Women < 50 mg/dL 
  Blood pressure 
 ≥ 130/≥ 85 mmHg 
  Fasting glucose 
 ≥ 100 mg/dL 
Insulin resistance, 
identified by 1 of the 
following: 
 Type 2 diabetes 
 Impaired fasting glucose 
 Impaired glucose 
tolerance 
 Or for those with normal 
fasting glucose levels (< 
110 mg/dL), glucose 
uptake below the lowest 
quartile for background 
population under 
investigation under 
hyperinsulinemic, 
euglycemic conditions 
 
Plus any 2 of the following: 
 Antihypertensive 
medication and/or high 
blood pressure (≥ 140 
mmHg systolic or ≥ 90 
mmHg diastolic) 
 Plasma triglycerides ≥ 
150 mg/dL (≥ 1.7 
mmol/L) 
 HDL cholesterol < 35 
mg/dL (< 0.9 mmol/L) in 
men or < 39 mg/dL (1.0 
mmol/L) in women 
 BMI > 30 kg/m2 and/or 
waist:hip ratio > 0.9 in 
men, > 0.85 in women 
 Urinary albumin 
excretion rate ≥ 20 
µg/min or 
albumin:creatinine ratio 
≥ 30 mg/g 
  Overweight/obesity 
 BMI > 25 kg/m
2
 
  Elevated triglycerides 
 ≥ 150 mg/dL (1.69    
mmol/L) 
  Low HDL cholesterol 
 Men < 40 mg/dL (1.04      
mmol/L) 
 Women < 50 mg/dL 
(1.29 mmol/L) 
  Elevated blood pressure 
 ≥ 130/85 mmHg 
  2-Hour postglucose   
challenge >140 mg/dL 
  Fasting glucose between  
110 and 126 mg/dL 
  Other risk factors 
Family history of type 2 
diabetes, hypertension, or 
CVD 
Polycystic ovary 
syndrome 
Senderaty lifestyle 
Advancing age 
Ethnic groups having high 
risk for type 2 diabetes or 
CVD 
 
Adapted and modified from Grundy, Brewer, Cleeman, Smith, and Lenfant (2004)  
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2.3 Genetic background of NAFLD 
 
Although NAFLD is considered a hepatic manifestation of metabolic syndrome, and the 
majority of patients with NAFLD present with metabolic risk factors, family-based 
genetic studies have shown that the presence of NASH and/or cryptogenic cirrhosis was 
not constantly associated with metabolic risk factors (Struben, Hespenheide, & 
Caldwell, 2000; Willner et al., 2001). Ethnic studies provided evidence that Asian 
patients with NAFLD presented with significantly lower body mass index (BMI) than 
other ethnic groups (Farrell, 2003). This was further supported by a study that reported 
increased prevalence of fatty liver in Asian Indian men presented with normal BMI 
(Petersen et al., 2006). A strong evidence of a genetic component is also reflected by the 
differences in the prevalence of NAFLD across different populations. In addition, a 
familial aggregation study has shown high heritability of NAFLD, with estimates of 
59% in siblings and 78% in parents with NAFLD (Schwimmer et al., 2009). 
Intriguingly, well-defined genetic markers for obesity (FTO−fat mass and obesity-
associated protein) and diabetes (TCF7L2–transcription factor 7-like 2) were not 
associated with NAFLD, indicating that fatty liver disease has its own genetic 
underpinnings (Hernaez, 2012). Based on this hypothesis, genetic studies can therefore 
be simplified into studies of genes involved in hepatic lipid metabolism, insulin 
resistance and oxidative stress. 
The imbalance or alteration in the hepatic lipid pathway especially the hepatic 
triglycerides, will promote the development of hepatic steatosis (Hernaez, 2012). Some 
of the genes involved in hepatic lipid metabolism are phosphatidylethanolamine N-
methyl transferase (PEMT), circadian locomoter output cycles protein kaput (CLOCK), 
fatty acid binding protein 2 (FABP2) and microsomal triglyceride transfer protein 
(MTTP). Study on six tagSNPs on the CLOCK gene found rs11932595 and rs6843722 
to be associated with NAFLD (Sookoian, Castano, Gemma, Gianotti, & Pirola, 2007). 
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Significantly higher frequency of Met/Met at residue 175 (loss of function SNP) was 
observed in NAFLD subjects compared to controls (Song et al., 2005). Insulin 
resistance is important in the “first hit” mechanism. More importantly, it has a central 
role in metabolic syndrome. Key genes involved in insulin sensitivity are glucokinase 
regulatory (GCKR), peroxisome proliferator-activated receptor gamma (PPARG) and 
melanocortin-4 receptor (MC4R). A genome-wide association study (GWAS) 
consortium showed GCKR to be associated with glycemic traits such as fasting glucose 
and HOMA-IR (Speliotes et al., 2011). A recent study by Bhat et al. (2013) provided 
evidence that polymorphisms of Pro12Ala and C161T on PPARG gene increased risk of 
NAFLD in Asian Indians. Meanwhile, oxidative stress is an underlying cause of 
NAFLD progression to NASH and cirrhosis. Meta-analysis data on tumor necrosis 
factor alpha gene (TNF-α), which is known to be involved in oxidative stress concluded 
that promoter polymorphism at position -238 but not -308 contributes to risk of NAFLD 
(J. K. Wang, Feng, Li, Li, & Tao, 2012). 
 
2.4 Single nucleotide polymorphism 
 
Single nucleotide polymorphism or SNP (pronounced “snip”) is one the most common 
genetic variations that occur at high density in the human genome. The ubiquity and the 
ease with which genotyping can be carried out, has facilitated the mushrooming studies 
of SNPs. By definition, SNP is a variation of the DNA sequence in which a single 
nucleotide of the sequence has been altered. These highly abundant SNPs occur in every 
1000 bases in the human genome (Sachidanandam et al., 2001). These SNPs may result 
in phenotypic variation depending on the location in the human genome. SNPs that 
occur in the coding regions genes may alter the encoded protein products, thus changing 
the function of the proteins. These SNPs are important in the human pathophysiology 
and always been related to the dominant and recessive inherited monogenic disorders 
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and are generally analysed for diagnostic purposes. Alteration of the primary structure 
of a protein involved in drug metabolism, brings us to a new aspect of the study of 
pharmacogenomics and translational medicine. This type of SNP is frequently analysed 
to assess the risk of an individual for a particular disease and the choices of drugs 
administered. It is also likely that common diseases are influenced by SNPs in the 
regulatory regions of genes. However, most SNPs have no direct known impact on the 
phenotype of an individual. These SNPs are located in non-coding regions of the 
genome and are useful as markers in population genetics (Jorde et al., 2000).  
The introduction of whole-genome SNP genotyping that has the ability to 
genotype millions of SNPs that cover the whole genome has made the production of 
high throughput genotyping data faster with greater power. This wide application of 
genotyping technology detects genomic regions in which the allele frequencies differ 
between patients and controls. The data generated would be useful to detect and isolate 
the disease-predisposing genes, and proteins encoded by these genes would potentially 
be valuable targets for developing new therapeutic drugs. High throughput genotyping 
requires advance laboratories and facilities, in addition to its high cost to run the 
genome-wide SNP genotyping. With that, an alternative to this whole-genome SNP 
mapping has been applied, which is the use of candidate genes, tagSNPs and SNP 
markers. Genotyping technology can be improved by effectively handling the key 
determinants which are cost, high throughput, assay design and accuracy. The present 
approach of improving the throughput and accuracy of the genotyping is by the use of 
microarray and DNA sequencing (Syvanen, 2001). The effectiveness of genome wide 
association studies is achievable by the completion of the International HapMap Project 
Phase I, II and III ("A haplotype map of the human genome," 2005; The international 
hapmap project," 2003). This approach has greatly increased the throughput and 
accuracy in a cost-effective way.  
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Affymetrix and Illumina are among the earliest platform used to generate this 
high-throughput genome-wide genotyping and have now been accessible in some 
standard laboratories. These platforms have now been used as standard technique in 
molecular genetics and clinical diagnostic laboratories. Genome-wide SNP genotyping 
is widely used to identify common genetic variant that underlies disease (Farrall & 
Morris, 2005; W. Y. Wang, Barratt, Clayton, & Todd, 2005). Although genome-wide 
SNP genotyping promises a good genotyping data, the experiments are extremely 
sensitive to the quality of DNA. Prior measurements of DNA are necessary and when 
the concentrations fall below the quality standard, counter measurements need to be 
taken such as DNA precipitation (Gibbs & Singleton, 2006). In 2008, the application of 
genome-wide SNP genotyping has found a non-synonymous variant of PNPLA3 
rs738409 to be highly associated with fat content in the liver (Romeo et al., 2008). This 
is a major breakthrough to the further studies of PNPLA3 rs738409 both in molecular 
genetics and functional studies. 
 
2.5 Single nucleotide polymorphism of candidate genes in NAFLD 
 
Various genes and single nucleotide polymorphisms have been implicated in the 
development of NAFLD. Among these genes, genes that are involved in lipid 
metabolism, amino acid catabolism, inflammation, fatty acid transport and insulin 
pathway are strongly associated with NAFLD (Greco et al., 2008). The much studied 
gene in NAFLD, patatin-like phospholipase domain-containing protein 3 (PNPLA3) is 
not limited to molecular genetics in humans but is also functional in animals (Fuchs et 
al., 2012; Qiao et al., 2011). The role of obesity-related gene, leptin receptor (LEPR) has 
been well studied, particularly in obesity and metabolic syndrome (Stylianou et al., 
2007; C. W. Yang et al., 2013).  There is also evidence of influence of angiotensin II 
type 1 receptor (AGTR1) gene polymorphisms in Japanese patients with NAFLD 
18 
(Yoneda et al., 2009b). Study of  tagSNPs of signal transducer and activator of 
transcription 3 (STAT3) showed both single marker and multimarker of the gene is 
associated with susceptibility to NAFLD (Sookoian et al., 2008). A GWAS of the 
NAFLD Database Study identified a variant in the farnesyl-diphosphate 
farnesyltransferase 1 gene (FDFT1) as a risk for NAFLD. The same GWAS showed 
variant in the collagen type XIII alpha 1 gene (COL13A1) to be associated with lobular 
inflammation (Chalasani et al., 2010). Peroxisome proliferator-activated receptor 
gamma (PPARG), sterol regulatory element-binding transcription factor 1 (SREBF1), 
tumour necrosis factor alpha (TNF-α), and caspace 3 (CASP3) are related to the 
discovery of a gene network involved in NAFLD using genome wide transcriptional 
profiling (Hui et al., 2008; Kohjima et al., 2007). 
 
Table 2.2   Genome-wide association studies in NAFLD 
GWAS Gene SNP Steatosis Inflammation Fibrosis 
Romeo et al., 2008 & 
Speliotes et al., 2010 
PNPLA3 rs738409 ↑↑     
Romeo et al., 2008 PNPLA3 rs6006460 ↓     
Chalasani et al., 
2010 
  
  
   
FDFT1 rs2645424   ↑   
COL13A1 rs1227756     ↑ 
PDGFA rs343064     ↑ 
LTBP3 rs1227756   ↑   
EFCAB4B rs887304   ↑   
Speliotes et al., 2010 
  
  
  
NCAN rs2228603 ↑     
LYPLAL1 rs12137855 ↑     
GCKR rs780094 ↑     
PPP1R3B rs4240624 ↑     
↑: increase; ↓: decrease; GWAS genome-wide association study 
 
 
19 
A loss of functional mutation of the phosphatidylethanolamine N-methyl 
transferase (PEMT) gene confers susceptibility to NAFLD (Y. J. Zhou et al., 2010). 
Genetic polymorphism in the promoter region of the cyclooxygenase 2 (COX-2) confers 
susceptibility to NAFLD in the Chinese population (Cao, Yang, & Dong, 2010). In a 
Japanese population, inducible nitric oxide synthase (iNOS) polymorphisms were found 
to be associated with NAFLD. The rs1060822, which is in strong LD with rs2297510, 
rs2297511 and rs2797512 was associated with increased in fibrosis (Yoneda et al., 
2009a). A multimarker study of rs2461823 and rs7643645 of the pregnane X receptor 
(NR1I2) proposed a combined effect of both SNPs on NAFLD severity. The rs7643645 
is also associated with ALT level (Sookoian et al., 2010). A lower risk of NAFLD and 
steatosis grade were shown by polymorphisms in the tumor necrosis factor (TNF)-
related apoptosis inducing ligand (TRAIL) (Yan et al., 2009). Kruppel-like factor 6 
(KLF6) expression was proportionally increased with the severity of NAFLD. The 
functional KLF6-IVS1-27G>A polymorphism was shown to be a predictor of fibrotic 
NAFLD (Miele et al., 2008). Peroxisome proliferators-activated receptor gamma 
coactivator 1 alpha (PPARGC1A) polymorphism significantly affects severity of 
NAFLD (Yoneda et al., 2008). 
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Table 2.3   Genetic factors associated with NAFLD progression 
Author Gene SNP Steatosis Inflammation Fibrosis 
Insulin sensitivity           
Carulli et al., 2009 & 
Dongiovanni et al., 2010 
ENPP1 rs1044498 ӨӨ ӨӨ ↑ 
Dongiovanni et al., 2010 IRS1 rs1801278 Ө Ө Ө 
Tokushige et al., 2009; 
Wang et al., 2008; Musso 
et al., 2008 & Wong et 
al., 2008 
ADIPOQ rs2241766 ӨӨӨ↑↑ ↑ Ө 
Tokushige et al., 2009; 
Wang et al., 2008; Musso 
et al., 2008 & Wong et 
al., 2008 
  rs1501299 ↓ӨӨ↑ Ө↑Ө   
Kotronen et al., 2009 ADIPOR1 rs6666089 Ө     
Kotronen et al., 2009 ADIPOR2 rs767870 ↓     
Dongiovanni et al., 2010 
& Chen et al., 2008 
PPARA rs1800206 Ө↑ Ө Ө 
Zhou et al 2010 PPARG rs3856806 Ө     
Dongiovanni et al., 2010; 
Gupta et al., 2010 & Rey 
et al., 2010 
  rs1801282 ӨӨӨ ӨӨ ӨӨ 
Zhou et al., 2010 PPARGC1A rs8192687 Ө     
Musso et al., 2009 TCF7L2 rs7903146 ↑ ↑ ↑ 
Yang et al., 2011 GCKR rs780094 ↑     
Haupt et al., 2009 MC4R rs17782313 Ө     
Zhou et al., 2010 LEP rs7799039 Ө     
Zain et al., 2013 LEPR rs1137100 Ө Ө ↓ 
    rs1137101 Ө Ө Ө 
↑: increase; ↓: decrease; Ө no association 
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Table 2.3 (continued)  Genetic factors associated with NAFLD progression  
Author Gene SNP Steatosis Inflammation Fibrosis 
Reactive oxidant species, or cytokine 
Zhou et al., 2010; Wong 
et al., 2008; Aller et al., 
2010; Hu et al., 2009; 
Tokushige et al., 2007 & 
Valenti et al., 2002 
TNF-α rs180062 ӨӨӨ ↑ӨӨ ↑Ө 
Wong et al., 2008; 
Tokushige et al., 2007 & 
Valenti et al., 2002 
  rs361525 ↑↑↑Ө ӨӨ Ө 
Wong et al., 2008 & 
Tokushige et al., 2007  
  rs1800630 Ө ↑ Ө 
Tokushige et al., 2007    rs1799964 Ө ↑   
Tokushige et al., 2007    rs1799724 Ө Ө   
Tokushige et al., 2007  TNF-β  rs909253 Ө Ө   
Carulli et al., 2009 IL-6 rs1800795 ↑ ↑   
Brun et al., 2006 CD14 rs2569190 Ө ↑   
Hashemi et al., 2011 & 
Oliveira et al., 2010 
GCLC rs4140528 Ө ↑   
El-Koofy et al., 2011, 
Namikawa et al., 2004 & 
Al-Serri et al., 2011 
SOD2 rs4880 ↑ Ө↑↑ ↑ 
Hernaez et al., 2011 HFE rs1800562 Ө Ө   
    rs1799945       
Aller et al., 2010 & 
Labruna et al., 2009 
UCP rs1800849 ↑ ↑   
Cao et al., 2010 PTGS2 rs689466 ↑     
Iwata et al., 2011 ABCB11 rs2287622 Ө Ө Ө 
Akyildiz et al., 2010 MIF rs755622 Ө Ө Ө 
Piao et al., 2003 & Varela 
et al., 2008 
CYP2E1 rs2031920 Ө↓ Ө   
Valenti et al., 2006 SERPINA1 rs28929474 ↑ ↑   
Sazci et al., 2008 MTHFR rs1801131 ↑ ↑   
Nozaki et al., 2004 IL1B rs16944 ↑ ↑   
Sookoian et al., 2009 CFTR/MRP rs17222723 ↑ Ө   
Sookoian et al., 2008 STAT3 rs6503695 ↑ Ө   
Zain et al., 2013 & 
Yoneda et al., 2009  
AGTR1 rs3772622 Ө↑ Ө↑ ↑ 
Miele et al., 2008 KLF6 rs3750861 ↑   ↑ 
↑: increase; ↓: decrease; Ө no association                                                                         Adapted and modified from Hernaez (2012) 
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NASH patients with fibrosis showed an over-expression of fibrogenic genes, 
including the leptin receptor and NASH patients without fibrosis showed an over-
expression of proinflammatory and proapoptotic genes. The upregulated gene 
expression of prohibitin suggests mitochondrial dysfunction in NASH patients (Cayon, 
Crespo, Guerra, & Pons-Romero, 2008). Metabolic factors but not ALT are associated 
with histological severity in NAFLD patients (V. W. Wong et al., 2009). Visceral 
adipose tissue, HOMA-IR and serum uric acid levels are the main determinants of 
NAFLD in obese patients (Fenkci, Rota, Sabir, & Akdag, 2007). NAFLD is associated 
with carotid artery wall thickness (Intima media thickness by USG) in diet controlled 
type 2 diabetes (Targher et al., 2006). Variation in the promoter region of fatty acid 
transport protein 5 (FATP5) is associated with hepatic steatosis, higher ALT level, 
insulin resistance and dyslipidemia (Auinger et al., 2010). Apolipoprotein A-V gene 
(APOA5) is associated with lipid profile in a number of studies (Can Demirdogen et al., 
2012; Hishida et al., 2012; S. Rafiq et al., 2012). The -55CT polymorphism of the 
uncoupling protein 3 (UCP3) promotes increased in insulin resistance, moderate to 
severe steatosis, and inflammation (Aller et al., 2010). Insulin sensitivity was also 
affected by polymorphisms in the transferrin receptor gene (TFRC) (Fernandez-Real et 
al., 2010). 
Romeo et al. (2008) carried out genome-wide association association scan for 
hepatic content. One nonsynonymous variant stood out from the rest, rs738409, which 
is responsible for the substitution of an isoleucine to methionine at position 148 in 
PNPLA3. This variant showed evidence of association with NAFLD. PNPLA3 is 
expressed in adipose and liver and can both hydrolyze liver fat and transfer fatty acids 
between lipids. It encodes a transmembrane protein whose expression is upregulated 
during fat cell differentiation. The expression is also reported to be higher in adipose 
tissue in obese compared to lean individuals. However, the precise role of PNPLA3 in 
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liver fat metabolism remains to be determined. Romeo et al. (2008) also observed 
association between PNPLA3 rs738409 variant and liver enzymes in Hispanics. 
Individuals of Hispanic descent carry an increased risk of NAFLD (45%) compared to 
individuals of European American (33%) or African American (24%) descent. 
Hispanics are also closely related to high risk of steatohepatitis and cirrhosis. The study 
also found that the T allele that is associated with decreased risk of NAFLD, and is 
commonly found in the African-American group, a group with the lowest risk of 
developing NAFLD (Karlsen, 2009; Romeo et al., 2008). This finding was replicated by 
another study that found that the association of PNPLA3 and NAFLD remains strong 
even after the adjustment of body mass index (BMI), age and sex (Kotronen et al., 
2009). It is reported that the hepatic and adipose tissue insulin sensitivity decrease with 
increase of hepatic fat level independent of the PNPLA3 genotype. This therefore 
indicates that the GG PNPLA3 genotype has no influence on insulin sensitivity but 
increase hepatic fat content. The serum ALT level which is associated with NAFLD, is 
found to be higher in G allele carriers  (Kotronen, Westerbacka, Bergholm, Pietilainen, 
& Yki-Jarvinen, 2007). 
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Table 2.4   Association studies between PNPLA3 rs738409 and NAFLD 
First Author, 
Year 
Population Study Design & 
Sample size (n) 
Diagnosis 
method 
Age NAFLD NAFLD 
spectrum 
Romeo et al., 
2008 
Mixed: Hispanics, 
African-
Americans, 
Caucasian 
Population-
based, n = 3450 
H-MRS Adult Yes No 
Sookoian et 
al., 2009 
Caucasian Hospital-based, 
n =266 
US and LB Adult Yes SS, NASH 
Kotronen et 
al., 2009 
Finnish Hospital-based, 
n =291 
H-MRS Adult Yes No 
Valenti et al., 
2010 
Caucasian Hospital-based, 
n = 149 
LB Pediatric Yes SS, NASH 
Valenti et al., 
2010 
Caucasian Hospital-based, 
n = 753 
LB Adult Yes SS, NASH 
Romeo et al., 
2010 
Caucasian Hospital-based, 
n = 678 
Morbid 
obese 
Adult Yes No 
Romeo et al., 
2010 
Caucasian Hospital-based, 
n = 475 
US. Over-
weight/ 
Obese 
Pediatric Yes No 
Rotman et al., 
2010 
Caucasian Mixed: 
Population and 
hospital-based, 
n = 894 
LB Adult Yes SS, NASH 
Speliotes et 
al., 2010 
Caucasian Mixed: 
Population and 
hospital-based, 
n = 2128 
LB Adult Yes SS, NASH 
Goran et al., 
2010 
Hispanic Population-
based, n = 327 
MRI Pediatric Yes No 
Davis et al., 
2010 
Hispanic Population-
based, n = 153 
H-MRS Pediatric Yes No 
Petit et al., 
2010 
Caucasian Hospital-based, 
n = 218 
H-MRS/ 
T2D 
Adult Yes No 
Kantartzis et 
al., 2010 
Caucasian Hospital-based, 
n = 330 
H-MRS/ 
T2D 
Adult Yes No 
Lin et al., 
2010 
Asian Population-
based, n = 520 
US Pediatric Yes No 
Hotta et al., 
2010 
Asian Hospital-based, 
n = 831 
LB Adult Yes SS, NASH 
Wagenknecht 
et al., 2011 
Mixed: Hispanic 
American and 
African American 
Population-
based, n = 1214 
CT scan Adult Yes No 
Cox, 2011 African American Hospital-based, 
n = 442 
CT scan/ 
T2D 
Adult Yes No 
Zain, 2012 Asian mixed: 
Malay, Chinese, 
Indian 
Hospital-based, 
n = 342 
LB Adult Yes SS, NASH, 
NASH 
severity 
CT computed tomography, H-MRS hydrogen magnetic resonance spectroscopy, LB liver biopsy, MRI magnetic resonance imaging 
NASH non-alcoholic steatohepatitis, SS simple steatosis, T2D type 2 diabetes, US ultrasonography 
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2.6 Copy number variation 
 
There are usually thousands of papers published every year on SNPs studies while less 
so can be found for CNVs. CNV studies are expensive and the characteristics of CNV 
with the likes of total number, genomic positions, gene content, frequency spectrum and 
patterns of linkage disequilibrium (LD) with one another remain unknown, which make 
the study capacity limited (K. K. Wong et al., 2007). While the frequencies of most 
SNPs have been determined in various populations, the situation is different for copy 
number variants. Up until now, the frequencies are not well defined. Some may report 
CNV as copy number polymorphism (CNP), however the appropriate term should be 
variant as the term “polymorphism” is commonly used to refer to genetic variants that 
have minor allele frequency of at least 1% in a given population. CNV is defined as 
copy number change involving 1 kb or more of DNA fragments (Hegele, 2007). Large 
CNVs of more than 1 Mb have also been reported and they tend to be localized at 
regions such as centromeres, telomeres and heterochromatin (Giglio et al., 2001). Most 
of CNVs in humans are inherited variations, but some are formed de novo at a 
significant rate, both in the germ line and in somatic cells (Hastings, Lupski, Rosenberg, 
& Ira, 2009). 
CNVs have now become one of the important genetic variabilities studied after 
SNPs, as it was estimated that almost 68% of the CNV regions were found to overlap 
with almost 300 proven disease-causing genes (Sebat et al., 2004). These CNVs are also 
accounted for by variability in phenotype, metabolism and disease susceptibility. 
Interestingly, some of the regions were associated with human microRNAs, thus 
reflecting the importance of microRNAs in human diversity (K. K. Wong et al., 2007). 
Approximately 12% of the human genome, is accounted for copy number variation 
(Redon et al., 2006). Due to numbers of CNVs overlapped the genes, changes in copy 
number therefore affect the expression levels of the gene thereby causing phenotypic 
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variability among individuals. Redundancy which are caused by these additional copies 
of genes alter the gene functions while other copies maintain the original function 
(Hastings et al., 2009). Some CNVs are essential to provide phenotypic variations in 
individuals. Nevertheless, some are disadvantageous. Copy number changes have been 
reported in cancer progression (Volik et al., 2006) and contribute to cancer 
susceptibility (Frank et al., 2007). 
Copy number change happens when two separated DNA sequences are joined 
together thereby causing a change in chromosomal structure. A high number of 
structural changes show recurrent end-points where the break-points at a given locus are 
confined to a few genomic positions, while others show non-recurrent endpoints. The 
recurrent CNVs often coincide with segmental duplications unlike the non-recurrent 
CNVs. Despite that, non-recurrent events tend to occur in the vicinity of regions that are 
rich in segmental duplications (Lee et al., 2006; Stankiewicz et al., 2003). While the 
recurrent CNVs are likely to be formed by homologous recombination, the non-
recurrent CNVs are not, due to limited short homology of 2-15 bp. The chromosomal 
structural changes of non-recurrent events are far more complex, in which it can occur 
from insertion of short sequences from elsewhere or include a mixture of duplications, 
triplications, inversions and deletions (J. M. Chen, Chuzhanova, Stenson, Ferec, & 
Cooper, 2005; Gajecka et al., 2008).  
New duplicates that are formed will increase the mutation rate as they served as 
a substrate for additional mutations (Schrider & Hahn, 2010). The duplication and/or 
deletion are the results of mutational mechanisms, which in humans consist of the most 
common non-allelic homologous recombination (NAHR), followed by non-homologous 
end joining (NHEJ) and replication slippage, and the least retrotransposition (Conrad et 
al., 2010; Kidd et al., 2008). NAHR is accounted for by the formation of the largest 
proportion of CNVs while replication slippage was suggested to be the simplest 
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mechanism that is responsible for the smaller variants such as tandem repeats. NAHR 
between homologous chromosomes or between sister chromatids results in both a 
duplication and a deletion while recombination on the same chromatid causes only 
deletion (Turner et al., 2008). Unlike duplication by NAHR which requires similar 
sequences, no sequence homology are required by NHEJ. CNVs formed by NHEJ gives 
both deletion and insertion of DNA (Hastings et al., 2009). Retrotransposition on the 
other hand, results only in new duplications (Conrad et al., 2010). 
 
2.7 Disease-related copy number variations 
 
CNV is one of the sources of genetic variation not only in the humans but also in the 
primates and rodents. The mechanism by which CNV influences gene expression is by 
altering the gene through disruption or duplication of CNVs regions-containing genes. 
Interindividual variation in drug response, immune defense and disease resistance are 
the results of some CNVs encompassing the genes. In a study of differences in CNVs of 
gene encoding chemokine (C-C motif) ligand 3-like 1 (CCL3L1), an immunodeficiency 
virus 1 (HIV-1)-suppressive chemokine and ligand for HIV receptor, it was reported 
that fewer numbers of the CCL3L1 copies as compared to the average increases 
susceptibility to HIV/AIDS (Freeman et al., 2006). A region that encompasses the 
putative tumor-suppressor genes was shown to be deleted in lung cancer and it is 
actually associated with copy-number loss in the individuals (K. K. Wong et al., 2007).  
The mechanisms by which the progression of heterozygous familial 
hypercholestrolemia (HeFH) occurs, normally involves small insertions or deletions, or 
missense, splicing, or nonsense mutations within the LDL receptor gene. However 
approximately one third of the patients are clinically diagnosed as HeFH without the 
presence of such mutations. CNVs in the low density lipoprotein receptor gene (LDLR) 
partially contribute to heterozygous familial hypercholesterolemia in affected patients. 
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There were overlaps observed between the reported CNVs and the genes involved in 
metabolic syndrome. About 22 or 40% of the 55 investigated genes contained a CNV or 
indel that have been observed in the general population (Lanktree & Hegele, 2008). 
The above-mentioned studies clearly depict the significant role of CNVs in some 
severe diseases such as cancer and HIV/AIDS. The role of copy number changes in 
NAFLD is however not well defined. To date, there is no published report yet on CNV 
in NAFLD. The closest study was to report on the association of CNVs with hepatic 
biomarkers in a population of more than 8000 Korean individuals (Kim, Cho, Yu, Sung, 
& Kim, 2010). One hundred CNVs were singnificantly associated with AST and 16 
with ALT. A total of 39 genes were identified within the regions. Among them was 
neuropeptide Y receptor type 5 (NPY5R) which was associated with dyslipidemia. In 
addition, more reports on CNVs-related metabolic traits such as obesity and diabetes are 
continuously documented.  
In a recent animal study that involved a construction of mouse strains with a 
deletion or duplication, it was shown that a duplication of Dp(11)17 resulted in obesity-
opposing characteristics, namely, reduced weight, decreased total and LDL cholesterol 
and increased insulin sensitivity, which is independent of food intake or level of 
activity. The Dp(11)17 also displayed protection against metabolic syndrome compared 
to the wild type. These findings help us to understand the underlying physiology of 
weight control and energy metabolism contributed by CNVs (Lacaria et al., 2012). A 
significant correlation was observed between copy number and expression of CNV 
genes modulating metabolic traits in mice such as body weight, triglycerides and 
glucose. These genes which include interlectin (It1na), defensin related cryptdin 1 
(Defcr-1), tripartite motif-containing 12 (TRIM12) and tripartite motif-containing 34 
(TRIM34) were found in three CNVs mapped in the genome in chromosomes 1, 4 and 
17 (Orozco et al., 2009).  
29 
Combined analyses in human studies have identified three CNVs associated with 
BMI, obesity, and other obesity-related traits. Several genes such as parkinson protein 2 
(PARK2), glycophorin A (GYPA), and sarcoglycan (SGCZ) genes were found to be 
encompassed by these CNVs (Zhao et al., 2012). In the same year, a deletion at position 
16p12.3 was reported in both European and Chinese populations, in which higher 
deletion frequency was observed in the European than that of the Chinese. The deletion 
in these populations was significantly associated with obesity (T. L. Yang et al., 2012). 
A putative association between CNV regions with type 2 diabetes was demonstrated in 
a Korean study (Bae et al., 2011). Several SNP-associated CNV markers were found to 
be associated with fasting insulin and HOMA-IR (Irvin et al., 2011). 
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CHAPTER THREE 
MATERIALS AND METHODS 
 
3.1 Materials 
 
3.1.1     Blood Collection 
 
Blood collection tubes; lavender and yellow top, syringe and needle, tourniquet, alcohol 
swab, cotton wool, sterile plaster, disposable latex examination gloves 
 
3.1.2     DNA extraction 
 
Absolute molecular grade ethanol (Merck, Germany), QIAamp DNA Blood Mini Kit 
(QIAGEN, Hilden, Germany); 1.5ml microcentrifuge tubes 
 
3.1.3     Agarose gel electrophoresis 
 
GenAgarose (Genaxis BIOTECHNOLOGY, USA); 10X TBE buffer (BST, Malaysia); 
6X Loading Dye Solution (Fermentas, Canada); GelRed (Biotium); 100bp DNA ladder 
(Vivantis, UK) 
 
3.1.4     Real-time polymerase chain reaction (RT-PCR) 
 
TaqMan assay (Applied Biosystems), master mix (Applied Biosystems), MicroAmp 
reaction tubes (Applied Biosystems), MicroAmp cap strip (Applied Biosystems) 
 
3.1.5     Sequenom MassARRAY 
 
96-well plate and plate sealing film (for quality control process). Experiment was run as 
a service by Chinese University of Hong Kong 
 
 
 
31 
3.1.6     Array CGH 
 
1 x TE pH8.0, Molecular Grade (Promega), Oligo aCGH Hybridization Kit (OGT), 
Human Cot-1 DNA
®
 (Life Technologies), Agilent Wash 1 and 2 (OGT), CytoSure 
genomic DNA labelling kit (OGT),  
 
3.1.7     Instruments 
BIO-RAD UV Transluminator; KODAK EDAS 290 camera; Gel Electrophoresis 
System with Power Pack (TRANSLAB, Malaysia & WEALTEC ELITE 300); Vortex 
machine, Microcentrifuge (Labnet, NJ, USA); Microwave (SAMSUNG, Korea); 
Freezer (Fisher & Paykel, Auckland); Refrigerator (TOSHIBA HYBRID PLASMA), 
Weighing Machine, Ice-maker Machine (Scotsman AF 80), micropipettes (20µL, 
200µL and 1000µL); Step One Real-Time PCR (Applied Biosystems), Real-Time PCR 
software (Applied Biosystems),magnetic stirrer, SureHyb hybridisation cassette 
(Agilent), gasket slides (OGT), glass dishes and rack, forcep, vacuum dessicator 
(SpeedVac
®
), PTC-200 Thermal Cycler (MJ Research), microarray scanner (Agilent), 
CytoSure Interpret software (OGT) 
 
3.2 Methods 
 
3.2.1     Subject recruitment 
 
The study involved a total of 144 patients and 198 controls among adults. Subjects were 
recruited from the University Malaya Medical Centre (UMMC). The study protocol was 
approved by the Medical Ethics Committee of UMMC and all subjects provided written 
informed consent to participate. Participants with the following criteria were excluded 
from the study; current or previous alcohol consumption of > 10g/day (Ruhl & 
Everhart, 2005), hepatitis B or C infection, autoimmune hepatitis, were taking drugs 
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that are known to cause steatosis. All cases were consecutive patients recruited from the 
adult hepatology outpatient clinic suspected to have NAFLD based on increased 
echogenicity (compared to renal cortex) on ultrasound with or without abnormal ALT. 
All NAFLD patients were biopsy-proven and the liver biopsy specimens were on an 
average 1.5 cm long and contained at least six portal tracts. The biopsy specimens were 
evaluated according to the NASH Clinical Research Network (Brunt, Kleiner, Wilson, 
Belt, & Neuschwander-Tetri, 2011; Kleiner et al., 2005) by a qualified pathologist 
blinded to patients, clinical and laboratory data. Patients with NAFLD were classified 
into simple steatosis and NASH. NASH patients were further classified into NASH 
without significant fibrosis (fibrosis score of < 2) and NASH with significant fibrosis 
(fibrosis score of 2 or greater). The control group without fatty liver consists of those 
who were genetically unrelated healthy subjects with normal body mass index (BMI) < 
25 kg/m
2
, normal fasting plasma glucose < 110 mg/dL and normal lipid profile. NAFLD 
was excluded in the controls by ultrasonography according to the absence of the 
following criteria; diffuse increase in bright echoes in the liver parenchyma (exceeding 
that of renal cortex and spleen) with impaired visualization of the peripheral portal and 
hepatic vein borders, and/or loss of definition of the diaphragm and poor delineation of 
the portal and hepatic radicles (Sanyal, 2002). For CNV study, 40 NASH patients were 
run as comparative array against 40 age, gender and ethnicity-matched controls using 
whole-genome aCGH microarrays. 
 
3.2.2     Clinical and laboratory assessments 
 
Standard protocol was used to determine the body mass index (BMI), waist 
circumference and blood pressure of the subjects. The biochemical tests for the 
determination of haemoglobin A1c (HbA1c), total cholesterol, triglycerides, high-
density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL), 
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alanine transferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl 
transpeptidase (GGT) level in all subjects were as standard clinical laboratory methods 
carried out in an accredited laboratory at UMMC.  
 
3.2.3     Sample preparation and DNA extraction 
 
Blood samples obtained from the subjects were collected into EDTA tubes. The EDTA 
tubes were centrifuged at 900 x g (3000 rpm) for 10 minutes. The buffy coat layer were 
separated and transferred into 1.5 mL centrifuge tubes. Genomic DNA was extracted 
from the concentrated lymphocytes of the buffy coat using the QiAamp DNA Mini Kit 
(Qiagen. Hilden, German) according to the manufacturer’s protocol. Twenty µL of 
Qiagen protease was added into a 1.5 mL microcentrifuge tube. A volume of 200 µL of 
the concentrated lymphocytes was then added into the microcentrifuge tube and 
followed by the addition of AL buffer. The mixture was mixed thoroughly by pulse 
vortex and then spun down for 15 seconds. The mixture-containing tube was incubated 
at 56
o
C in a heating block for 10 minutes. After that, the mixture was spun down for 15 
seconds to remove any water vapors or droplets formed on the tube lid. A volume of 
200 µL of ethanol (96-100%) was then added. The mixture was mixed thoroughly and 
spun down for 15 seconds again. Next, the mixture was transferred to the QiAamp Mini 
spin column without wetting the rim. The column was centrifuged at 6000 x g (8000 
rpm) for three minutes. The collection tube containing the filtrate was discarded and 
changed with a new one. A volume of 500 µL of AW1 buffer was added into the spin 
column. The column was centrifuged at 6000 x g (8000 rpm) for one minute. The 
filtrate-containing collection tube was discarded and changed with a new one. A volume 
of 500 µL of AW2 buffer was then added into the spin column and centrifuged at 20000 
x g (14000 rpm) for two minutes. The filtrate inside the collection tube was discarded 
without changing the collection tube. The spin column was centrifuged at 8000 rpm for 
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drying. The column was placed in a new 1.5 mL microcentrifuge tube. A volume of 150 
µL of AE buffer was added into the column and incubated for 10 minutes at room 
temperature. The column was then centrifuged at 6000 x g (8000 rpm) for one minute 
and the QiAamp spin column was discarded. The end product inside the 
microcentrifuge tube is the DNA. The product was run under 1% gel electrophoresis 
and the quality of the DNA was checked using nanodrop 2000c (Thermo Scientific). 
 
3.2.4     Agarose gel electrophoresis 
 
Gel electrophoresis was carried out to determine the presence of DNA. The genomic 
DNA extraction product was run under 1% agarose gel electrophoresis. The size of the 
casting tray determines the volume of gel to be made. A small gel tray of 30 mL was 
prepared by adding 0.3 g of agarose powder and 30 mL of 0.5x TBE buffer into a 
conical flask. The mixture was then heated in a microwave until the agarose powder 
was totally dissolved in the buffer. The mixture was then allowed to cool down. In the 
meantime, the casting tray and comb were assembled. The mixture was quickly poured 
onto the casting tray and left to solidify. After the gel was ready, the gel tray was moved 
into the gel tank filled with 0.5x TBE buffer. The buffer amount was ensured to 
adequately cover the surface of the gel. A volume of 1 µL of the genomic DNA was 
mixed with 1.5 µL of loading dye and then loaded into the well. The loading dye was 
first prepared by diluting a volume of 1 µL of GelRed into 599 µL of 6x loading dye. 
The sample was run together with a 100 bp ladder at 110 V for about 20 to 30 minutes. 
After that, the product was viewed under ultraviolet (UV) light using BIO-RAD UV 
Transluminator 2000. The gel picture was captured using KODAK EDAS 290 gel 
documentation system and the file was saved. 
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3.2.5     DNA measurement  
 
The quality of DNA was checked each time using nanodrop 2000c (Thermo Scientific) 
to ensure that 260/280 and 260/230 absorbance ratios exceeded 1.8 to indicate high 
quality DNA. 
 
3.2.6     Selection of SNPs 
 
SNPs were selected based on findings from reported genome-wide association studies, 
meta-analysis, gene-linkage studies, population candidate gene studies and knowledge 
of tagging SNPs using International HapMap database (hapmap.ncbi.nlm.nih.gov/). 
 
3.2.7     Genotyping 
 
3.2.7.1      Real-time polymerase chain reaction (RT-PCR) 
 
The extracted genomic DNA was used for the genotyping. The PNPLA3 rs738409 
variant and AGTR1 variants (rs3772622, rs3772627, rs3772630, rs3772633, and 
rs2276736) were genotyped using a predesigned Taqman SNP genotyping assay 
(Applied Biosystems, Foster City, CA, USA) on a Step One Real-Time PCR instrument 
(Applied Biosystems). The total reaction volume for each well was 10 µl containing 5 
µl universal mastermix (Applied Biosystems), 0.5 µl assay mix, 3.5 µl distilled water 
and 1 µl genomic DNA. The plate was setup at 95 
o
C holding stage for 20 s, 45 cycles 
of 95 
o
C denaturation  for 3 s and 60 
o
C annealing for 20 s and ran on a fast reaction 
(approximately 40 minutes for each run). Negative controls were introduced for every 
run to ensure the genotyping quality. 
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3.2.7.2      Sequenom MassARRAY 
 
Twenty-nine SNPs from various genes that included LEPR, GCKR, iNOS, TRAIL, 
SREBF1, CLOCK, COL13A1, FABP2, UCP3, PPARG, COX-2, NR1I2, KLF6, TFRC, 
PPARGC1A, FATP5, STAT3, APOA5, PEMT, and FDFT1 were genotyped at the 
University of Hong Kong, Genome Research Centre using the Sequenom MassARRAY 
technology platform with the iPLEX GOLD chemistry (Sequenom, San Diego, CA) 
according to the manufacturer’s protocols. Briefly, MassARRAY AssayDesign software 
package (v4.0) was used to design the specific assays with proximal SNPs filtering. 
Quality of the PCR fragment amplification and extension primer specificity was 
checked prior to running the reaction. A volume of 1 µL of genomic DNA at 10-20 
ng/µL were used in each amplification reaction. Residual nucleotides were 
dephosphorylated prior the iPLEX Gold reaction. Following a single-base extension, 
reaction products were desalted with SpectroClean resin (Sequenom, San Diego, CA) 
and 10 nL was spotted onto the SpectroCHIP using the MassARRAY Nanodispenser. 
MassARRAY Analyzer Compact MALDI-TOF mass spectrometer was used to 
determine the mass. For proper data acquisition and analysis, the MassARRAY® Typer 
4.0 software was used. Genotypes were called after cluster analysis using the default 
setting of Gaussian mixture model. Inspection of the clusters were done to ensure a 
clear cluster separation with good signal to noise cut-off. A manual review was done to 
further clarify uncertain genotype calls. Assay with less than 80% call rate within the 
same SpectroChip was considered to have failed. A blank and five duplicates were 
introduced as quality controls. SpectroChip with more than 25% call rate in the blank 
control or with less than 99.5% concordance in duplicate checks along with more than 
10% call rate in blank check were considered to have failed and the genotyping would 
be required to be repeated. 
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3.2.8     Statistical analysis 
 
All values are presented as mean ± standard deviation for continuous data and as 
percentages for categorical data. Prior to analyzing, all variables were tested for 
normality. For normally distributed variables (Age, BMI, waist circumference, ALT, 
HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, and systolic blood 
pressure), independent t-test was performed to determine the comparison between two 
groups. For skewed variables; HbA1c, AST, GGT, diastolic blood pressure, steatosis 
grade, lobular inflammation, ballooning, and fibrosis, Mann-Whitney U test was 
applied. Analysis of Variance (ANOVA) and Kruskal-Wallis test were conducted for 
comparison of three groups, for normally distributed and skewed variables, respectively. 
A goodness-of fit χ2 test was used to assess whether each individual variant was in 
equilibrium at each locus in the population (Hardy-Weinberg equilibirum). A P value of 
less than 0.05 indicated a lack of agreement with the equilibrium. 
Association of allele was performed using logistic regression. Likelihood tests 
indicated a significant effect of ethnicity but no significant effect of age and gender on 
the association. Multiple logistic regression was used to adjust the potential effect of 
ethnicity on susceptibility to NAFLD. The calibration and fit of the model were 
assessed using Hosmer Lemeshow goodness of fit and receiver operating characteristic 
(ROC) curves.  
Univariate analysis of association of genotypes and histological ordinal variables 
was assessed using the Jonckheere-Terpstra test. Ordinal regression is perfomed for 
multivariate analysis of histological ordinal variables. To correct for testing for multiple 
histological parameters, the false discovery rate (FDR) was calculated using Benjamini-
Hochberg procedure (Benjamini and Hochberg, 1995). For easier interpretation of the 
results, logistic regression was used to obtain the odds ratio. Analyses were performed 
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using SPSS 16.0 (Chicago IL) with a two sided P < 0.05 considered to be statistically 
significant. 
The Generalized Multifactor Dimensionality Reduction (GMDR) method was 
employed to investigate the influence of gene-gene interaction on NAFLD (Lou et al., 
2007). A 10-fold cross validation with exhaustive search that considered all possible 
combinations was selected. GMDR provides a cross-validation consistency score which 
is a measure of the degree of consistency with which the selected interaction is 
identified as the best model among all possibilities considered. The testing balanced 
accuracy generated is a measure of the degree by which the interaction accurately 
predicts case-control status. Testing accuracy is a measure of the strength of gene-gene 
interaction with a power of 80% at an accuracy of 0.58-0.60, given a sample of < 500 
(G. B. Chen et al., 2011). Ethnicity was first determined as a covariate in the analysis 
and used in the gene-gene interaction analysis. Permutation testing based on 1000 
shuffles was performed to obtain empirical p-value. Logistic regression model was 
performed to confirm the results of gene interaction analyses. 
Linkage disequilibrium and haplotype analyses for the five SNPs were 
performed using Haploview 4.2 program. The odds ratio for the haploypes was 
calculated using R software version 2.11.1. 
An estimated sample size of 135 cases and controls would provide 80% power at 
an α of 0.05 with the following assumptions: the allele frequency ranged from 0.24-
0.45, the baseline risk for the Malaysian population was 0.17, and the minimum 
detectable odds ratio was 2.0. 
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3.2.9     Whole genome array CGH for CNV detection 
Figure 3.1   Overview of the array CGH procedure 
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3.2.9.1      Sample preparation for aCGH 
 
Forty samples from patients with NASH were run as comparative array against 40 age, 
gender, and ethnicity-matched controls using whole-genome aCGH microarrays. The 
genomic DNA was prepared and purified to a standard in which the 260/280 absorbance 
ratio exceeds 1.8. Ideally the 260/230 absorbance ratio should also exceed 1.8. The final 
volume of the sample was 18 µl. At least 1.0 µg of DNA was required and similar 
starting amounts of sample and reference DNA were used. 
 
3.2.9.2      Array CGH  
 
Array-CGH was performed according to the protocol established by the manufacturer 
(Oxford Gene Technology). It was carried out using the SurePrint G3 Human CGH 2 x 
400K array (Agilent Technologies, Santa Clare, CA, USA) for genome wide 
identification of putative disease-associated CNVs. Each oligonucleotide-based 
microarray slide contained 410,739 probes that enable profiling of molecular genomic 
imbalances with 5.3 kb average resolution. Each probe on the array is 60-mer in length 
and covers both non-coding and coding regions of the human genome. A total of 1.0 µg 
gDNA of patient’s sample and 1.0 µg normal control gDNA were labeled with Cy3 and 
Cy5 dyes respectively using the CytoSure Genomic DNA labeling kit (Oxford Gene 
Technology, Oxford, UK). Probes were then purified using Microcon Centrifugation 
Filters, Ultracel YM-30 (Millipore, Billerica, MA, USA) and mixed thoroughly. This 
was followed by denaturation and pre-annealing with 50 µg of human Cot-1 DNA 
(Invitrogen, California). Hybridization of the mixture to the array slide was executed at 
a constant rotation at 65°C for 40 hours. The slide was then washed with Agilent wash 
buffer 1 and 2, and scanned immediately using an Agilent Microarray scanner (Agilent 
Technologies, Santa Clara, CA, USA). Data was extracted from scanned images using 
the Feature Extraction Software, version 10.7.3.1 (Agilent Technologies, USA). The 
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raw data obtained thereafter was uploaded into the CytoSure™ Interpret software 
version 4.2.5 (Oxford Gene Technology, Oxford, UK), normalized and converted into 
.cgh files.  Data normalization software was used to improve the inconsistencies in dye 
incorporation. The data was segmented using a modified Circular Binary Segmentation 
(CBS) algorithm (Venkatraman & Olshen, 2007). Genomic aberrations were identified 
by applying a threshold of log2 ratio value of 0.3 for gains and 0.6 for losses. 
Chromosomal aberrations were reported in accordance to the human genome sequence 
assembly Build 37, Hg 19 (www.ncbi.nlm.nih.gov). 
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Figure 3.2   Summary of the methods 
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CHAPTER FOUR 
RESULTS 
 
4.1 Demographics and clinical data 
 
The demographics and clinical characteristics of the NAFLD and control groups are 
described in Table 4.1. The differences between the two groups with regard to BMI, 
HbA1c, LDL cholesterol, total cholesterol, triglycerides, AST, ALT and GGT reflect 
the nature of the selection of the cases and controls. 
 
Table 4.1   Demographics and clinical data of the subjects 
Characteristics n (%) or mean ± SD  
 
Control (n = 198) NAFLD (n = 144) P value 
Gender 
  
  0.084 
   Males 85 (43) 77 (53)   − 
   Females 113 (57) 67 (47)   − 
Ethnicity 
  
  0.044 
   Malays 80 (41) 59 (41)   − 
   Chinese 54 (27) 54 (38)   − 
   Indians 64 (32) 31 (21)   − 
Age (years) 53.1 ± 11.5 51.2 ± 12.0   0.136 
BMI (kg/m2) 22.7 ± 2.6 28.7 ± 4.4 <0.0001 
HbA1c (%) 5.7 ± 0.8 6.6 ± 1.7 <0.0001 
HDL cholesterol (mg/dl) 49.5 ± 12.9 48.5 ± 12.7   0.310 
LDL cholesterol (mg/dl) 89.5 ± 22.4 117.1 ± 40.0 <0.0001 
Total cholesterol (mg/dl) 176.4 ± 26.9 196.7 ± 44.0 <0.0001 
Triglycerides (mg/dl) 118.4 ± 32.3 155.0 ± 62.7 <0.0001 
AST (IU/L) 21.8 ± 9.5 42.9 ± 25.4 <0.0001 
ALT (IU/L) 36.0 ± 16.6 83.0 ± 48.5 <0.0001 
GGT (IU/L) 44.0 ± 25.4 111.6 ± 115.5 <0.0001 
 
Data are expressed as mean ± SD for continuous data and as percentage for categorical data. P values obtained using Mann-Whitney 
U test except gender used Chi-square test. 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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Table 4.2 shows the demographics and clinical data of the patients with simple steatosis 
and with NASH. The BMI, HbA1c, waist circumference, triglycerides, systolic and 
diastolic blood pressure were significantly higher in the NASH group (P < 0.05) as 
compared to the simple steatosis group. 
 
Table 4.2   Demographics and clinical data of the NAFLD patients 
Characteristics n (%) or mean ± SD 
Simple steatosis 
(n = 33) 
NASH 
(n = 111) 
P value 
Gender, n (%)   0.461 
   Males 20 (61) 57 (51) − 
   Females 13 (39) 54 (49) − 
Age (years) 50.7 ± 11.8 51.2 ± 12.1 0.820 
BMI (kg/m2) 26.7 ± 3.9 29.2 ± 4.4 0.003 
HbA1c (%)* 6.1 ± 1.3 6.7 ± 1.7 0.021 
Waist circumference (cm) 89.2 ± 11.2 95.2 ± 10.4 0.005 
HDL cholesterol (mg/dl) 50.2 ± 15.1 48.0 ± 11.9 0.391 
LDL cholesterol (mg/dl) 114.7 ± 42.8 117.8 ± 39.3 0.698 
Total cholesterol (mg/dl) 191.6 ± 44.9 198.2 ± 43.8 0.448 
Triglycerides (mg/dl) 124.6 ± 42.0 164.1 ± 65.1 0.001 
AST (IU/L)* 37.6 ± 21.3 44.5 ± 26.3 0.139 
ALT (IU/L) 71.9 ± 50.0 86.4 ± 47.8 0.134 
GGT (IU/L)* 99.4 ± 106.6 115.3 ± 118.2 0.132 
Systolic blood pressure (mmHg) 125.2 ± 13.0 134.2 ± 14.1 0.001 
Diastolic blood pressure (mmHg)* 78.2 ± 9.1 83.8 ± 9.7 0.003 
 
Data are expressed as mean ± SD for continuous data and as percentage for categorical data. *P-values obtained using Mann-
Whitney U test, all other comparisons used independent t-test. Gender used Chi-square test. 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease, NASH 
non-alcoholic steatohepatitis 
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4.2 Single nucleotide polymorphism  
 
4.2.1     Single nucleotide polymorphism: PNPLA3 
 
4.2.1.1     Genotypes and allele frequencies of PNPLA3 rs738409  polymorphism 
 
The association tests of PNPLA3 rs738409 for the different NAFLD spectrum are 
presented in Table 4.3. The frequency of the risk allele G is significantly higher in the 
NASH (48%) and in the NAFLD (45%) when each is compared to the control group 
(24%). The genotype distribution was in Hardy-Weinberg equilibrium for all the 
patients and controls of each ethnic subgroup. 
There was a significant association between the risk allele G and NAFLD in the 
pooled subjects (OR 2.23, 95% CI  1.60-3.11, P < 0.0001) as well as after stratification 
into the three ethnic subgroups, (OR 1.93, 95% CI  1.11-3.36, P = 0.02; OR 3.50, 95% 
CI  1.67-7.33, P = 0.001 and OR 2.00, 95% CI 1.21-3.21, P = 0.007, for Chinese, Indian 
and Malay, respectively). The power for the significant associations is shown to be 
99%, 89%, 72%, 96%, 99%, 77%, 99%, and 63%, for rs738409 with NAFLD, rs738409 
with NAFLD in Malay, rs738409 with NAFLD in Chinese, rs738409 with NAFLD in 
Indian, rs738409 with NASH, rs738409 with NASH without significant fibrosis, 
rs738409 with NASH with significant fibrosis, and rs738409 with NASH with 
significant fibrosis compared to simple steatosis, respectively. 
PNPLA3 gene polymorphism at position 148 influences insulin secretion levels 
and obesity. Thus, adjustment for type 2 diabetes and BMI was performed. However, 
the results remain significant (OR 2.29, 95% CI  1.63-3.23, P < 0.0001 and OR 2.19, 
95% CI 1.42-3.37, P < 0.0001, for type 2 diabetes and obesity, respectively) 
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Table 4.3   Association tests of PNPLA3 rs738409 in different NAFLD spectrum 
NAFLD spectrum 
G allele  
frequency 
P value OR (CI) 
Control as reference       
   NAFLD vs. control    
      Overall 0.45 vs. 0.24 <0.0001 2.23 (1.60-3.11)* 
         Malays 0.42 vs. 0.24 0.007 2.00 (1.21-3.21) 
         Chinese 0.49 vs. 0.32 0.020 1.93 (1.11-3.36) 
         Indians 0.44 vs. 0.18 0.001 3.50 (1.67-7.33) 
   Simple steatosis vs. control 0.35 vs. 0.24 0.272 1.37 (0.78-2.42)* 
   All NASH vs. control 0.48 vs. 0.24 <0.0001 2.58 (1.80-3.69)* 
      NASH
a 
 vs. control 0.39 vs. 0.24 0.023 1.86 (1.09-3.18)* 
      NASH
b
 vs. control 0.52 vs. 0.24 <0.0001 2.99 (1.99-4.50)* 
Simple steatosis as reference   
 
  
   All NASH vs. simple steatosis 0.48 vs. 0.35 0.083 1.63 (0.94-2.81)* 
      NASH
a
 vs. simple steatosis 0.39 vs. 0.35 0.600 1.20 (0.61-2.38)* 
      NASH
b
 vs. simple steatosis 0.52 vs. 0.35 0.035 1.85 (1.05-3.26)* 
NASHa as reference   
 
  
   NASH
b
 vs NASH
a
 0.52 vs 0.39 0.088 1.62 (0.93-2.81)* 
 
*P values adjusted for ethnicity 
 
CI confident interval, OR odds ratio, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, NASHa non-
alcoholic steatohepatitis without significant fibrosis, NASHb non-alcoholic steatohepatitis with significant fibrosis 
 
4.2.1.2     PNPLA3 rs738409 polymorphism and liver histology 
 
The NAFLD patients were then divided into simple steatosis and NASH group, 
following which association analysis was performed (Table 4.3). The G allele is shown 
to be associated with NASH (OR 2.64, 95% CI 1.85-3.75, P < 0.0001) but not with 
simple steatosis. NASH patients were further stratified into two groups; NASH without 
significant fibrosis (fibrosis score < 2) and NASH with significant fibrosis (fibrosis 
score ≥ 2) and went on to compare these two groups of patients with that of the simple 
steatosis group. Results revealed that the G allele frequency was significantly higher in 
the NASH group with significant fibrosis compared to group with simple steatosis 
(OR 1.85, 95% CI 1.05-3.26, P = 0.035), but the G allele frequency was similar 
between the NASH group without significant fibrosis and the simple steatosis group, 
suggesting that the G allele is associated with severe stage of NASH. 
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Investigation was carried out on the association of PNPLA3 rs738409 with the 
histological features of NAFLD; steatosis, lobular inflammation, hepatocellular 
ballooning and fibrosis. It was shown that there is a significant association between the 
GG genotype with fibrosis stage (P = 0.038) but not with the other histological features 
(patients with genotype GG compared to CC, had mean score 2.03 vs. 1.52) (Table 4.4).  
 
Table 4.4   Comparison of various clinical and histological parameters between the 
PNPLA3 rs738409 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 48) CG (n = 63) GG (n = 33) P value 
Age (years)  50.9 ± 12.2 52.1 ± 12.0 49.5± 12.1 0.585 
BMI (kg/m2)  28.8 ± 4.4 28.5 ± 4.7 28.7 ± 3.8 0.936 
HbA1c (%)*  6.5 ± 1.8 6.6 ± 1.6 6.6 ± 1.6 0.759 
Waist circumference (cm)  94.3 ± 10.2 93.9 ± 12.0 92.9 ± 9.8 0.838 
HDL cholesterol (mg/dl)  49.4 ± 13.91 47.7 ± 13.6 48.7 ± 8.6 0.768 
LDL cholesterol (mg/dl)  117.9 ± 37.1 119.9 ± 40.2 110.7 ± 44.1 0.558 
Total cholesterol (mg/dl)  203.9 ± 41.0 195.0 ± 44.3 189.6 ± 47.3 0.327 
Triglycerides (mg/dl)  170.3 ± 81.8 155.0 ± 51.5 132.8 ± 41.8 0.029 
AST (IU/L)*  43.8 ± 25.1 40.7 ± 23.2 45.9 ± 29.8 0.858 
ALT (IU/L)  86.1 ± 50.3 79.2 ± 40.8 86.0 ± 59.2 0.705 
GGT (IU/L)*  121.0 ± 117.7 106.4 ± 114.9 107.9 ± 116.2 0.276 
Systolic BP (mmHg)  130.4 ± 13.3 133.4 ± 13.9 132.3 ± 16.6 0.548 
Diastolic BP (mmHg)*  81.5 ± 10.2 83.4 ± 8.8 82.2 ± 11.3 0.477 
Steatosis grade*  1.8 ± 0.8 1.9 ± 0.8 1.7 ± 0.8 0.434 
Lobular inflammation*  1.2 ± 0.6 1.3 ± 0.6 1.4 ± 0.6 0.472 
Ballooning*  1.1 ± 0.6 1.2 ± 0.6 1.3 ± 0.6 0.396 
Fibrosis*  1.5 ± 1.0 1.7 ± 1.0 2.0 ± 0.9 0.038 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
 
Investigation on the magnitude of the effect of the risk allele G with the 
histological features was further carried out. Patients bearing at least a single risk alle G 
of rs738409 were more likely to have a fibrosis score ≥ 2 (OR 1.95, 95% CI  1.17-3.26, 
P = 0.013). The association remains significant after the adjustment of other histological 
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features (P = 0.012). However, there was no association between the risk allele and 
steatosis, lobular inflammation or hepatocellular ballooning (Table 4.5). 
 
Table 4.5   Association of G allele of rs738409 with histological features in NAFLD 
patients 
 
 Histology Univariate 
P valuea 
multivariate p valueb 
(FDR q valueg) 
OR (95% CI) 
Steatosis 
     > 33% vs. < 33% 0.91 0.892 (0.446) 0.88 (0.52-1.47)c 
Lobular inflammation 
     ≥ 2 foci vs. < 2 foci 0.237 0.202 (0.135) 1.13 (0.64-1.99)d 
Hepatocellular ballooning 
     ≥ 1 vs. < 1 0.176 0.168 (0.168) 1.07 (0.61-1.87)e 
Fibrosis 
     ≥ 2 vs. < 2 0.013 0.012 (0.024) 1.95 (1.17-3.26)f 
 
OR odds ratio, CI confident interval 
aJonckheere-Terpstra test 
bOrdinal regression 
c, d, e, fMultivariate logistic regression 
gFalse discovery rate, q < 0.05 is significant 
 
4.2.1.3     Analysis of various clinical parameters with PNPLA3 rs738409 genotypes 
 
Next, the clinical parameters between the PNPLA3 rs738409 genotypes among patients 
with NAFLD were compared (Table 4.4). Patients with the GG genotype have a 
significantly lower level of plasma triglycerides compared to those with the CC 
genotype (P = 0.029). The levels of triglyceride between the three groups: simple 
steatosis, NASH without significant fibrosis and NASH with significant fibrosis, were 
then compared (Figure 4.1). A significant difference between the three groups (P = 
0.002) was observed. Compared to those with simple steatosis, the triglycerides level is 
significantly higher in the NASH group with significant fibrosis (P = 0.006) and 
without significant fibrosis (P < 0.0001). The triglyceride level is lower in the NASH 
group with significant fibrosis compared to the NASH group without significant 
fibrosis, but this did not achieve statistical significance. 
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Figure 4.1   The comparison of plasma triglycerides level in the NAFLD spectrum  
 
The boxplot showed the extreme values, 25th, 50th (median) and 75th percentiles and outliers 
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4.2.2     Single nucleotide polymorphism: AGTR1 
 
4.2.2.1     Genotypes and allele frequencies of AGTR1 polymorphisms 
 
The genotypes of each SNP were in Hardy-Weinberg equilibrium for both NAFLD 
cases and controls, for pooled subjects as well as after stratification by ethnicity. The 
association tests between NAFLD and control subjects are shown in Table 4.6. None of 
the SNPs were associated with susceptibility to NAFLD. However, after ethnic 
stratification, in the Indian ethnic subgroup, the rs2276736, rs3772630 and rs3772627 
were found to be protective against NAFLD (OR 0.40, 95% CI  0.20-0.81, P = 0.010; 
OR 0.43, 95% CI  0.22-0.86, P = 0.016; and OR 0.46, 95% CI  0.23-0.91, P = 0.026, 
respectively). The sample power for the significant findings is shown to be > 81%.  
Next, the NAFLD group was divided into simple steatosis and NASH, however, 
no significant association was found between the five SNPs with susceptibility to 
NASH in the pooled subjects (Table 4.6). Results by ethnicity group showed that in the 
Indian ethnic subgroup, the three SNPs (rs2276736, rs3772630 and rs3772627) were 
also protective against NASH (OR 0.42, 95% CI  0.21-0.86, P = 0.017; OR 0.46, 95% 
CI  0.22-0.92, P = 0.029; and OR 0.49, 95% CI  0.24-0.98, P = 0.045, respectively).  
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              Table 4.6   Association tests of AGTR1 SNPs and NAFLD 
NAFLD spectrum 
All ethnicities* 
 
Malay 
 
Chinese 
 
Indian 
MAF OR (CI) P 
 
MAF OR (CI) P 
 
MAF OR (CI) P 
 
MAF OR (CI) P 
rs2276736 (T > C) 
               Control as reference 0.42 1.00 
  
0.35 1.00 
  
0.43 1.00 
  
0.49 1.00 
    NAFLD 0.38 0.82 (0.48-1.37) 0.445 
 
0.36 1.03 (0.61-1.15) 0.917 
 
0.44 1.08 (0.62-1.88) 0.778 
 
0.27 0.40 (0.20-0.81) 0.010 
   Simple steatosis 0.41 0.99 (0.55-1.79) 0.968 
 
0.33 0.93 (0.37-2.31) 0.873 
 
0.50 1.35 (0.62-2.93) 0.450 
 
0.25 0.35 (0.07-1.81) 0.209 
   NASH 0.36 0.78 (0.46-1.34) 0.366 
 
0.36 1.05 (0.61-1.81) 0.848 
 
0.42 0.97 (0.53-1.78) 0.925 
 
0.30 0.42 (0.21-0.86) 0.017 
rs3772622 (A > G) 
               Control as reference 0.38 1.00 
  
0.38 1.00 
  
0.41 1.00 
  
0.34 1.00 
    NAFLD 0.42 1.17 (0.87-1.59) 0.301 
 
0.45 1.30 (0.81-2.07) 0.275 
 
0.40 0.97 (0.58-1.61) 0.896 
 
0.40 1.32 (0.69-2.53) 0.409 
   Simple steatosis 0.38 0.97 (0.57-1.65) 0.912 
 
0.33 0.83 (0.35-1.97) 0.666 
 
0.38 0.91 (0.43-1.94) 0.804 
 
0.5 1.96 (0.45-8.55) 0.371 
   NASH 0.43 1.22 (0.88-1.69) 0.226 
 
0.48 1.46 (0.88-2.42) 0.142 
 
0.41 0.99 (0.58-1.71) 0.981 
 
0.39 1.24 (0.62-2.46) 0.546 
rs3772633 (A > G) 
               Control as reference 0.23 1.00 
  
0.23 1.00 
  
0.30 1.00 
  
0.19 1.00 
    NAFLD 0.28 1.21 (0.86-1.70) 0.282 
 
0.28 1.28 (0.75-2.18) 0.370 
 
0.34 1.23 (0.70-2.16) 0.475 
 
0.19 1.04 (0.49-2.21) 0.922 
   Simple steatosis 0.24 0.99 (0.53-1.84) 0.965 
 
0.17 0.66 (0.21-2.08) 0.473 
 
0.35 1.27 (0.58-2.80) 0.550 
 
0.12 0.61 (0.07-5.34) 0.656 
   NASH 0.30 1.31 (0.91-1.88) 0.150 
 
0.31 1.45 (0.83-2.55) 0.190 
 
0.34 1.20 (0.65-2.23) 0.564 
 
0.22 1.23 (0.57-2.66) 0.597 
 
             * Results based on combining results across ethnicities 
                    CI confident interval, MAF minor allele frequency, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, OR odds ratio 
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              Table 4.6 (continued)   Association tests of AGTR1 SNPs and NAFLD 
NAFLD spectrum 
All ethnicities* 
 
Malay 
 
Chinese 
 
Indian 
MAF OR (CI) P 
 
MAF OR (CI) P 
 
MAF OR (CI) P 
 
MAF OR (CI) P 
rs3772630 (A > G) 
               Control as reference 0.42 1.00 
  
0.35 1.00 
  
0.44 1.00 
  
0.49 1.00 
    NAFLD 0.39 1.03 (0.76-1.38) 0.859 
 
0.37 1.10 (0.67-1.81) 0.695 
 
0.45 1.08 (0.62-1.88) 0.779 
 
0.31 0.43 (0.22-0.86) 0.016 
   Simple steatosis 0.42 1.01 (0.73-1.39) 0.951 
 
0.38 1.11 (0.46-2.67) 0.813 
 
0.50 1.31 (0.60-2.87) 0.504 
 
0.25 0.35 (0.07-1.81) 0.209 
   NASH 0.38 1.09 (0.67-1.78) 0.728 
 
0.37 1.10 (0.65-1.88) 0.719 
 
0.43 0.99 (0.54-1.80) 0.971 
 
0.31 0.46 (0.22-0.92) 0.029 
rs3772627 (T > C) 
               Control as reference 0.42 1.00 
  
0.38 1.00 
  
0.44 1.00 
  
0.48 1.00 
    NAFLD 0.38 0.62 (0.33-1.15) 0.128 
 
0.36 0.92 (0.56-1.52) 0.742 
 
0.45 1.08 (0.63-1.85) 0.783 
 
0.31 0.46 (0.23-0.91) 0.026 
   Simple steatosis 0.41 0.63 (0.38-1.04) 0.073 
 
0.33 0.84 (0.34-2.06) 0.697 
 
0.50 1.29 (0.60-2.76) 0.516 
 
0.25 0.37 (0.07-1.92) 0.236 
   NASH 0.37 0.71 (0.28-1.82) 0.473 
 
0.36 0.94 (0.55-1.61) 0.831 
 
0.43 0.99 (0.55-1.78) 0.971 
 
0.31 0.49 (0.24-0.98) 0.045 
 
             * Results based on combining results across ethnicities 
                   CI confident interval, MAF minor allele frequency, NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis,  OR odds    ratio 
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Among the three protective SNPs, rs2276736 showed the lowest P value (OR 
0.40, 95% CI  0.20-0.81, P = 0.010). To investigate whether the genotypes of SNP 
rs2276736 were associated with the clinical and histological parameters, the age, BMI, 
HbA1c, waist circumference, HDL cholesterol, LDL cholesterol, total cholesterol, 
triglycerides, AST, ALT, GGT, systolic blood pressure, diastolic blood pressure, 
steatosis, lobular inflammation, ballooning and fibrosis grade were compared between 
the different genotypes (Table 4.7). None of the histological parameters was 
significantly different among the genotypes. However, both BMI and waist 
circumference were found to be lower in the CC genotypes, further strengthening the 
case for the protective effect of the SNP. 
 
Table 4.7   Comparison of various clinical and histological parameters between the 
AGTR1 rs2276736 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  TT (n = 51) TC (n = 78) CC (n = 15) P value 
Age (years)  51.5 ± 11.4 51.3 ± 11.8 48.7 ± 15.4 0.718 
BMI (kg/m2)  29.6 ± 4.5 28.6 ± 4.3 26.0 ± 3.6 0.017 
HbA1c (%)*  6.6 ± 1.7 6.7 ± 1.8 5.9 ± 1.0 0.385 
Waist circumference (cm)  96.0 ± 9.7 93.8 ± 11.1 86.8 ± 11.4 0.016 
HDL cholesterol (mg/dl)  48.7 ± 12.0 48.7 ± 13.9 47.2 ± 8.1 0.917 
LDL cholesterol (mg/dl)  115.5 ± 39.7 116.6 ± 41.1 125.2 ± 36.9 0.706 
Total cholesterol (mg/dl)  194.3 ± 45.3 197.3 ± 44.1 202.1 ± 41.1 0.827 
Triglycerides (mg/dl)  163.5 ± 68.7 152.2 ± 58.5 140.9 ± 62.7 0.399 
AST (IU/L)*  42.9 ± 26.0 42.7 ± 25.4 43.7 ± 24.7 0.976 
ALT (IU/L)  80.5 ± 48.5 83.1 ± 48.2 91.3 ± 52.4 0.753 
GGT (IU/L)*  122.3 ± 123.9 106.0 ± 116.1 105.7 ± 81.3 0.424 
Systolic BP (mmHg)  133.3 ± 15.1 130.7 ± 14.4 130.3 ± 18.1 0.589 
Diastolic BP (mmHg)*  83.6 ± 9.0 82.4 ± 10.2 79.7 ± 10.5 0.328 
Steatosis grade*  1.8 ± 0.7 1.8 ± 0.8 2.2 ± 0.9 0.148 
Lobular inflammation*  1.2 ± 0.5 1.3 ± 0.6 1.5 ± 0.6 0.229 
Ballooning*  1.2 ± 0.6 1.2 ± 0.6 1.3 ± 0.7 0.802 
Fibrosis*  1.8 ± 0.9 1.7 ± 1.0 1.6 ± 1.1 0.624 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
  
54 
 
4.2.2.2     AGTR1 polymorphisms and liver histology 
 
Of the five SNPs, rs3772622 was the only SNP to show association with liver histology 
in the NAFLD patients (Table 4.8). The GG genotype of this SNP is significantly 
associated with increased fibrosis (P = 0.009) (Figure 4.2). It has to be noted that the 
rs3772622 is not among the SNPs that have been found to be protective. To investigate 
whether the G allele of the rs3772622 is associated with risk of fibrosis, univariate and 
multivariate tests were performed. The G allele of this SNP was shown to be associated 
with presence of fibrosis (P = 0.003). Subjects with the G allele has a propensity of 2.18 
times to develop fibrosis score of ≥ 2. The association remains significant (P = 0.003) 
after adjustment of other histological attributes (Table 4.8). Investigation of the 
remaining SNPs and their association with histological features of NAFLD were also 
performed, however none of them showed a significant association. 
 
Table 4.8   Association of G allele of rs3772622 with histological features in NAFLD 
patients 
 Histology Univariate 
P valuea 
multivariate p valueb 
(FDR q valueg) 
OR (95% CI) 
Steatosis 
     > 33% vs. < 33% 0. 589 0.546 (0.728) 0.98 (0.61-1.56)c 
Lobular inflammation 
     ≥ 2 foci vs. < 2 foci 0. 953 0.251 (0.502) 0.89 (0.55-1.45)d 
Hepatocellular ballooning 
     ≥ 1 vs. < 1 0. 395 0.744 (0.744) 2.08 (0.84-5.14)e 
Fibrosis 
     ≥ 2 vs. < 2 0. 003 0.003 (0.012) 2.18 (1.32-3.60)f 
 
OR odds ratio, CI confident interval 
aJonckheere-Terpstra test 
bOrdinal regression 
c, d, e, fMultivariate logistic regression 
gFalse discovery rate, q < 0.05 is significant 
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Figure 4.2   Mean fibrosis score among the genotypes of rs3772622  
 
P value calculated from comparison between three groups using Kruskal-Wallis test 
 
4.2.2.3    Linkage disequilibrium and haplotype analysis of AGTR1 polymorphisms 
 
Linkage disequilibrium (LD) analysis revealed a strong LD between the five SNPs in 
pooled subjects and even after ethnic stratification, except between rs3772633 and 
rs3772622. Variants rs2276736 and rs3772630 are in complete LD in the Chinese and 
Malays, however variants rs2276736 and rs3772627 are in complete LD in the Chinese 
only (Figure 4.3).  
Four haplotypes with frequencies of above 5% are presented in Table 4.9. In 
pooled subjects, haplotypes ATATG, GCGCA and ATATA are more frequent than the 
others (35.1%, 21.8% and 20.9%, respectively). Similar results are observed in the 
Malays (37.8%, 22.7% and 23.2%, respectively). Meanwhile in the Chinese, the most 
frequent haplotypes are ATATG (34.8%) and GCGCA (25.9%). The Indians on the 
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other hand has high frequency of haplotypes ATATG (31.4%), ATATA (22.3%) and 
ACGCA (24.7%). Each of the following haplotypes, ATATG, GCGCA, ATATA and 
ACGCA is significantly different among the ethnic groups (P < 0.0001, for each 
haplotype respectively). Haplotype analysis revealed that haplotype ACGCA was 
protective against NAFLD in the Indians (OR 0.42, 95% CI 0.15-0.95, P = 0.03). Since 
rs2276736, rs3772630 and rs3772627 are presented in similar structure and some were 
in complete LD, the haplotype among the three SNPs was further analysed. It was found 
that the Indians presenting with the CGC haplotype were protected (OR 0.41, 95% CI 
0.21-0.84, P = 0.015) against NAFLD. 
 
 
Figure 4.3   Linkage disequilibrium among five SNPs of AGTR1 gene 
Indian Chinese 
Malay All ethnicities 
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                  Table 4.9   Haplotype frequencies of AGTR1 polymorphisms 
Haplotype Ethnicity 
  Chinese (n=108) Indian (n=95) Malay (n=139) Total (n=342) 
  
Case 
(%) 
Ctrl 
(%) 
P OR
a
(95% CI) 
Case 
(%) 
Ctrl 
(%) 
P OR
a
 (95% CI) 
Case 
(%) 
Ctrl 
(%) 
P OR
a
 (95% CI) 
Case 
(%) 
Ctrl 
(%) 
P
c
 OR
a
 (95% CI) 
ATATG 33 37 0.60 Referent 33 31 0.75 Referent 43 34 0.15 Referent 37 34 0.37 Referent 
GCGCA 26 26 0.99 1.07 (0.54-2.10) 12 18 0.28 0.59 (0.20-1.68) 24 22 0.59 0.74 (0.38-1.44) 22 22 0.40 0.83 (0.54-1.28) 
ATATA 16 18 0.67 1.02 (0.45-2.32) 31 18 0.05 1.62 (0.59-3.28) 18 27 0.09 0.54 (0.29-1.03) 20 22 0.62 0.86 (0.48-1.54) 
ACGCA 15 14 0.84 1.26 (0.53-2.96) 15 29 0.03 0.42 (0.15-0.95) 8 12 0.34 0.53 (0.22-1.28) 13 18 0.23 0.66 (0.34-1.29) 
Others
b 
10 5 -  - 9 4 -   - 7 5 -   - 8 4 -   - 
Total 100 100 - -  100 100  -  - 100 100  - -  100 100  - -  
 
                                      cP values based on combining results across ethnicities 
                         CI confidence interval, Ctrl control, OR odds ratio,  a OR estimated odds ratio by R, b Haplotypes with total frequencies below 5% in all subjects 
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4.2.3     Single nucleotide polymorphism: LEPR 
 
4.2.3.1     Genotypes and allele frequencies of LEPR polymorphisms 
 
Table 4.10 shows the allele frequencies and association between LEPR rs1137100 and 
rs1137101 with NAFLD. The genotypes of each SNPs were first checked and ensured 
to be in Hardy-Weinburg equilibirum for both NAFLD cases and controls, for pooled 
subjects as well as after stratification by ethnicity. There is a significant association 
observed for both rs1137100 and rs1137101 with susceptibility to NAFLD (OR 1.64, 
95% CI 1.18-2.28, P = 0.003; and OR 1.61, 95% CI 1.11-2.34, P = 0.013, respectively). 
The association is also observed for rs1137100 in the Malays after ethnic stratification 
(OR 2.18, 95% CI  1.21-3.95, P = 0.010). However, no association is found in all the 
three ethnic subgroups studied for rs1137101.  
Patients with NAFLD were then stratified into simple steatosis (n = 33) and 
NASH (n = 111) following which, association analysis was performed (Table 4.10). 
Both SNPs were associated with NASH (OR 1.49, 95% CI 1.05-2.12, p = 0.026; and 
OR 1.57, 95% CI 1.05-2.35, P = 0.029, respectively). However, only rs1137100 is 
found to be associated with simple steatosis (OR 2.27, 95% CI 1.27-4.08, P = 0.006). 
NASH patients were further stratified into two groups; NASH without significant 
fibrosis (fibrosis score < 2) and NASH with significant fibrosis (fibrosis score ≥ 2). A 
significant association with NASH without significant fibrosis was observed for 
rs1137100 (OR 2.18, 95% CI 1.24-3.84, P = 0.007). The power for the significant 
associations is shown to be 92%, 85%, 60%, 85%, 66%, 79%, and 93%, for rs1137100 
with NAFLD, rs1137101 with NAFLD, rs1137100 with NAFLD in Malay, rs1137100 
with simple steatosis, rs1137100 with NASH, rs1137101 with NASH, and rs1137100 
with NASH without significant fibrosis, respectively. 
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Table 4.10   Association tests of LEPR polymorphisms in different NAFLD spectrum 
NAFLD spectrum rs1137100 
 
rs1137101 
 
G allele 
frequency 
P value OR (CI) 
 
G alelle 
frequency 
P value OR (CI) 
Control as reference         
 
    
NAFLD vs. control        
   Overall 0.64 vs. 0.51 0.003 1.64 (1.18-2.28) 
 
0.82 vs. 0.72 0.013 1.61 (1.11-2.34) 
   Malays 0.71 vs. 0.58 0.010 2.18 (1.21-3.95) 
 
0.85 vs. 0.79 0.199 1.53 (0.80-2.92) 
   Chinese 0.77 vs. 0.78 0.861 0.94 (0.47-1.87) 
 
0.89 vs. 0.84 0.358 1.42 (0.68-2.97) 
   Indians 0.26 vs. 0.19 0.278 1.48 (0.73-3.01) 
 
0.65 vs. 0.55 0.203 1.51 (0.80-2.84) 
Simple steatosis vs. control 0.71 vs. 0.51 0.006 2.27 (1.27-4.08) 
 
0.83 vs. 0.72 0.113 1.74 (0.88-3.47) 
All NASH vs. control 0.61 vs. 0.51 0.026 1.49 (1.05-2.12) 
 
0.82 vs. 0.72 0.029 1.57 (1.05-2.35) 
   NASHa vs. control 0.73 vs. 0.51 0.007 2.18 (1.24-3.84) 
 
0.86 vs. 0.72 0.069 1.91 (0.95-3.82) 
   NASHb vs. control 0.55 vs. 0.51 0.264 1.25 (0.84-1.86) 
 
0.79 vs.0.72 0.114 1.44 (0.78-1.52) 
Simple steatosis as reference 
    
 
  All NASH vs. simple steatosis 0.61 vs. 0.71 0.163 0.64 (0.34-1.20) 
 
0.82 vs. 0.83 0.810 0.91 (0.65-1.86) 
   NASHa vs. simple steatosis 0.73 vs. 0.71 0.823 0.91 (0.41-2.05) 
 
0.86 vs. 0.83 0.857 1.09 (0.44-2.72) 
   NASHb vs. simple steatosis 0.55 vs. 0.71 0.053 0.51 (0.26-1.01) 
 
0.79 vs 0.83 0.511 0.77 (0.34-1.70) 
NASHa as reference 
    
 
  
   NASHb vs NASHa 0.55 vs. 0.73 0.079 0.56 (0.29-1.07) 
 
0.79 vs 0.86 0.436 0.73 (0.33-1.60) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, NASHa non-
alcoholic steatohepatitis without significant fibrosis; NASHb non-alcoholic steatohepatitis with significant fibrosis 
 
The polymorphism of the rs1137100 was earlier found to be associated with 
simple steatosis (fatty liver) in the Malays. The analysis was continued by comparing 
the distribution of various clinical and histological parameters among the three major 
ethnic subgroups (Table 4.11). The parameters that are associated with NAFLD such as 
BMI, AST and ALT enzymes were found to be the highest in the Malays as compared 
to the Chinese and Indians (P < 0.05). 
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Table 4.11   Comparison of various clinical and histological parameters between three 
major ethnic groups among NAFLD patients 
Characteristics NAFLD, n = 144 (Mean ± SD) 
 Malay (n = 59) Chinese (n = 54) Indian (n = 31) P value 
Age (years) 48.1 ± 12.7 53.5 ± 12.1 52.8 ± 9.5 0.038 
BMI (kg/m2) 30.0 ± 4.3 27.4 ± 4.7 28.5 ± 3.2 0.006 
HbA1c (%)* 6.9 ± 1.8 5.9 ± 0.9 7.0 ± 2.1 0.003 
Waist circumference (cm) 95.8 ± 10.5 90.1 ± 11.7 96.7 ± 8.2 0.004 
HDL cholesterol (mg/dl) 49.9 ± 13.9 50.5 ± 10.5 42.4 ± 12.3 0.007 
LDL cholesterol (mg/dl) 115.8 ± 46.8 115.0 ± 34.5 123.4 ± 35.2 0.616 
Total cholesterol (mg/dl) 197.4 ± 49.9 195.4 ± 38.1 197.8 ± 42.8 0.962 
Triglycerides (mg/dl) 164.9 ± 65.7 137.8 ± 44.7 166.2 ± 77.4 0.037 
AST (IU/L)* 48.4 ± 27.9 38.5 ± 22.7 40.3 ± 23.5 0.091 
ALT (IU/L) 95.5 ± 54.9 74.5 ± 42.8 74.3 ± 40.4 0.037 
GGT (IU/L)* 140.8 ± 122.9 89.9 ± 114.9 93.9 ± 90.6 0.005 
Systolic BP (mmHg) 135.6 ± 14.8 126.7 ± 14.1 132.5 ± 15.0 0.006 
Diastolic BP (mmHg)* 84.5 ± 10.4 80.3 ± 9.1 82.7 ± 9.5 0.054 
Steatosis grade* 1.9 ± 0.8 1.7 ± 0.8 1.7 ± 0.7 0.288 
Lobular inflammation* 1.3 ± 0.6 1.3 ± 0.6 1.4 ± 0.5 0.845 
Ballooning* 1.2 ± 0.6 1.2 ± 0.6 1.4 ± 0.5 0.113 
Fibrosis* 1.6 ± 0.9 1.5 ± 0.9 2.3 ± 1.1 0.003 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
 
4.2.3.2     LEPR polymorphisms and liver histology 
 
The distribution of various clinical and histological parameters of NAFLD among the 
genotypes of LEPR rs1137100 and rs1137101 were then investigated. However, only 
rs1137100 showed a significant difference between the genotypes with fibrosis stage (P 
= 0.004) but not with other clinical and histological features (Table 4.12). Genotype GG 
is significantly associated with decreased fibrosis score (patients with genotype GG 
compared to AA, had mean score of 1.48 vs. 2.29). For the purpose of determining the 
magnitude of effect of allele G with fibrosis score, univariate and multivariate analysis 
were performed (Table 4.13). A single allele G of rs1137100 in an individual is found to 
be protective against fibrosis (OR 0.47, 95% CI  0.28-0.78, P = 0.001). The association 
remained significant even after the adjustment of other histological features (P < 0.001). 
61 
 
However, no association was found between the G allele of rs1137100 with steatosis, 
lobular inflammation and hepatocellular ballooning. 
 
Table 4.12   Comparison of various clinical and histological parameters between the 
LEPR rs1137100 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 21) AG (n = 63) GG (n = 60) P value 
Age (years)  52.9 ± 10.1 51.1 ± 12.3 50.5 ± 12.5 0.735 
BMI (kg/m2)  28.2 ± 2.9 28.8 ± 5.1 28.7 ± 4.1 0.887 
HbA1c (%)*  7.3 ± 2.3 6.5 ± 1.6 6.4 ± 1.4 0.243 
Waist circumference (cm)  95.2 ± 8.3 92.6 ± 12.4 94.7 ± 9.9 0.477 
HDL cholesterol (mg/dl)  47.5 ± 16.7 48.4 ± 13.3 49.0 ± 10.5 0.907 
LDL cholesterol (mg/dl)  114.8 ± 40.2 118.2 ± 40.4 116.8 ± 40.2 0.942 
Total cholesterol (mg/dl)  192.3 ± 45.2 202.5 ± 42.7 192.2 ± 44.8 0.380 
Triglycerides (mg/dl)  153.7 ± 77.3 167.5 ± 66.9 142.4 ± 49.7 0.084 
AST (IU/L)*  37.5 ± 21.8 45.9 ± 28.5 41.6 ± 22.9 0.598 
ALT (IU/L)  71.0 ± 36.2 85.0 ± 49.7 85.3 ± 51.0 0.469 
GGT (IU/L)*  96.7 ± 98.0 112.5 ± 116.0 116.0 ± 121.8 0.558 
Systolic BP (mmHg)  133.8 ± 13.3 130.4 ± 15.4 130.0 ± 15.2 0.654 
Diastolic BP (mmHg)*  83.1 ± 9.9 82.4 ± 11.0 82.5 ± 8.7 0.877 
Steatosis grade*  1.8 ± 0.7 1.8 ± 0.8 1.8 ± 0.8 0.920 
Lobular inflammation*  1.3 ± 0.5 1.3 ± 0.6 1.3 ± 0.6 0.937 
Ballooning*  1.4 ± 0.5 1.2 ± 0.6 1.2 ± 0.6 0.426 
Fibrosis*  2.3 ± 1.5 1.8 ± 0.8 1.5 ± 1.0 0.004 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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Table 4.13   Association of LEPR rs1137100 G allele with histological features among 
NAFLD patients 
 Histology Univariate 
P valuea 
multivariate p-valueb 
(FDR q-valueg) 
OR (95% CI) 
Steatosis 
     > 33% vs. < 33% 0.717 0.880 (1.000) 0.84 (0.52-1.35)c 
Lobular inflammation 
     ≥ 2 foci vs. < 2 foci 0.722 0.270 (0.540) 1.01 (0.62-1.65)d 
Hepatocellular ballooning 
     ≥ 1 vs. < 1 0.456 0.901 (0.901) 0.77 (0.33-1.79)e 
Fibrosis 
     ≥ 2 vs. < 2 0.001 <0.001 (0.002) 0.47 (0.28-0.78)f 
 
OR, odds ratio; CI, confident interval 
aJonckheere-Terpstra test 
bOrdinal regression 
c, d, e, fMultivariate logistic regression 
gFalse discovery rate, q < 0.05 is significant 
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4.2.4     Single nucleotide polymorphism: GCKR 
 
4.2.4.1     Genotypes and allele frequencies of GCKR polymorphisms 
 
The genotype distribution of each SNP rs1260326 C>T and rs780094 C>T was in 
Hardy-Weinberg equilibrium for both NAFLD cases and controls, as well as after 
stratification by ethnicity. Assessment in the pooled subjects showed that the frequency 
of risk allele T was higher in patients with NAFLD compared to controls (OR 1.49, 
95% CI 1.09-2.05, P = 0.012; and OR 1.51, 95% CI 1.09–2.09, P = 0.013, for 
rs1260326 and rs780094, respectively). Higher frequency of T allele was also observed 
in the Indian NAFLD patients than that of the controls (OR 2.64, 95% CI 1.28-5.43, P = 
0.009 and OR 4.35, 95% CI 1.93–9.81, P < 0.0001, for rs1260326 and rs780094, 
respectively) but this was not seen in the Malays and Chinese (Table 4.14). Data thus 
indicate an association of T allele with susceptibility to NAFLD. To investigate the next 
objective which is whether T allele is associated with NAFLD spectrum, patients with 
NAFLD were grouped into simple steatosis (n = 33) and NASH (n = 111), following 
which NASH patients were further stratified into NASH with no significant fibrosis 
(fibrosis score < 2, n = 37) and NASH with significant fibrosis (fibrosis score ≥ 2, n = 
74). Significant association was replicated in the NASH (OR 1.55, 95% CI 1.10–2.17, P 
= 0.013 and OR 1.56, 95% CI 1.10–2.22, P = 0.012, for rs1260326 and rs780094, 
respectively) and NASH with significant fibrosis (OR 1.49, 95% CI 1.01–2.21, P = 
0.044 and OR 1.52, 95% CI 1.03–2.26, P = 0.038, for rs1260326 and rs780094, 
respectively). No significant finding was observed between both SNPs and simple 
steatosis and NASH without significant fibrosis (Table 4.14). The power for the 
significant associations is shown to be 75%, 83%, 77%, 95%, 82%, 83%, 48% and 57%, 
for rs1260326 with NAFLD, rs780094 with NAFLD, rs1260326 with NAFLD in 
Indian, rs780094 with NAFLD in Indian, rs1260326 with NASH, rs780094 with NASH, 
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rs1260326 with NASH with significant fibrosis, rs780094 with NASH with significant 
fibrosis, respectively.  
GCKR polymorphisms confer risk of type 2 diabetes. Adjustment of type 2 
diabetes however did not affect the significant results (OR 1.47, 95% CI 1.05–2.08, P = 
0.027 and OR 1.70, 95% CI 1.21–2.38, P = 0.002, for rs1260326 and rs780094, 
respectively). 
 
Table 4.14   Association tests of GCKR polymorphisms in different NAFLD spectrum 
NAFLD spectrum rs1260326 
 
rs780094 
 
G allele 
frequency 
P value OR (CI) 
 
G alelle 
frequency 
P value OR (CI) 
Control as reference         
 
    
NAFLD vs. control        
   Overall 0.47 vs 0.37 0.012 1.49 (1.09-2.05) 
 
0.46 vs. 0.35 0.013 1.51 (1.09-2.09) 
   Malays 0.47 vs 0.43 0.466 1.20 (0.74-1.95) 
 
0.46 vs. 0.42 0.497 1.19 (0.72-1.98) 
   Chinese 0.53 vs 0.44 0.501 1.20 (0.71-2.04) 
 
0.44 vs. 0.44 0.893 1.04 (0.61-1.76) 
   Indians 0.37 vs 0.19 0.009 2.64 (1.28-5.43) 
 
0.45 vs. 0.20 < 0.0001 4.35 (1.93-9.81) 
Simple steatosis vs. control 0.45 vs 0.37 0.276 1.35 (0.79-2.29) 
 
0.45 vs. 0.35 0.162 1.48 (0.86-2.54) 
All NASH vs. control 0.49 vs 0.37 0.013 1.55 (1.10-2.17) 
 
0.47 vs. 0.35 0.012 1.56 (1.10-2.22) 
   NASHa vs. control 0.51 vs 0.37 0.051 1.68 (0.99-2.82) 
 
0.49 vs. 0.35 0.080 1.60 (0.95-2.71) 
   NASHb vs. control 0.46 vs 0.37 0.044 1.49 (1.01-2.21) 
 
0.45 vs.0.35 0.038 1.52 (1.03-2.26) 
Simple steatosis as reference 
    
 
  All NASH vs. simple steatosis 0.49 vs 0.45 0.720 1.11 (0.64-1.91) 
 
0.47 vs 0.45 0.840 1.04 (0.57-1.83) 
   NASHa vs. simple steatosis 0.51 vs. 0.45 0.452 1.30 (0.66-2.58) 
 
0.49 vs. 0.45 0.640 1.19 (0.58-2.46) 
   NASHb vs. simple steatosis 0.46 vs. 0.45 0.810 1.07 (0.61-1.89) 
 
0.45 vs 0.45 0.908 0.97 (0.53-1.77) 
NASHa as reference 
    
 
  
   NASHb vs NASHa 0.46 vs. 0.51 0.506 0.82 (0.46-1.47) 
 
0.49 vs 0.45 0.579 0.84 (0.46-1.54) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease, NASH non-alcoholic steatohepatitis, NASHa non-
alcoholic steatohepatitis without significant fibrosis; NASHb non-alcoholic steatohepatitis with significant fibrosis 
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4.2.4.2     GCKR polymorphisms and liver histology 
 
None of the NAFLD-associated parameters were different among the genotypes of 
GCKR rs1260326 and rs780094. However, comparison of histological attributes among 
the genotypes revealed a significantly higher score of hepatic steatosis in patients 
homozygous for the T allele (homozygous TT compared to homozygous CC, had a 
mean score of 2.18 vs 1.63, P = 0.008) (Table 4.15). Both univariate and multivariate 
analysis were applied in order to determine the magnitude of effect of the risk allele T 
with the NAFLD histological features (Table 4.16). Carrier of allele T exhibited 1.76 
risk to develop hepatic steatosis than the non-carrier (OR  1.76,  95% CI  1.08–2.85, P = 
0.004) and this significant finding remained after adjustment with other histological 
features (P = 0.04). This significant finding however was not seen with lobular 
inflammation, hepatocellular ballooning and fibrosis. 
 
Table 4.15   Comparison of various clinical and histological parameters between the 
GCKR rs1260326 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 41) CT (n = 70) TT (n = 33) P value 
Age (years)  50.8 ± 12.5 51.8 ± 11.5 50.0 ± 12.8 0.774 
BMI (kg/m2)  28.8 ± 4.2 28.9 ± 4.6 28.0 ± 4.2 0.597 
HbA1c (%)*  7.0 ± 1.9 6.4 ± 1.6 6.4 ± 1.4 0.136 
Waist circumference (cm)  95.1 ± 10.1 93.6 ± 11.3 92.7 ± 11.1 0.626 
HDL cholesterol (mg/dl)  49.4 ± 13.1 47.6 ± 12.6 49.3 ± 12.8 0.714 
LDL cholesterol (mg/dl)  113.6 ± 34.0 122.3 ± 44.4 110.6 ± 36.6 0.309 
Total cholesterol (mg/dl)  194.8 ± 40.3 199.2 ± 48.2 193.9 ± 39.6 0.802 
Triglycerides (mg/dl)  169.2 ± 77.8 145.8 ± 54.0 157.0 ± 57.1 0.160 
AST (IU/L)*  38.3 ± 21.7 43.8 ± 26.0 46.9 ± 28.0 0.518 
ALT (IU/L)  74.7 ± 36.2 84.5 ± 52.0 90.4 ± 53.8 0.365 
GGT (IU/L)*  88.1 ± 70.7 132.8 ± 143.8 96.0 ± 82.7 0.222 
Systolic BP (mmHg)  133.9 ± 14.8 132.4 ± 14.3 126.9 ± 16.2 0.109 
Diastolic BP (mmHg)*  83.0 ± 10.7 82.6 ± 9.5 81.9 ± 9.8 0.775 
Steatosis grade*  1.6 ± 0.7 1.7 ± 0.7 2.2 ± 0.8 0.008 
Lobular inflammation*  1.4 ± 0.5 1.2 ± 0.6 1.4 ± 0.6 0.086 
Ballooning*  1.2 ± 0.7 1.2 ± 0.5 1.3 ± 0.7 0.672 
Fibrosis*  1.8 ± 1.0 1.7 ± 1.0 1.6 ± 0.9 0.570 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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Table 4.16   Association of GCKR rs1260326 T allele with histological features among 
NAFLD patients 
 Histology Univariate 
P valuea 
multivariate p-valueb 
(FDR q-valueg) 
OR (95% CI) 
Steatosis 
     > 33% vs. < 33% 0. 004 0.040 (0.016) 1.76 (1.08-2.85)c 
Lobular inflammation 
     ≥ 2 foci vs. < 2 foci 0. 750 0.639 (0.750) 1.18 (0.73-1.91)d 
Hepatocellular ballooning 
     ≥ 1 vs. < 1 0. 739 0.281 (0.985) 1.05 (0.47-2.33)e 
Fibrosis 
     ≥ 2 vs. < 2 0. 414 0.859 (0.828) 0.81 (0.51-1.29)f 
 
OR, odds ratio; CI, confident interval 
aJonckheere-Terpstra test 
bOrdinal regression 
c, d, e, fMultivariate logistic regression 
gFalse discovery rate, q < 0.05 is significant 
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4.2.5     Single nucleotide polymorphism: iNOS 
 
A SNP of iNOS gene rs1060822 T/C was genotyped in this study. The rs1060822 is 
located in the coding region on chromosome 17. The rs1060822 is a synonymous 
coding SNP where different alleles encode for the same amino acid glycine. Table 4.17 
shows the association test between NAFLD and control subjects with NAFLD. No 
allelic association with NAFLD was observed (OR 0.96, 95% CI 0.61-1.50, P = 0.839). 
The genotypes deviated from Hardy-Weinberg equilibrium and thus analysis by 
ethnicity stratification and by comparison of parameters among the genotypes did not 
proceed further. 
 
Table 4.17   Allelic association of iNOS polymorphism  
SNP C allele frequency P value OR (CI) 
rs1060822 (T > C)    
NAFLD vs. control 0.76 vs. 0.77 0.839 0.96 (0.61-1.50) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
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4.2.6     Single nucleotide polymorphism: TRAIL  
 
A SNP of TRAIL gene rs1131568 A/G was genotyped in this study. The rs1131568 is an 
untranslated-3 SNP, located in the non-coding region on chromosome 3. Table 4.18 
shows the association test between NAFLD and control subjects with NAFLD. The 
genotypes were in Hardy-Weinberg equilibrium. No allelic association with NAFLD 
was observed in the pooled subjects (OR 1.05, 95% CI 0.76-1.65, P = 0.760) nor after 
stratification by ethnicity (OR 0.99, 95% CI  0.76-2.55, P = 0.955; OR 1.39, 95% CI  
0.46-1.48, P = 0.286; and OR 0.91, 95% CI  0.49-1.69, P = 0.766, for Malay, Chinese 
and Indian, respectively).  
 
Table 4.18   Allelic association of TRAIL polymorphism 
SNP G allele frequency P value OR (CI) 
rs1131568 (A > G)    
NAFLD vs. control    
   Overall 0.69 vs. 0.67 0.760 1.05 (0.76-1.65) 
   Malays 0.72 vs. 0.72 0.955 0.99 (0.76-2.55) 
   Chinese 0.68 vs. 0.72 0.286 1.39 (0.46-1.48) 
   Indians 0.65 vs. 0.66 0.766 0.91 (0.49-1.69) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of parameters between the TRAIL rs1131568 genotypes 
among NAFLD patients is shown in Table 4.19. Only diastolic blood pressure is 
different among the genotypes where the highest is observed in those with GG genotype 
(P = 0.033). 
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Table 4.19   Comparison of various clinical and histological parameters between the 
TRAIL rs1131568 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 19) CG (n = 52) GG (n = 73) P value 
Age (years)  45.9 ± 12.7 51.5 ± 12.0 51.9± 11.5 0.151 
BMI (kg/m2)  29.1 ± 5.2 27.7 ± 3.7 29.3 ± 4.6 0.130 
HbA1c (%)*  6.3 ± 1.6 6.4 ± 1.7 6.8 ± 1.6 0.133 
Waist circumference (cm)  91.8 ± 11.6 91.9 ± 9.8 95.6 ± 11.1 0.115 
HDL cholesterol (mg/dl)  44.4 ± 8.5 48.7 ± 14.0 49.9 ± 12.6 0.259 
LDL cholesterol (mg/dl)  122.1 ± 36.7 117.5 ± 43.7 113.5 ± 35.7 0.667 
Total cholesterol (mg/dl)  197.6 ± 45.0 197.4 ± 49.3 194.6 ± 38.3 0.908 
Triglycerides (mg/dl)  150.3 ± 83.5 165.4 ± 60.5 148.8 ± 57.9 0.314 
AST (IU/L)*  41.7 ± 26.9 40.1 ± 19.4 45.5 ± 29.1 0.887 
ALT (IU/L)  80.9 ± 46.8 83.2 ± 48.0 83.6 ± 50.9 0.978 
GGT (IU/L)*  89.8 ± 84.6 124.9 ± 130.0 108.8 ± 113.5 0.696 
Systolic BP (mmHg)  129.9 ± 20.8 130.4 ± 13.9 132.2 ± 14.3 0.752 
Diastolic BP (mmHg)*  80.7 ± 14.2 80.4 ± 8.0 84.5 ± 9.7 0.033 
Steatosis grade*  1.9 ± 0.7 1.8 ± 0.8 1.8 ± 0.8 0.698 
Lobular inflammation*  1.5 ± 0.5 1.4 ± 0.5 1.2 ± 0.6 0.176 
Ballooning*  1.3 ± 0.5 1.2 ± 0.6 1.2 ± 0.6 0.698 
Fibrosis*  1.9 ± 1.0 1.7 ± 0.9 1.7 ± 1.0 0.637 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.7     Single nucleotide polymorphism: SREBF1  
 
A total of two SNPs of SREBF1 gene rs1186803 G/A and rs2297508 C/G were 
genotyped in this study. Both are untranslated-3 SNPs, located in the non-coding region 
on chromosome 13. Table 4.20 shows the association test between NAFLD and control 
subjects with NAFLD. The genotypes were in Hardy-Weinberg equilibrium. No allelic 
association with NAFLD was observed for rs1186803 (P > 0.05). However, there is a 
difference between cases and controls in the Indian for rs2297508 (OR 3.56, 95% CI 
1.41-7.98, P = 0.007). 
 
Table 4.20   Allelic association of SREBF1 polymorphisms  
SNP Risk allele frequency P value OR (CI) 
rs1186803 (G > A)    
NAFLD vs. control    
   Overall 0.77 vs. 0.78 0.847 0.96 (0.66-1.41) 
   Malays 0.73 vs. 0.82 0.097 0.61 (0.34-1.10) 
   Chinese 0.81 vs. 0.75 0.341 1.40 (0.70-2.81) 
   Indians 0.84 vs. 0.76 0.263 1.51 (0.76-3.04) 
rs2297508 (C > G)    
NAFLD vs. control    
   Overall 0.78 vs. 0.77 0.375 1.19 (0.81-1.75) 
   Malays 0.73 vs. 0.81 0.108 0.61 (0.34-1.11) 
   Chinese 0.81 vs. 0.75 0.341 1.40 (0.70-2.81) 
   Indians 0.89 vs. 0.79 0.007 3.56 (1.41-7.98) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of parameters between the  genotypes among NAFLD 
patients was therefore performed in the SREBF1 rs2297508 (Table 4.21). Diastolic 
blood pressure and GGT were found higher in the CC genotype (P < 0.05). A marginal 
association was found in the systolic blood pressure (P = 0.05). 
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Table 4.21   Comparison of various clinical and histological parameters between the 
SREBF1 rs2297508 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 5) CG (n = 54) GG (n = 85) P value 
Age (years)  45.7 ± 10.6 51.1 ± 12.1 51.3 ± 11.5 0.538 
BMI (kg/m2)  30.1 ± 5.2 28.7 ± 4.8 28.5 ± 4.1 0.633 
HbA1c (%)*  6.1 ± 0.7 7.0 ± 2.1 6.4 ± 1.3 0.612 
Waist circumference (cm)  94.4 ± 11.6 94.8 ± 10.8 95.0 ± 11.0 0.641 
HDL cholesterol (mg/dl)  56.1 ± 20.5 46.7 ± 10.1 49.2 ± 13.3 0.189 
LDL cholesterol (mg/dl)  134.9 ± 61.7 120.5 ± 38.2 112.1 ± 37.1 0.233 
Total cholesterol (mg/dl)  224.6 ± 67.0 198.3 ± 45.4 192.8 ± 34.5 0.183 
Triglycerides (mg/dl)  158.2 ± 74.3 163.2 ± 68.2 149.5 ± 56.0 0.465 
AST (IU/L)*  57.2 ± 16.9 40.9 ± 26.2 43.4 ± 25.5 0.085 
ALT (IU/L)  121.5 ± 44.7 76.2 ± 50.4 84.5 ± 47.5 0.094 
GGT (IU/L)*  240.8 ± 164.6 86.8 ± 70.7 119.0 ± 129.5 0.039 
Systolic BP (mmHg)  142.5 ± 12.5 133.3 ± 13.9 129.2 ± 14.1 0.050 
Diastolic BP (mmHg)*  92.7 ± 6.9 82.4 ± 8.9 81.9 ± 10.0 0.031 
Steatosis grade*  1.9 ± 0.7 1.8 ± 0.8 1.8 ± 0.8 0.642 
Lobular inflammation*  1.3 ± 0.8 1.4 ± 0.6 1.4 ± 0.6 0.726 
Ballooning*  1.0 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 0.419 
Fibrosis*  1.7 ± 1.0 1.8 ±1.1 1.7 ± 0.9 0.967 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.8     Single nucleotide polymorphism: CLOCK 
 
A total of four SNPs of CLOCK gene rs1193259 A/G, rs4864548 G/A, rs6843722 A/C 
and rs6850524 G/C were genotyped in this study. The rs4864548 is a non-coding SNP, 
located in the locus region near-gene-5 on chromosome 4. The following SNPs 
rs1193259, rs6843722 and rs6850524 are in the intronic regions on chromosome 4. 
Table 4.22 shows the association test between NAFLD and control subjects with 
NAFLD. The genotypes were in Hardy-Weinberg equilibrium. No allelic association 
with NAFLD was observed for all four SNPs in the pooled (p > 0.05) nor after 
stratification by ethnicity (P > 0.05).  
 
Table 4.22   Allelic association of CLOCK polymorphisms  
SNP Risk allele frequency P value OR (CI) 
rs1193259 (A > G)    
NAFLD vs. control    
   Overall 0.19 vs. 0.20 0.920 0.98 (0.67-1.44) 
   Malays 0.19 vs. 0.11 0.098 1.75 (0.90-3.41) 
   Chinese 0.08 vs. 0.15 0.114 0.48 (0.19-1.20) 
   Indians 0.37 vs. 0.36 0.880 1.05 (0.57-1.93) 
rs4864548 (G > A)    
NAFLD vs. control    
   Overall 0.60 vs. 0.57 0.928 1.02 (0.74-1.39) 
   Malays 0.58 vs. 0.63 0.446 0.83 (0.52-1.34) 
   Chinese 0.62 vs. 0.61 0.882 1.05 (0.62-1.86) 
   Indians 0.56 vs. 0.51 0.451 1.27 (0.68-2.39) 
rs6843722 (A > C)    
NAFLD vs. control    
   Overall 0.58 vs. 0.57 0.966 0.99 (0.73-1.35) 
   Malays 0.56 vs. 0.58 0.409 0.82 (0.51-1.31) 
   Chinese 0.62 vs. 0.60 0.885 1.04 (0.59-1.84) 
   Indians 0.53 vs. 0.49 0.603 1.18 (0.64-2.17) 
rs6850524 (G > C)    
NAFLD vs. control    
   Overall 0.30 vs. 0.29 0.670 1.07 (0.77-1.49) 
   Malays 0.33 vs. 0.29 0.464 1.17 (0.71-1.94) 
   Chinese 0.29 vs. 0.25 0.540 1.16 (0.65-2.07) 
   Indians 0.24 vs. 0.30 0.425 0.75 (0.37-1.51) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
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Although none of the SNPs showed significance, lowest P-value was recorded 
by CLOCK rs6850524. The clinical and histological parameters were compared 
between genotypes of this SNP among NAFLD patients (Table 4.23). No parameters 
were significantly different among the genotypes (P > 0.05). 
 
Table 4.23   Comparison of various clinical and histological parameters between the 
CLOCK rs6850524 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  GG (n = 72) GC (n = 56) CC (n = 16) P value 
Age (years)  49.9 ± 11.3 51.9 ± 12.8 53.9 ± 12.3 0.407 
BMI (kg/m2)  29.3 ± 4.4 28.7 ± 4.3 28.1 ± 4.1 0.332 
HbA1c (%)*  6.7 ± 1.8 6.4 ± 1.5 6.4 ± 1.4 0.769 
Waist circumference (cm)  95.3 ± 11.2 93.3 ± 10.5 89.9 ± 10.4 0.192 
HDL cholesterol (mg/dl)  47.8 ± 10.6 47.5 ± 12.7 55.2 ± 18.4 0.189 
LDL cholesterol (mg/dl)  117.1 ± 44.0 117.9 ± 35.2 114.1 ± 37.6 0.233 
Total cholesterol (mg/dl)  196.9 ± 45.6 195.3 ± 41.4 200.2 ± 48.5 0.183 
Triglycerides (mg/dl)  150.0 ± 59.6 158.2 ± 67.7 165.0 ± 59.4 0.465 
AST (IU/L)*  42.0 ± 25.8 43.5 ± 24.2 44.9 ± 26.5 0.815 
ALT (IU/L)  79.8 ± 44.7 86.5 ± 51.2 85.5 ± 52.2 0.727 
GGT (IU/L)*  95.3 ± 90.9 119.0 ± 129.1 159.0 ± 152.0 0.701 
Systolic BP (mmHg)  133.5 ± 16.0 128.3 ± 15.0 132.2 ± 10.2 0.177 
Diastolic BP (mmHg)*  83.7 ± 10.5 80.9 ± 8.9 83.1 ± 10.0 0.386 
Steatosis grade*  1.8 ± 0.8 1.9 ± 0.8 1.8 ± 0.9 0.814 
Lobular inflammation*  1.3 ± 0.6 1.3 ± 0.6 1.4 ± 0.5 0.788 
Ballooning*  1.3 ± 0.6 1.1 ± 0.6 1.0 ± 0.6 0.094 
Fibrosis*  1.9 ± 1.0 1.6 ± 0.9 1.6 ± 0.9 0.215 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.9     Single nucleotide polymorphism: COL13A1 
 
A SNP of COL13A1 gene rs1227756 G/A was genotyped in this study. The rs1227756 
is a non-coding SNP, located in the intronic region on chromosome 10. Table 4.24 
shows the association test between NAFLD and control subjects with NAFLD. No 
allelic association with NAFLD was observed (OR 0.80, 95% CI 0.58-1.09, P = 0.159). 
The genotypes deviated from Hardy-Weinberg equilibrium and thus analysis by ethnic 
stratification and by comparison of parameters among the genotypes did not proceed 
further. 
 
Table 4.24   Allelic association of COL13A1 polymorphism  
SNP A allele frequency P value OR (CI) 
rs1227756 (G > A)    
NAFLD vs. control 0.29 vs. 0.35 0.159 0.80 (0.58-1.09) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
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4.2.10     Single nucleotide polymorphism: FABP2 
 
A SNP of FABP2 gene rs1799883 A/G was genotyped in this study. The polymorphism 
of rs1799883 is a missense mutation, substituting the amino acid threonine to alanine. 
The rs1799883 is located on chromosome 10. Table 4.25 shows the association test 
between NAFLD and control subjects with NAFLD. The genotypes were in Hardy-
Weinberg equilibrium. No allelic association with NAFLD was observed in the pooled 
subjects (OR 1.14, 95% CI 0.84-1.77, P = 0.296) nor after stratification by ethnicity 
(OR 1.27, 95% CI  0.80-2.52, P = 0.216; OR 1.70, 95% CI  0.91-3.18, P = 0.096; and 
OR 0.87, 95% CI  0.47-1.63, P = 0.661, for Malay, Chinese and Indian, respectively).  
 
Table 4.25   Allelic association of FABP2 polymorphism 
SNP G allele frequency P value OR (CI) 
rs1799883 (A > G)    
NAFLD vs. control    
   Overall 0.81 vs. 0.77 0.296 1.14 (0.84-1.77) 
   Malays 0.85 vs. 0.83 0.216 1.27 (0.80-2.52) 
   Chinese 0.81 vs. 0.71 0.096 1.70 (0.91-3.18) 
   Indians 0.71 vs. 0.74 0.661 0.87 (0.47-1.63) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
FABP2 rs1799883 genotypes among NAFLD patients is shown in Table 4.26. None of 
the parameters were different between the genotypes (P > 0.05).  
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Table 4.26   Comparison of various clinical and histological parameters between the 
FABP2 rs1799883 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 8) AG (n = 40) GG (n = 96) P value 
Age (years)  49.5 ± 9.5 54.9 ± 10.3 49.5 ± 12.3 0.060 
BMI (kg/m2)  26.6 ± 2.8 28.8 ± 4.9 28.8 ± 4.3 0.402 
HbA1c (%)*  5.8 ± 0.8 6.4 ± 1.5 6.7 ± 1.7 0.140 
Waist circumference (cm)  88.3 ± 6.3 92.3 ± 12.6 94.6 ± 10.2 0.235 
HDL cholesterol (mg/dl)  49.2 ± 13.8 49.8 ± 14.4 48.1 ± 11.9 0.780 
LDL cholesterol (mg/dl)  117.9 ± 31.2 125.0 ± 39.4 112.1 ± 38.9 0.238 
Total cholesterol (mg/dl)  195.5 ± 43.1 207.3 ± 40.8 191.2 ± 43.8 0.151 
Triglycerides (mg/dl)  135.0 ± 77.7 158.6 ± 63.2 155.1 ± 61.3 0.625 
AST (IU/L)*  34.1 ± 15.2 39.3 ± 20.9 45.3 ± 27.7 0.491 
ALT (IU/L)  71.6 ± 32.4 77.5 ± 43.2 86.3 ± 52.2 0.509 
GGT (IU/L)*  62.9 ± 32.1 118.8 ± 131.1 113.8 ± 114.8 0.640 
Systolic BP (mmHg)  130.6 ± 10.2 131.1 ± 15.6 131.4 ± 15.2 0.988 
Diastolic BP (mmHg)*  81.7 ± 6.5 82.0 ± 10.5 82.8 ± 10.0 0.758 
Steatosis grade*  1.8 ± 0.7 1.7 ± 0.7 1.9 ± 0.8 0.418 
Lobular inflammation*  1.8 ± 0.5 1.3 ± 0.6 1.3 ± 0.6 0.067 
Ballooning*  1.5 ± 0.5 1.1 ± 0.6 1.2 ± 0.6 0.209 
Fibrosis*  2.1 ± 0.4 1.7 ± 1.0 1.7 ± 1.0 0.213 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.11     Single nucleotide polymorphism: UCP3 
 
A SNP of UCP3 gene rs1800849 C/T was genotyped in this study. The rs1800849 is an 
untranslated-5 SNP, located in the non-coding region on chromosome 11. Table 4.27 
shows the association test between NAFLD and control subjects with NAFLD. The 
genotypes were in Hardy-Weinberg equilibrium. No allelic association with NAFLD 
was observed in the pooled subjects (OR 1.33, 95% CI 0.94-1.90, P = 0.109) nor after 
stratification by ethnicity (OR 1.57, 95% CI  0.94-2.64, P = 0.086; OR 1.61, 95% CI  
0.84-3.08, P = 0.149; and OR 0.67, 95% CI  0.31-1.46, P = 0.352, for Malay, Chinese 
and Indian, respectively).  
 
Table 4.27   Allelic association of UCP3 polymorphism 
SNP T allele frequency P value OR (CI) 
rs1800849 (C > T)    
NAFLD vs. control    
   Overall 0.30 vs. 0.24 0.109 1.33 (0.94-1.90) 
   Malays 0.34 vs. 0.24 0.086 1.57 (0.94-2.64) 
   Chinese 0.31 vs. 0.23 0.149 1.61 (0.84-3.08) 
   Indians 0.20 vs. 0.26 0.352 0.67 (0.31-1.46) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
UCP3 rs1800849 genotypes among NAFLD patients is shown in Table 4.28. None of 
the parameters were different between the genotypes (P > 0.05).  
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Table 4.28   Comparison of various clinical and histological parameters between the 
UCP3 rs1800849 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 69) CT (n = 62) TT (n = 13) P value 
Age (years)  50.6 ± 11.6 51.3 ± 12.1 51.6 ± 13.9 0.925 
BMI (kg/m2)  28.6 ± 4.7 28.3 ± 3.7 30.7 ± 5.3 0.224 
HbA1c (%)*  6.4 ± 1.5 6.7 ± 1.7 7.1 ± 2.1 0.543 
Waist circumference (cm)  93.3 ± 11.6 93.4 ± 9.4 96.8 ± 13.2 0.606 
HDL cholesterol (mg/dl)  49.4 ± 13.6 47.5 ± 12.3 49.8 ± 8.3 0.780 
LDL cholesterol (mg/dl)  116.5 ± 40.2 116.3 ± 37.5 112.1 ± 40.3 0.238 
Total cholesterol (mg/dl)  195.5 ± 42.5 195.6 ± 44.7 198.9 ± 44.2 0.151 
Triglycerides (mg/dl)  150.4 ± 64.0 153.6 ± 57.2 188.6 ± 73.9 0.625 
AST (IU/L)*  41.4 ± 26.4 43.4 ± 20.7 51.0 ± 40.4 0.298 
ALT (IU/L)  78.5 ± 50.9 87.8 ± 46.2 86.3 ± 52.7 0.548 
GGT (IU/L)*  104.6 ± 109.6 119.5 ± 117.9 120.6 ± 153.2 0.569 
Systolic BP (mmHg)  129.4 ± 14.8 132.3 ± 14.9 136.5 ± 16.2 0.244 
Diastolic BP (mmHg)*  83.0 ± 9.9 81.2 ± 9.5 86.4 ± 13.3 0.327 
Steatosis grade*  1.7 ± 0.7 1.8 ± 0.8 2.3 ± 0.9 0.129 
Lobular inflammation*  1.3 ± 0.6 1.4 ± 0.6 1.3 ± 0.5 0.563 
Ballooning*  1.2 ± 0.6 1.2 ± 0.6 1.3 ± 0.5 0.909 
Fibrosis*  1.6 ± 0.9 1.8 ± 1.1 1.8 ± 1.0 0.568 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease  
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4.2.12     Single nucleotide polymorphism: PPARG 
 
A SNP of PPARG gene rs1801282 C/G was genotyped in this study. The polymorphism 
of rs1801282 is a missense mutation, substituting the amino acid proline to alanine. The 
rs1801282 is located on chromosome 3. Table 4.29 shows the association test between 
NAFLD and control subjects with NAFLD. The genotypes were in Hardy-Weinberg 
equilibrium. No allelic association with NAFLD was observed in the pooled subjects 
(OR 1.02, 95% CI  0.52-1.99, P = 0.966) nor after stratification by ethnicity (OR 1.73, 
95% CI  0.50-5.97, P = 0.385; OR 3.12, 95% CI  0.31-11.00, P = 0.331; and OR 0.80, 
95% CI  0.30-2.08, P = 0.642, for Malay, Chinese and Indian, respectively).  
 
Table 4.29   Allelic association of PPARG polymorphism 
SNP G allele frequency P value OR (CI) 
rs1801282 (C > G)    
NAFLD vs. control    
   Overall 0.06 vs. 0.06 0.966 1.02 (0.52-1.99) 
   Malays 0.05 vs. 0.03 0.385 1.73 (0.50-5.97) 
   Chinese 0.03 vs. 0.01 0.331 3.12 (0.31-11.00) 
   Indians 0.12 vs. 0.14 0.642 0.80 (0.30-2.08) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
PPARG rs1801282 genotypes among NAFLD patients is shown in Table 4.30. 
Ballooning score was found different between the genotypes (P = 0.040). 
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Table 4.30   Comparison of various clinical and histological parameters between the 
PPARG rs1801282 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 128) CG (n = 16) GG (n = 0) P value 
Age (years)  50.7 ± 12.1 53.4 ± 10.8 - 0.392 
BMI (kg/m2)  28.7 ± 4.5 28.6 ± 3.5 - 0.938 
HbA1c (%)*  6.6 ± 1.7 6.4 ± 1.2 - 0.979 
Waist circumference (cm)  93.6 ± 11.0 95.1 ± 9.3 - 0.609 
HDL cholesterol (mg/dl)  48.7 ± 13.0 48.1 ± 10.2 - 0.866 
LDL cholesterol (mg/dl)  115.5 ± 38.2 121.3 ± 42.7 - 0.564 
Total cholesterol (mg/dl)  195.1 ± 43.5 201.7 ± 42.4 - 0.563 
Triglycerides (mg/dl)  156.4 ± 64.9 144.4 ± 38.2 - 0.475 
AST (IU/L)*  43.1 ± 26.3 42.7 ± 19.7 - 0.687 
ALT (IU/L)  84.1 ± 50.9 75.6 ± 30.2 - 0.519 
GGT (IU/L)*  113.2 ± 121.0 105.5 ± 76.7 - 0.507 
Systolic BP (mmHg)  131.0 ± 15.0 133.3 ± 15.3 - 0.548 
Diastolic BP (mmHg)*  82.5 ± 10.1 83.2 ± 9.1 - 0.940 
Steatosis grade*  1.8 ± 0.8 1.6 ± 0.7 - 0.326 
Lobular inflammation*  1.3 ± 0.6 1.1 ± 0.6 - 0.228 
Ballooning*  1.3 ± 0.6 0.9 ± 0.4 - 0.040 
Fibrosis*  1.8 ± 0.9 1.4 ± 1.2 - 0.119 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.13     Single nucleotide polymorphism: COX-2 
 
A SNP of COX-2 gene rs20417 G/C was genotyped in this study. The rs20417 is a non-
coding SNP, located in the locus region near-gene-5 on chromosome 1. Table 4.31 
shows the association test between NAFLD and control subjects with NAFLD. No 
allelic association with NAFLD was observed (OR 0.62, 95% CI 0.28-1.38, P = 0.245). 
The genotypes deviated from Hardy-Weinberg equilibrium and thus analysis by ethnic 
stratification and by comparison of parameters among the genotypes did not proceed 
further. 
 
Table 4.31   Allelic association of COX-2 polymorphism  
SNP C allele frequency P value OR (CI) 
rs20417 (G > C)    
NAFLD vs. control 0.01 vs. 0.04 0.245 0.62 (0.28-1.38) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
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4.2.14     Single nucleotide polymorphism: NR1I2 
 
A total of two SNPs of NR1I2 gene rs2461823 A/G and rs7643645 A/G were genotyped 
in this study. Both are non-coding SNPs, located in the intronic regions on chromosome 
3. Table 4.32 shows the association test between NAFLD and control subjects with 
NAFLD. The genotypes were in Hardy-Weinberg equilibrium. No allelic association 
with NAFLD was observed for both SNPs in the pooled subjects (P > 0.05) nor after 
stratification by ethnicity (P > 0.05). 
 
Table 4.32   Allelic association of NR1I2 polymorphisms  
SNP G allele frequency P value OR (CI) 
rs2461823 (A > G)    
NAFLD vs. control    
   Overall 0.74 vs. 0.60 0.291 1.18 (0.87-1.61) 
   Malays 0.65 vs. 0.65 0.986 1.01 (0.60-1.67) 
   Chinese 0.65 vs. 0.57 0.226 1.41 (0.81-2.44) 
   Indians 0.63 vs. 0.57 0.477 1.23 (0.69-2.20) 
rs7643645 (A > G)    
NAFLD vs. control    
   Overall 0.43 vs. 0.45 0.201 0.84 (0.65-1.10) 
   Malays 0.43 vs. 0.47 0.509 0.86 (0.55-1.35) 
   Chinese 0.44 vs. 0.43 0.896 1.04 (0.62-1.72) 
   Indians 0.44 vs. 0.43 0.945 1.02 (0.58-1.79) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
Analysis of comparison of clinical and histological parameters between the 
NR1I2 rs2461823 genotypes among NAFLD patients is shown in Table 4.33. None of 
the parameters were different between the genotypes (P > 0.05).  
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Table 4.33   Comparison of various clinical and histological parameters between the 
NR1I2 rs2461823 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 18) AG (n = 69) GG (n = 57) P value 
Age (years)  51.9 ± 13.6 50.5 ± 11.0 51.6 ± 12.8 0.835 
BMI (kg/m2)  29.1 ± 4.1 28.9 ± 4.9 28.2 ± 3.8 0.602 
HbA1c (%)*  6.6 ± 1.6 6.5 ± 1.6 6.6 ± 1.8 0.934 
Waist circumference (cm)  95.7 ± 11.6 93.3 ± 11.7 93.9 ± 9.7 0.723 
HDL cholesterol (mg/dl)  50.0 ± 14.2 48.1 ± 12.2 48.6 ± 13.0 0.852 
LDL cholesterol (mg/dl)  117.4 ± 39.6 116.4 ± 42.4 117.9 ± 37.8 0.976 
Total cholesterol (mg/dl)  193.3 ± 39.5 198.4 ± 46.1 195.9 ± 43.3 0.888 
Triglycerides (mg/dl)  141.4 ± 41.6 156.6 ± 67.1 157.4 ± 63.1 0.621 
AST (IU/L)*  35.4 ± 23.5 46.4 ± 26.0 41.0 ± 24.8 0.104 
ALT (IU/L)  67.2 ± 51.8 85.8 ± 43.0 84.3 ± 53.4 0.333 
GGT (IU/L)*  86.4 ± 72.1 129.8 ± 135.8 97.6 ± 96.3 0.408 
Systolic BP (mmHg)  134.5 ± 16.8 129.5 ± 13.5 133.5 ± 16.1 0.264 
Diastolic BP (mmHg)*  82.3 ± 10.6 81.9 ± 8.8 83.3 ± 10.9 0.724 
Steatosis grade*  1.4 ± 0.6 1.9 ± 0.8 1.8 ± 0.8 0.094 
Lobular inflammation*  1.3 ± 0.6 1.3 ± 0.6 1.3 ± 0.6 0.857 
Ballooning*  1.2 ± 0.6 1.3 ± 0.6 1.2 ± 0.5 0.909 
Fibrosis*  2.0 ± 1.2 1.7 ± 1.0 1.6 ± 0.9 0.569 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.15     Single nucleotide polymorphism: KLF6 
 
A SNP of KLF6 gene rs3750861 C/T was genotyped in this study. The rs3750861 is a 
non-coding SNP, located in the intronic region on chromosome 10. Table 4.34 shows 
the association test between NAFLD and control subjects with NAFLD. The genotypes 
were in Hardy-Weinberg equilibrium. No allelic association with NAFLD was observed 
in the pooled subjects (OR 1.09, 95% CI 0.61-1.96, P = 0.778) nor after stratification by 
ethnicity (OR 1.36, 95% CI  0.58-3.20, P = 0.485; OR 1.33, 95% CI  0.28-6.27, P = 
0.716; and OR 0.98, 95% CI  0.36-2.72, P = 0.974, for Malay, Chinese and Indian, 
respectively). 
 
Table 4.34   Allelic association of KLF6 polymorphism 
SNP T allele frequency P value OR (CI) 
rs3750861 (C > T)    
NAFLD vs. control    
   Overall 0.07 vs. 0.07 0.778 1.09 (0.61-1.96) 
   Malays 0.09 vs. 0.06 0.485 1.36 (0.58-3.20) 
   Chinese 0.04 vs. 0.03 0.716 1.33 (0.28-6.27) 
   Indians 0.10 vs. 0.10 0.974 0.98 (0.36-2.72) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
Analysis of comparison of clinical and histological parameters between the 
KLF6 rs3750861 genotypes among NAFLD patients is shown in Table 4.35. Systolic 
blood pressure was different between the genotypes in which the highest was in those 
with TT genotype (P = 0.004). 
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Table 4.35   Comparison of various clinical and histological parameters between the 
KLF6 rs3750861 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 126) CT (n = 16) TT (n = 2) P value 
Age (years)  50.98 ± 12.2 52.5 ± 11.5 59.0 ± 7.1 0.572 
BMI (kg/m2)  28.7 ± 4.4 27.7 ± 3.7 34.8 ± 4.0 0.602 
HbA1c (%)*  6.6 ± 1.7 6.2 ± 1.1 6.5 ± 0.6 0.890 
Waist circumference (cm)  93.8 ± 11.2 92.4 ± 8.2 104.5 ± 4.9 0.336 
HDL cholesterol (mg/dl)  48.7 ± 12.4 46.1 ± 15.7 53.6 ± 8.5 0.606 
LDL cholesterol (mg/dl)  116.7 ± 39.6 118.5 ± 44.9 135.3 ± 24.8 0.800 
Total cholesterol (mg/dl)  196.5 ± 44.4 196.4 ± 43.7 212.4 ± 32.8 0.881 
Triglycerides (mg/dl)  155.7 ± 63.4 152.9 ± 61.6 127.0 ± 11.9 0.807 
AST (IU/L)*  42.9 ± 25.4 45.1 ± 27.0 25.5 ± 7.8 0.488 
ALT (IU/L)  82.7 ± 47.2 89.8 ± 60.5 51.0 ± 1.4 0.553 
GGT (IU/L)*  107.4 ± 106.1 151.0 ± 175.9 39.5 ± 6.3 0.457 
Systolic BP (mmHg)  131.1 ± 15.0 130.8 ± 10.4 166.5 ± 2.1 0.004 
Diastolic BP (mmHg)*  82.3 ± 9.9 82.0 ± 8.3 99.0 ± 1.4 0.096 
Steatosis grade*  1.8 ± 0.8 1.8 ± 0.8 2.5 ± 0.7 0.443 
Lobular inflammation*  1.3 ± 0.6 1.3 ± 0.6 1.5 ± 0.7 0.867 
Ballooning*  1.2 ± 0.6 1.3 ± 0.6 1.0 ± 0.0 0.815 
Fibrosis*  1.7 ± 1.0 1.8 ± 0.8 2.0 ± 0.0 0.737 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.16     Single nucleotide polymorphism: TFRC 
 
A SNP of TFRC gene rs3817672 G/A was genotyped in this study. The polymorphism 
of rs3817672 is a missense mutation, substituting the amino acid glycine with serine. 
The rs3817672 is located on chromosome 3. Table 4.36 shows the association test 
between NAFLD and control subjects with NAFLD. The genotypes were in Hardy-
Weinberg equilibrium. No allelic association with NAFLD was observed in the pooled 
subjctes (OR 0.81, 95% CI  0.53-1.16, P = 0.245) nor after stratification by ethnicity 
(OR 0.99, 95% CI  0.56-1.75, P = 0.963; OR 1.08, 95% CI  0.49-2.39, P = 0.841; and 
OR 0.65, 95% CI  0.34-1.25, P = 0.200, for Malay, Chinese and Indian, respectively). 
 
Table 4.36   Allelic association of TFRC polymorphism 
SNP A allele frequency P value OR (CI) 
rs3817672 (G > A)    
NAFLD vs. control    
   Overall 0.22 vs. 0.26 0.245 0.81 (0.53-1.16) 
   Malays 0.24 vs. 0.24 0.963 0.99 (0.56-1.75) 
   Chinese 0.16 vs. 0.15 0.841 1.08 (0.49-2.39) 
   Indians 0.28 vs. 0.38 0.200 0.65 (0.34-1.25) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
TFRC rs3817672 genotypes among NAFLD patients is shown in Table 4.37. None of 
the parameters were different between the genotypes (P > 0.05).  
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Table 4.37   Comparison of various clinical and histological parameters between the 
TFRC rs3817672 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  GG (n = 87) GA (n = 50) AA (n = 7) P value 
Age (years)  51.1 ± 11.4 50.6 ± 13.5 55.0 ± 10.3 0.661 
BMI (kg/m2)  28.6 ± 4.5 28.6 ± 3.9 30.1 ± 5.8 0.602 
HbA1c (%)*  6.5 ± 1.6 6.7 ± 1.9 6.0 ± 0.8 0.816 
Waist circumference (cm)  94.2 ± 11.2 93.1 ± 10.0 94.6 ± 9.3 0.854 
HDL cholesterol (mg/dl)  48.1 ± 13.9 49.2 ± 10.9 48.3 ± 10.7 0.894 
LDL cholesterol (mg/dl)  116.4 ± 41.3 117.9 ± 39.1 119.9 ± 34.1 0.962 
Total cholesterol (mg/dl)  195.5 ± 45.1 198.5 ± 42.7 201.4 ± 43.5 0.883 
Triglycerides (mg/dl)  154.7 ± 61.3 152.7 ± 64.9 174.1 ± 70.1 0.701 
AST (IU/L)*  43.3 ± 26.4 43.7 ± 24.3 32.9 ± 10.1 0.661 
ALT (IU/L)  79.7 ± 41.2 91.3 ± 60.8 64.9 ± 19.9 0.242 
GGT (IU/L)*  106.6 ± 114.9 124.8 ± 123.0 79.5 ± 45.6 0.410 
Systolic BP (mmHg)  130.4 ± 14.7 132.5 ± 15.0 139.5 ± 18.2 0.251 
Diastolic BP (mmHg)*  82.2 ± 10.2 82.5 ± 9.1 87.1 ± 11.1 0.490 
Steatosis grade*  1.8 ± 0.8 1.8 ± 0.8 2.1 ± 0.7 0.423 
Lobular inflammation*  1.3 ± 0.6 1.4 ± 0.5 1.3 ± 0.5 0.669 
Ballooning*  1.2 ± 0.6 1.2 ± 0.6 1.1 ± 0.4 0.899 
Fibrosis*  1.7 ± 1.0 1.8 ± 1.0 1.6 ± 1.1 0.770 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.17     Single nucleotide polymorphism: PPARGC1A 
 
A SNP of PPARGC1A gene rs3755863 G/A was genotyped in this study. The 
rs3755863 is located in the coding region on chromosome 4. The rs3755863 is a 
synonymous coding SNP where different alleles encode for the same amino acid 
threonine. Table 4.38 shows the association test between NAFLD and control subjects 
with NAFLD. The genotypes were in Hardy-Weinberg equilibrium. No allelic 
association with NAFLD was observed in the pooled subjects (OR 1.35, 95% CI  0.99-
1.86, P = 0.061) nor after stratification by ethnicity (OR 1.61, 95% CI  0.95-2.73, P = 
0.076; OR 1.40, 95% CI  0.82-2.41, P = 0.222; and OR 0.99, 95% CI  0.54-1.83, P = 
0.984, for Malay, Chinese and Indian, respectively). 
 
Table 4.38   Allelic association of PPARGC1A polymorphism 
SNP A allele frequency P value OR (CI) 
rs3755863 (G > A)    
NAFLD vs. control    
   Overall 0.49 vs. 0.41 0.061 1.35 (0.99-1.86) 
   Malays 0.55 vs. 0.45 0.076 1.61 (0.95-2.73) 
   Chinese 0.49 vs. 0.41 0.222 1.40 (0.82-2.41) 
   Indians 0.35 vs. 0.35 0.984 0.99 (0.54-1.83) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the  
PPARGC1A rs3755863 genotypes among NAFLD patients is shown in Table 4.39. 
Fibrosis score was found significantly higher in GG genotype (P = 0.046).  
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Table 4.39   Comparison of various clinical and histological parameters between the 
PPARGC1A rs3755863 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  GG (n = 39) GA (n = 69) AA (n = 36) P value 
Age (years)  50.0 ± 12.8 52.2 ± 11.0 50.4 ± 13.2 0.604 
BMI (kg/m2)  28.1 ± 3.3 29.1 ± 5.1 28.3 ± 4.0 0.602 
HbA1c (%)*  6.8 ± 1.8 6.5 ± 1.7 6.4 ± 1.5 0.660 
Waist circumference (cm)  95.0 ± 10.2 93.9 ± 11.6 92.2 ± 10.4 0.544 
HDL cholesterol (mg/dl)  46.7 ± 12.1 49.3 ± 13.5 48.9 ± 11.9 0.571 
LDL cholesterol (mg/dl)  118.8 ± 39.2 114.6 ± 40.6 120.2 ± 40.5 0.763 
Total cholesterol (mg/dl)  194.7 ± 45.4 196.4 ± 42.5 199.8 ± 46.1 0.880 
Triglycerides (mg/dl)  145.4 ± 66.8 155.7 ± 65.0 164.7 ± 52.3 0.411 
AST (IU/L)*  43.2 ± 28.0 42.1 ± 23.7 44.2 ± 26.0 0.915 
ALT (IU/L)  82.1 ± 44.0 83.8 ± 54.3 82.9 ± 42.0 0.983 
GGT (IU/L)*  90.6 ± 99.8 121.8 ± 125.8 115.5 ± 110.6 0.368 
Systolic BP (mmHg)  130.0 ± 14.7 132.2 ± 13.2 132.2 ± 18.7 0.742 
Diastolic BP (mmHg)*  81.5 ± 11.5 83.0 ± 9.1 82.8 ± 9.5 0.950 
Steatosis grade*  1.8 ± 0.7 1.7 ± 0.8 2.1 ± 0.8 0.089 
Lobular inflammation*  1.4 ± 0.5 1.3 ± 0.6 1.3 ± 0.6 0.590 
Ballooning*  1.3 ± 0.5 1.2 ± 0.6 1.1 ± 0.6 0.587 
Fibrosis*  2.1 ± 1.0 1.6 ± 1.0 1.5 ± 0.9 0.046 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.18     Single nucleotide polymorphism: FATP5 
 
A SNP of FATP5 gene rs56225452 C/T was genotyped in this study. The rs56225452 is 
a non-coding SNP, located in the locus region near-gene-5 on chromosome 19. Table 
4.40 shows the association test between NAFLD and control subjects with NAFLD. The 
genotypes were in Hardy-Weinberg equilibrium. No allelic association with NAFLD 
was observed in the pooled subjects (OR 0.90, 95% CI  0.53-1.51, P = 0.681) nor after 
stratification by ethnicity (OR 0.92, 95% CI  0.41-2.06, P = 0.835; OR 3.12, 95% CI  
0.31-11.02, P = 0.331; and OR 1.02, 95% CI  0.46-2.27, P = 0.952, for Malay, Chinese 
and Indian, respectively). 
 
Table 4.40   Allelic association of FATP5 polymorphism 
SNP T allele frequency P value OR (CI) 
rs56225452 (C > T)    
NAFLD vs. control    
   Overall 0.09 vs. 0.10 0.681 0.90 (0.53-1.51) 
   Malays 0.09 vs. 0.09 0.835 0.92 (0.41-2.06) 
   Chinese 0.03 vs. 0.01 0.331 3.12 (0.31-11.02) 
   Indians 0.18 vs. 0.18 0.952 1.02 (0.46-2.27) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
FATP5 rs56225452 genotypes among NAFLD patients is shown in Table 4.41. 
Difference was observed in triglycerides level ( P = 0.028) and fibrosis score (P = 
0.018) between the genotypes. 
  
91 
 
Table 4.41   Comparison of various clinical and histological parameters between the 
FATP5 rs56225452 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 121) CT (n = 19) TT (n = 4) P value 
Age (years)  50.5 ± 12.0 53.7 ± 10.6 52.0 ± 19.7 0.566 
BMI (kg/m2)  28.9 ± 4.4 27.5 ± 4.3 25.5 ± 0.9 0.193 
HbA1c (%)*  6.5 ± 1.6 7.2 ± 2.3 7.3 ± 1.3 0.144 
Waist circumference (cm)  94.0 ± 11.2 92.9 ± 9.9 91.0 ± 7.0 0.822 
HDL cholesterol (mg/dl)  49.1 ± 12.0 45.6 ± 17.0 49.9 ± 11.4 0.550 
LDL cholesterol (mg/dl)  116.4 ± 38.7 113.6 ± 43.6 116.2 ± 16.2 0.966 
Total cholesterol (mg/dl)  195.7 ± 43.5 198.4 ± 46.1 184.0 ± 19.8 0.868 
Triglycerides (mg/dl)  151.1 ± 56.0 188.1 ± 72.8 109.7 ± 21.1 0.028 
AST (IU/L)*  41.9 ± 24.7 47.7 ± 27.2 59.0 ± 50.3 0.617 
ALT (IU/L)  81.2 ± 48.9 94.2 ± 49.9 92.0 ± 52.8 0.553 
GGT (IU/L)*  105.6 ± 110.2 153.5 ± 148.3 133.7 ± 152.5 0.596 
Systolic BP (mmHg)  130.9 ± 15.0 132.6 ± 16.2 135.0 ± 11.5 0.826 
Diastolic BP (mmHg)*  82.4 ± 9.9 84.1 ± 9.6 79.0 ± 14.9 0.669 
Steatosis grade*  1.8 ± 0.8 1.7 ± 0.8 2.0 ± 0.0 0.550 
Lobular inflammation*  1.3 ± 0.6 1.1 ± 0.5 1.7 ± 0.6 0.164 
Ballooning*  1.2 ± 0.6 1.0 ± 0.7 1.7 ± 0.6 0.143 
Fibrosis*  1.7 ± 1.0 1.4 ± 0.8 3.3 ± 0.6 0.018 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.19     Single nucleotide polymorphism: STAT3  
 
A total of two SNPs of STAT3 gene rs6503695 T/C and rs9891119 A/C were genotyped 
in this study. Both are non-coding SNPs, located in the intronic regions on chromosome 
17. Table 4.42 shows the association test between NAFLD and control subjects with 
NAFLD. The genotypes of rs6503695 were in Hardy-Weinberg equilibrium but not for 
rs9891119 . No allelic association with NAFLD was observed for both SNPs in the 
pooled subjects (P > 0.05) nor after stratification by ethnicity (P > 0.05). 
 
Table 4.42   Allelic association of STAT3 polymorphism 
SNP C allele frequency P value OR (CI) 
rs6503695 (T > C)    
NAFLD vs. control    
   Overall 0.49 vs. 0.42 0.064 1.35 (0.98-1.86) 
   Malays 0.48 vs. 0.44 0.486 1.20 (0.71-2.03) 
   Chinese 0.49 vs. 0.44 0.499 1.20 (0.71-2.05) 
   Indians 0.50 vs. 0.36 0.075 1.77 (0.94-3.32) 
rs9891119 (A > C)    
NAFLD vs. control 0.24 vs. 0.26 0.194 0.84 (0.64-1.09) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
STAT3 rs6503695 genotypes among NAFLD patients is shown in Table 4.43. No 
difference in parameters was observed between the genotypes (P > 0.05). 
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Table 4.43   Comparison of various clinical and histological parameters between the 
STAT3 rs6503695 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  TT (n = 34) TC (n = 76) CC (n = 31) P value 
Age (years)  50.6 ± 10.8 50.8 ± 12.5 51.7 ± 12.0 0.929 
BMI (kg/m2)  28.4 ± 4.3 28.7 ± 4.5 28.9 ± 4.4 0.872 
HbA1c (%)*  6.5 ± 1.8 6.7 ± 1.8 6.3 ± 1.0 0.464 
Waist circumference (cm)  93.8 ± 8.8 93.5 ± 11.4 94.3 ± 11.7 0.954 
HDL cholesterol (mg/dl)  49.6 ± 11.0 48.3 ± 12.4 48.5 ± 15.0 0.882 
LDL cholesterol (mg/dl)  115.2 ± 35.4 117.6 ± 41.2 114.1 ± 37.3 0.913 
Total cholesterol (mg/dl)  195.1 ± 40.3 198.8 ± 44.6 189.2 ± 43.4 0.577 
Triglycerides (mg/dl)  154.2 ± 64.8 159.2 ± 61.6 145.3 ± 63.2 0.581 
AST (IU/L)*  40.9 ± 23.5 45.1 ± 25.2 40.6 ± 28.9 0.488 
ALT (IU/L)  78.2 ± 50.0 89.7 ± 52.2 72.4 ± 37.3 0.553 
GGT (IU/L)*  113.7 ± 138.0 119.9 ± 106.3 92.2 ± 116.8 0.083 
Systolic BP (mmHg)  127.0 ± 11.6 132.2 ± 16.1 133.5 ± 15.0 0.158 
Diastolic BP (mmHg)*  79.7 ± 8.6 83.4 ± 10.0 83.4 ± 10.8 0.169 
Steatosis grade*  1.8 ± 0.7 1.9 ± 0.8 1.7 ± 0.8 0.757 
Lobular inflammation*  1.4 ± 0.5 1.2 ± 0.6 1.4 ± 0.6 0.465 
Ballooning*  1.3 ± 0.5 1.2 ± 0.7 1.1 ± 0.5 0.424 
Fibrosis*  1.6 ± 0.8 1.7 ± 0.9 1.9 ± 1.2 0.568 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
 
  
94 
 
4.2.20     Single nucleotide polymorphism: APOA5  
 
A SNP of APOA5 gene rs662799 G/A was genotyped in this study. The rs662799 is a 
non-coding SNP, located in the locus region near-gene-5 on chromosome 11. Table 4.44 
shows the association test between NAFLD and control subjects with NAFLD. The 
genotypes were in Hardy-Weinberg equilibrium. One sample from the controls was 
with no call, thus in total 144 cases and 197 controls were genotyped. No allelic 
association with NAFLD was observed in the pooled subjects (OR 1.39, 95% CI  0.98-
1.95, P = 0.063) nor after stratification by ethnicity (OR 1.18, 95% CI  0.71-1.96, P = 
0.519; OR 1.32, 95% CI  0.72-2.44, P = 0.359; and OR 2.06, 95% CI  0.92-4.63, P = 
0.080, for Malay, Chinese and Indian, respectively). 
 
Table 4.44   Allelic association of APOA5 polymorphism 
SNP A allele frequency P value OR (CI) 
rs662799 (G > A)    
NAFLD vs. control    
   Overall 0.76 vs. 0.70 0.063 1.39 (0.98-1.95) 
   Malays 0.69 vs. 0.65 0.519 1.18 (0.71-1.96) 
   Chinese 0.77 vs. 0.72 0.359 1.32 (0.72-2.44) 
   Indians 0.87 vs. 0.74 0.080 2.06 (0.92-4.63) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
APOA5 rs662799 genotypes among NAFLD patients is shown in Table 4.45. Difference 
was observed in triglycerides level in which highest level was shown in those with GG 
genotype (P = 0.001). 
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Table 4.45   Comparison of various clinical and histological parameters between the 
APOA5 rs662799 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  GG (n = 8) GA (n = 54) AA (n = 82) P value 
Age (years)  49.9 ± 9.9 50.8 ± 12.4 51.2 ± 11.8 0.958 
BMI (kg/m2)  29.4 ± 3.8 28.5 ± 4.2 28.7 ± 4.6 0.875 
HbA1c (%)*  6.7 ± 1.7 6.3 ± 1.4 6.7 ± 1.8 0.471 
Waist circumference (cm)  95.9 ± 4.7 93.3 ± 9.3 93.9 ± 12.1 0.823 
HDL cholesterol (mg/dl)  47.4 ± 16.3 48.7 ± 12.7 48.7 ± 12.5 0.968 
LDL cholesterol (mg/dl)  111.1 ± 42.6 114.6 ± 41.3 117.5 ± 37.2 0.863 
Total cholesterol (mg/dl)  198.1 ± 43.0 198.8 ± 45.6 193.6 ± 42.0 0.786 
Triglycerides (mg/dl)  199.4 ± 48.6 172.4 ± 64.6 139.3 ± 57.6 0.001 
AST (IU/L)*  41.9 ± 21.6 44.2 ± 27.9 42.4 ± 24.5 0.935 
ALT (IU/L)  88.2 ± 41.0 85.7 ± 48.9 81.0 ± 50.0 0.832 
GGT (IU/L)*  98.0 ± 43.7 133.2 ± 139.4 99.4 ± 102.1 0.436 
Systolic BP (mmHg)  135.0 ± 12.3 131.4 ± 14.6 130.8 ± 15.6 0.779 
Diastolic BP (mmHg)*  87.9 ± 10.4 80.8 ± 9.7 83.2 ± 9.9 0.098 
Steatosis grade*  2.0 ± 0.8 1.8 ± 0.8 1.8 ± 0.8 0.785 
Lobular inflammation*  1.6 ± 0.5 1.3 ± 0.5 1.3 ± 0.6 0.445 
Ballooning*  1.1 ± 0.7 1.2 ± 0.6 1.3 ± 0.6 0.489 
Fibrosis*  1.6 ± 1.4 1.6 ± 0.9 1.8± 1.0 0.650 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.21     Single nucleotide polymorphism: PEMT 
 
A SNP of PEMT gene rs7946 C/T was genotyped in this study. The polymorphism of 
rs7946 is a missense mutation, substituting the amino acid valine with methionine. The 
rs7946 is located on chromosome 17. Table 4.46 shows the association test between 
NAFLD and control subjects with NAFLD. The genotypes were in Hardy-Weinberg 
equilibrium. Two samples from the controls and one from cases were with no call, thus 
in total 143 cases and 196 controls were genotyped. No allelic association with NAFLD 
was observed in the pooled subjects (OR 0.91, 95% CI 0.65-1.26, P = 0.551) nor after 
stratification by ethnicity (OR 1.12, 95% CI  0.67-1.87, P = 0.663; OR 1.15, 95% CI  
0.55-2.42, P = 0.706; and OR 0.78, 95% CI  0.43-1.42, P = 0.409, for Malay, Chinese 
and Indian, respectively).  
 
Table 4.46   Allelic association of PEMT polymorphism 
SNP T allele frequency P value OR (CI) 
rs7946 (C > T)    
NAFLD vs. control    
   Overall 0.28 vs. 0.32 0.551 0.91 (0.65-1.26) 
   Malays 0.28 vs. 0.26 0.663 1.12 (0.67-1.87) 
   Chinese 0.19 vs. 0.17 0.706 1.15 (0.55-2.42) 
   Indians 0.43 vs. 0.50 0.409 0.78 (0.43-1.42) 
 
CI confident interval, OR odds ratio,  NAFLD non-alcoholic fatty liver disease 
 
 
Analysis of comparison of clinical and histological parameters between the 
PEMT rs7946 genotypes among NAFLD patients is shown in Table 4.47. There was no 
difference in parameters observed between the genotypes (P > 0.05) 
  
97 
 
Table 4.47   Comparison of various clinical and histological parameters between the 
PEMT rs7946 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 73) CT (n = 55) TT (n = 12) P value 
Age (years)  51.3 ± 12.1 49.2 ± 12.3 56.9 ± 7.2 0.117 
BMI (kg/m2)  28.8 ± 4.3 28.3 ± 4.5 29.2 ± 4.6 0.716 
HbA1c (%)*  6.6 ± 1.6 6.5 ± 1.7 6.9 ± 1.8 0.466 
Waist circumference (cm)  93.1 ± 10.7 94.5 ± 11.4 94.0 ± 10.6 0.778 
HDL cholesterol (mg/dl)  48.9 ± 10.5 47.6 ± 14.2 51.9 ± 17.5 0.553 
LDL cholesterol (mg/dl)  117.1 ± 36.1 113.6 ± 39.5 120.0 ± 53.7 0.821 
Total cholesterol (mg/dl)  198.2 ± 41.1 191.1 ± 43.8 202.1 ± 56.5 0.572 
Triglycerides (mg/dl)  159.9 ± 67.4 150.5 ± 60.7 146.5 ± 39.0 0.627 
AST (IU/L)*  43.9 ± 27.6 41.4 ± 24.6 44.3 ± 17.7 0.655 
ALT (IU/L)  80.7 ± 44.5 85.4 ± 55.6 84.9 ± 47.5 0.867 
GGT (IU/L)*  120.5 ± 134.1 101.0 ± 91.7 117.1 ± 113.1 0.639 
Systolic BP (mmHg)  130.2 ± 15.2 131.5 ± 15.3 136.4 ± 12.8 0.411 
Diastolic BP (mmHg)*  83.5 ± 9.8 80.9 ± 10.7 84.1 ± 7.3 0.139 
Steatosis grade*  1.9 ± 0.8 1.7 ± 0.7 1.9 ± 0.9 0.547 
Lobular inflammation*  1.3 ± 0.6 1.3 ± 0.6 1.5 ± 0.5 0.453 
Ballooning*  1.3 ± 0.6 1.2 ± 0.6 1.3 ± 0.5 0.573 
Fibrosis*  1.7 ± 0.9 1.6 ± 1.0 2.3 ± 1.1 0.207 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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4.2.22     Single nucleotide polymorphism: Other candidate genes 
  
Farnesyl-diphosphate farnesyltransferase 1 gene (FDFT1)  rs2645424 C/T and inducible 
nitric oxide synthase (iNOS) rs2797512 A/C are non-coding SNPs in the intronic region 
on chromosome 8 and 9. The genotype distribution of both SNPs deviated from Hardy-
Weinberg equilibrium. The association test did not proceed since more than 30% of the 
samples failed to be genotyped. 
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4.3 Gene-gene interaction analysis 
 
4.3.1     AGTR1 and PNPLA3 gene interaction 
 
The overall results, pooling all subjects, indicate a lack of evidence for an association 
between AGTR1 gene and NAFLD, which is in contrast with the positive findings by 
Yoneda et al. (2009b). The PNPLA3 study showed a strong association of PNPLA3 
variant with the occurence of NAFLD (Zain et al., 2012a), and therefore attempt was 
made to find out whether there is any gene-gene interaction between PNPLA3 and 
AGTR1. The results with the two-locus and three-locus models are shown in Table 4.48. 
The two-locus model has the highest testing accuracy while the three-locus model has 
the best cross-validation consistency. Investigation of the gene-gene interaction on the 
occurence of NAFLD, identified a significant effect of PNPLA3 and AGTR1 interaction 
(empirical P = 0.007). The best GMDR model suggested for the interaction was the 
three-locus model. The significant interaction was confirmed by logistic regression (P = 
0.017). 
 
Table 4.48   Best fitted gene-gene interaction model between AGTR1 and PNPLA3 
Locus 
number 
Model Cross-validation 
consistency 
Testing accuracy (%) P value* 
2 AGTR1 (rs2276736), 
PNPLA3 (rs738409) 
8/10 63.68 0.038 
3 AGTR1 (rs3772627), 
AGTRI (rs3772630), 
PNPLA3 (rs738409) 
9/10 62.88 0.007 
 
*P values based on 1000 permutations. Analysis of GMDR with adjustment of ethnicity 
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Genotype association in additive model revealed that the risk genotypes (AGTR1 
rs3772627 TT, AGTR1 rs3772630 AA and PNPLA3 rs738409 GG) versus one risk 
factor (AGTR1 rs3772627 TC, AGTR1 rs3772630 AG and PNPLA3 rs738409 CG) 
versus the protective genotypes (AGTR1 rs3772627 CC, AGTR1 rs3772630 GG and 
PNPLA3 rs738409 CC), conferred enhanced risk for NAFLD (OR 2.23, 95% CI  1.16-
4.31, P = 0.017). Since the protective effect was seen in the Indian ethnic subgroup, the 
association was additionally tested specifically in this group. The risk for NAFLD in 
this group was dramatically enhanced (OR 12.41, 95% CI 1.61-55.42, P = 0.016) 
following genotypes combinations. The association of AGTR1 SNPs with NAFLD 
following stratification by PNPLA3 genotypes was further evaluated. The results 
however indicated the absence of significant association. 
 
4.3.2     LEPR and PNPLA3 gene interaction 
 
Functionally, both LEPR and PNPLA3 genes play important roles in lipid regulation. 
An analysis was performed to find out whether there is an interaction between the two 
genes on susceptibility to NAFLD. The results of the gene-gene interaction analysis are 
demonstrated in Table 4.49. There are two best combinations (two-locus and three-
locus) yielded by the analysis. Both two-locus and three-locus models have a perfect 
cross-validation consistency and similar testing accuracy. Investigation of the gene-gene 
interaction on the susceptibility to NAFLD identified a significant effect of LEPR 
rs1137100 and PNPLA3 rs738409 interaction (empirical P = 0.001 and empirical P = 
0.011, for rs1137100 and rs1137101 respectively). The best GMDR model suggested 
for the interaction was the two-locus model. The significant interaction was confirmed 
by logistic regression (p < 0.0001).  
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Table 4.49   Best fitted gene-gene interaction model between LEPR and PNPLA3 
Locus 
number 
Model Cross-validation 
consistency 
Testing accuracy (%) P value* 
2 LEPR (rs1137100), 
PNPLA3 (rs738409) 
10/10 63.3 0.001 
3 LEPR (rs1137100), 
LEPR (rs1137101), 
PNPLA3 (rs738409) 
10/10 63.0 0.011 
 
aP value based on 1000 permutations. Analysis of GMDR with adjustment of ethnicity 
 
 
The effects of combined alleles from each variant of the two different genes, 
LEPR rs1137100 and PNPLA3 rs738409 were further evaluated in additive model, and 
tested as follows; two risk factors vs. one risk factor vs. no risk factor. The risk of 
NAFLD is first to be noted as 1.64 for LEPR rs1137100 and 2.23 for PNPLA3 
rs738409. Although not shown in the table, it is noteworthy that the risk of NAFLD 
increased to 3.73 with the combined effect of risk allele of both SNPs (OR 3.73, 95% CI  
1.84-7.55, P < 0.0001). 
 
4.3.3     GCKR and PNPLA3 gene interaction 
 
Variants of both the GCKR and PNPLA3 genes (Zain et al., 2012a) have been 
postulated to confer risk of NAFLD in this study population and involved in hepatic fat 
content. Hence, the interaction between the two genes on risk of NAFLD was 
investigated (Table 4.50). Two best models were derived from the interaction. Having a 
perfect cross-validation consistency, the three-locus model (GCKR rs1260326, GCKR 
rs780094, PNPLA3 rs738409) was suggested to be the best model (empirical P = 0.003).  
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Table 4.50   Best fitted gene-gene interaction model between GCKR and PNPLA3 
Locus 
number 
Model Cross-validation 
consistency 
Testing accuracy (%) P value* 
2 GCKR (rs780094), 
PNPLA3 (rs738409) 
6/10 61.0 0.001 
3 GCKR (rs1260326), 
GCKR (rs780094), 
PNPLA3 (rs738409) 
10/10 59.0 0.003 
 
aP value based on 1000 permutations. Analysis of GMDR with adjustment of ethnicity 
 
 
This finding was confirmed by performing the additive logistic regression model 
that takes into account all risk alleles of three SNPs. Analysis yielded an odds ratio of 
3.87 with the combined effect of the three SNPs (OR 3.87, 95% CI 1.29-11.61, P = 
0.016) which is a greater risk of NAFLD than either SNP alone: 1.49 risk for GCKR 
rs1260326, 1.51 risk for GCKR rs780094 and 2.23 risk for PNPLA3 rs738409. 
  
103 
 
4.4 Copy number variation 
 
Analysis of copy number on the basis of log ratio and probe incidence filtering, 
exhibited a total of 521 copy number alterations (CNAs) (P < 0.05). Molecular genomic 
profiling successfully identified five genomic regions; 14q11.2 (n = 25, 62.5%), 
12p13.31 (n = 20, 50.0%), 11p15.4 (n = 18, 45.0%), 5p15.33 (n = 17, 42.5%), and 
12p13.2 (n = 16, 40.0%) that were most frequently amplified among NASH patients 
(Table 4.51). The most frequently deleted CNAs were located on region 11q11 (n = 14, 
35.0%), 12p13.2 (n = 13, 32.5%), 16q12.2 (n = 13, 32.5%), 4q13.2 (n = 13, 32.5%), 
1q21.3 (n = 13, 32.5%), and 14q24.3 (n = 13, 32.5%) (Table 4.52). There are 11 
amplified CNAs present in at least 1/3 of the samples. On the other hand, only 6 deleted 
CNAs were present in at least 1/3 of the samples. CNAs involving chromosome 11q11, 
12p13.2 and 16q12.2 were informative both as gain and loss events. They exhibited 
almost similar number of samples for gain and loss events which may suggest a 
generally unstable nature of these regions. There was one CNA that showed a clear-cut 
gain, 16p12.2 (n = 11, 27.5%), which could be involved in the development of the 
disease and could be considered as a potential biomarker candidate for NAFLD. More 
than 50% of genomic regions were informative as gains only, however, it appears that 
the regions were presented with not more than 27.5% (n = 11) (Table 4.53). Meanwhile, 
less than 10% of the genomic regions were informative as losses only. These regions 
bear a frequency of not more than 7.5% (n = 3) (Table 4.54). The percentages in the 
parentheses indicate the frequency of each event. The most commonly amplified region, 
14q11.2 contains a few olfactory receptor (OR) and T cell receptor family genes 
whereas forkhead box genes (FOX) are located on the second most amplified 
chromosome 12p13.31. 
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Table 4.51   Top 5% most amplified CNAs 
CYTOBAND 
NASH 
Gain (%) 
NASH 
Loss (%) 
CNV 
COVERAGE 
CNV  
in DGV 
Size 
(Mb) 
Start End 
14q11.2 62.5 15.0 100 Yes 0.02 19376762 20420849 
12p13.31 50.0 17.5 100 Yes 0.08 9637323 9718846 
11p15.4 45.0 30.0 100 Yes 0.02 8500104 8598491 
5p15.33 42.5 7.5 100 Yes 0.10 449199 673013 
12p13.2 40.0 32.5 100 Yes 0.04 11218244 11256467 
16q12.2 37.5 32.5 100 Yes 0.02 55832511 55853358 
1q44 35.0 15.0 100 Yes 0.07 248601802 248672268 
6p21.32 35.0 27.5 100 Yes 0.17 32413439 32592800 
8p23.1 32.5 5.0 100 Yes 0.41 7169490 7786708 
11q11 32.5 35.0 100 Yes 0.08 55368154 55450788 
13q21.1 32.5 15.0 100 Yes 0.02 57760478 57783723 
3q29 30.0 12.5 100 Yes 0.10 195354124 195456540 
3q26.1 30.0 20.0 100 Yes 0.07 162514534 162619141 
6p25.3 30.0 20.0 100 Yes 0.08 299363 378956 
4q13.2 27.5 32.5 100 Yes 0.09 69392545 69483277 
7q31.1 27.5 25.0 100 Yes 0.01 111227035 111333959 
16p12.2 27.5 0 100 Yes 0.02 21570472 21585470 
22q11.23 27.5 27.5 100 Yes 0.05 24347959 24395353 
5q35.3 25.0 20.0 100 Yes 0.02 180410254 180429788 
10q11.22 25.0 2.5 100 Yes 0.09 46968072 47551468 
12p11.21 25.0 5.0 100 Yes 0.41 31277996 31346297 
14q32.33 25.0 17.5 0 No 0.03 106531557 106559103 
15q11.2 25.0 12.5 100 Yes 0.12 20172544 22409391 
22q13.1 25.0 22.5 100 Yes 0.03 39359112 39385485 
1p31.1 22.5 7.5 100 Yes 0.03 72768855 72795480 
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Table 4.52   Top 5% most deleted CNAs 
 
CYTOBAND 
NASH 
Gain (%) 
NASH 
Loss (%) 
CNV 
COVERAGE 
CNV 
in DGV 
Size 
(Mb) 
Start End 
11q11 32.5 35.0 100 Yes 0.08 55368154 55450788 
12p13.2 40.0 32.5 100 Yes 0.04 11218244 11256467 
16q12.2 37.5 32.5 100 Yes 0.02 55832511 55853358 
4q13.2 27.5 32.5 100 Yes 0.09 69392545 69483277 
1q21.3 20.0 32.5 100 Yes 0.02 152569857 152586281 
14q24.3 20.0 32.5 100 Yes 0.02 78329728 78368494 
11p15.4 45.0 30.0 100 Yes 0.02 8500104 8598491 
6p21.32 35.0 27.5 100 Yes 0.17 32413439 32592800 
22q11.23 27.5 27.5 100 Yes 0.05 24347959 24395353 
7q31.1 27.5 25.0 100 Yes 0.01 111227035 111333959 
1q24.2 12.5 25.0 100 Yes 0.01 169227144 169241333 
22q13.1 25.0 22.5 100 Yes 0.03 39359112 39385485 
3q26.1 30.0 20.0 100 Yes 0.07 162514534 162619141 
6p25.3 30.0 20.0 100 Yes 0.08 299363 378956 
5q35.3 25.0 20.0 100 Yes 0.02 180410254 180429788 
16p11.2 20.0 20.0 100 Yes 0.80 32573808 32651084 
1q21.2 12.5 20.0 100 Yes 0.20 149041933 149241652 
12p13.31 50.0 17.5 100 Yes 0.08 9637323 9718846 
14q32.33 25.0 17.5 0 No 0.03 106531557 106559103 
15q11.1-q11.2 20.0 17.5 0 No 1.98 20432851 22409391 
6p22.1 17.5 17.5 100 Yes 0.05 29854870 29961707 
20p13 15.0 17.5 100 Yes 0.02 4769772 4785367 
14q11.2 62.5 15.0 100 Yes 0.02 19376762 20420849 
1q44 35.0 15.0 100 Yes 0.07 248601802 248672268 
13q21.1 32.5 15.0 100 Yes 0.02 57760478 57783723 
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Table 4.53   Top 5% copy number gain only 
 
CYTOBAND 
NASH  
Gain (%) 
CNV 
COVERAGE 
CNV 
in DGV 
Size (Mb) Start End 
16p12.2 27.5 100 Yes 0.02 21570472 21585470 
12q24.33 17.5 0 No 0.02 131797898 131815396 
7q36.3 15.0 0 No 0.02 158243089 158279162 
15q22.31 15.0 0 No 0.31 66254326 66562391 
19q13.41 15.0 100 Yes 0.05 52186797 52240114 
22q13.2 15.0 0 No 0.05 42907649 42957173 
2q37.1 12.5 0 No 0.06 234502414 234563295 
7q36.1 12.5 59 Yes 0.33 151555495 151900894 
7p14.1 12.5 0 No 0.02 38311203 38329752 
9p21.1 12.5 0 No 0.01 28610932 28739593 
11p15.1 12.5 0 No 0.20 17357360 17559681 
21p11.2-p11.1 12.5 0 No 0.14 10861051 11000494 
2q35 10.0 67 Yes 0.02 220364652 220386647 
2p25.3 10.0 0 No 0.06 17019 78843 
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Table 4.54   Top 5% copy number loss only 
CYTOBAND 
NASH 
Loss (%) 
CNV 
COVERAGE 
CNV 
in DGV 
Size (Mb) Start End 
3p26.1 7.5 0 No 0.04 4240523 4276049 
9p24.2 7.5 0 No 0.15 2901047 3047813 
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CHAPTER FIVE 
DISCUSSION 
 
5.1 Single nucleotide polymorphism 
 
5.1.1     Single nucleotide polymorphism: PNPLA3 
 
In the present study, the association of PNPLA3 rs738409 G allele with susceptibility to 
NAFLD as has been shown in a genome-wide association study was confirmed (Romeo 
et al., 2008). More importantly, this study showed a positive association of the risk 
allele G with risk of NASH and with fibrosis stage but not with other histological 
parameters. Thus, the G allele is not only associated with occurence of NASH but also 
with presence of fibrosis. 
The risk allele G was found to be significantly associated with susceptibility to 
NAFLD after stratification into the three major ethnic subgroups, the Chinese, Indian 
and Malay. The Malaysian Indians migrated to Malaysia from Southern India in the 
1800s (Periasamy, 2007). Studies have suggested that Indians from India were proto-
Asian origin with West Eurasian admixture, hence giving them the genetic affinity 
towards both Asian and European (Bamshad et al., 2001; Jorde & Wooding, 2004). 
Compared to the other ethnic groups, the Malaysian Indians appear to have a high 
prevalence of NAFLD as is so with the Europeans. The Malaysian Chinese on the other 
hand, are descendance from the Hans from Southern China (Hock, 2007) and it is noted 
that the results of the Chinese subgroup in this study are consistent with the finding  in 
the Taiwanese Hans (Lin et al., 2011) as proven by positive associations in both 
populations. The results of this study are consistent with the results of the previous 
studies of different populations including Hispanics (Romeo et al., 2008), Argentinian 
(Sookoian et al., 2009), Germans (Kantartzis et al., 2009), Italian (Romeo et al., 2010a; 
Romeo et al., 2010b; Valenti et al., 2010), Japanese (Hotta et al., 2010), Taiwanese (Lin 
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et al., 2011), and African Americans (Cox et al., 2011). The present study thus confirms 
earlier findings that the rs738409 plays a significant role in susceptibility to NAFLD.  
The finding of an association between the PNPLA3 variant with NASH in this 
population was also successfully replicated as was observed in several studies (Hotta et 
al., 2010; Rotman, Koh, Zmuda, Kleiner, & Liang, 2010; Sookoian et al., 2009). There 
are more patients with NASH in this study population compared to those with simple 
steatosis, which is probably reflective of the patients who are seen at the UMMC, which 
is a tertiary referral centre. 
A novel finding in this study is that the G allele is associated with the severity of 
NASH. Most of the NAFLD biopsy-proven studies to date only looked at two spectrum 
of NAFLD: simple steatosis and NASH (Hotta et al., 2010; Rotman et al., 2010; 
Sookoian et al., 2009). Prediciting steatohepatitis is more important as NASH can 
potentially progress and treatment should be considered at an early stage of NASH. 
Compared to those with simple steatosis, the G allele is significantly higher in patients 
with NASH with significant fibrosis but not in NASH patients without significant 
fibrosis. Furthermore, the G allele frequency in NASH with significant fibrosis is higher 
than that of NASH without significant fibrosis. It is also revealed that the G allele is 
associated with a higher fibrosis score but not with the other histological features of 
NAFLD. The association of rs738409 G allele with higher fibrosis score was also 
observed in other studies (Hotta et al., 2010; Rotman et al., 2010; Valenti et al., 2010). 
One Asian study found that the G allele is associated with fibrosis score but not with 
steatosis (Hotta et al., 2010). The results of the present study were in concordance with 
that of Hotta et al, and in addition, there was no association with lobular inflammation 
and hepatocellular ballooning.  
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There have been conflicting reports of the correlation between presence of G 
allele and serum transaminase levels (Hotta et al., 2010; Kotronen et al., 2009; Lin et 
al., 2011; Romeo et al., 2008; Romeo et al., 2010a; Romeo et al., 2010b; Sookoian et 
al., 2009; Valenti et al., 2010). The rs738409 G allele was shown to be associated with 
increased levels of both serum AST and ALT in the Argentinian (Sookoian et al., 2009), 
Italian (Romeo et al., 2010a; Romeo et al., 2010b), Japanese (Hotta et al., 2010), and the 
Taiwanese (Lin et al., 2011). In the Hispanics (Romeo et al., 2008) and in an Italian 
population (Valenti et al., 2010), the G allele was found to be related with increased 
serum ALT only. The G allele was found to be associated with increased serum AST 
level only in the Finnish population (Kotronen et al., 2009). However the serum level of 
AST/ALT was found not to be significantly associated with the G allele in the African 
Americans (Cox et al., 2011; Romeo et al., 2008), European Americans (Romeo et al., 
2008), Germans (Kantartzis et al., 2009), and in the present study (Zain et al., 2012a). 
The differences in these findings are probably due to the differences in the recruited 
subjects in the various studies, ranging from adults with NAFLD (Hotta et al., 2010; 
Kotronen et al., 2009; Romeo et al., 2008; Sookoian et al., 2009; Valenti et al., 2010), 
either obese or diabetic adults (Kantartzis et al., 2009), obese adults (Romeo et al., 
2010b), and obese children (Lin et al., 2011; Romeo et al., 2010a).  
Two studies reported a decreased level of plasma triglycerides in the NAFLD 
subjects  harboring the G allele (Hotta et al., 2010; Speliotes, Butler, Palmer, Voight, & 
Hirschhorn, 2010). This finding is in agreement with the present study, in which 
decreased level of plasma triglycerides was found amongst the NAFLD patients with 
GG genotype despite a significantly higher level of triglyceride in the NAFLD patients 
as compared to controls, suggesting that genetic  susceptibility of G allele plays a much 
more important role than triglyceride levels in the pathogenesis of NAFLD. In the 
present study, the triglyceride levels were further analyzed in the NAFLD spectrum. 
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The triglyceride levels are higher in NASH without significant fibrosis compared to 
NASH with significant fibrosis, suggesting that the triglyceride level subsides along 
with the degree of hepatocellular injury (Jou, Choi, & Diehl, 2008). 
 
5.1.2     Single nucleotide polymorphism: AGTR1 
 
Angiotensin II appears to have an important role in the progression to non-alcoholic 
steatohepatitis (NASH) (Oakley et al., 2009; Yoshiji et al., 2001). Angiotensin II acts on 
angiotensin II type 1 receptor to activate hepatic stellate cells (HSCs). The activated 
HSCs will express the transforming growth factor-β 1 (TGF-β 1), a profibrogenic 
cytokine, as a counter response to liver injury (X. Li, Meng, Wu, Zhang, & Yang, 2007; 
Yoshiji et al., 2001). The preventive role of AGTR1 blocker in the progression to NASH 
was succesfully observed in the animal and human studies (Fujita et al., 2007; Hirose et 
al., 2007; Moreno et al., 2010; Yokohama et al., 2004). The deletion of angiotensin II 
type 1 receptor in animal studies has been shown to reduce hepatic steatosis suggesting 
AGTR1 is an important regulator of hepatic steatosis (Nabeshima, Tazuma, Kanno, 
Hyogo, & Chayama, 2009). 
In the present study, data indicated that the five previously reported SNPs of the 
angiotensin II type I receptor (AGTR1) gene (rs3772622, rs3772627, rs3772630, 
rs3772633, and rs2276736) were not associated with susceptibility to non-alcoholic 
fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This is in 
contrast with the Japanese study which showed that these AGTR1 polymorphisms were 
significantly associated with the occurence of NAFLD and NASH (Yoneda et al., 
2009b).  
Among the SNPs studied, rs2276736, rs3772630 and rs3772627 were found to 
be protective against NAFLD and NASH in the Indian ethnic subgroup. Interestingly, 
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these three SNPs share the same linkage disequilibrium structure. It was revealed that 
haplotype ACGCA is protective against NAFLD in the Indians. The study by Yoneda et 
al (2009b) reported that the protective haplotype in the Japanese was ATATG. The 
discrepancy in the findings may be explained by ethnic differences between the 
populations studied. The three major ethnic subgroups in Malaysia, namely the Malay, 
Chinese and Indian are of the south Asian origin with the Chinese are of the Hans 
descendant of Southern China (Hock, 2007), Indians from Southern India (Periasamy, 
2007), whereas the Malays are the indigenous ethnic group. There is a supportive 
evidence that the Japanese are from the north Asian (Northern China and Korea) origin 
but not the south Asian (Southern China and Southeast Asia) based on the classical 
marker polymorphisms, Y chormosome and mitochondrial DNA (Hammer et al., 2006; 
Omoto & Saitou, 1997). The difference in the association studies between the two 
population probably reflects the difference in the genetic pools of the Malaysian and the 
Japanese. 
The results from this study indicated that there was no difference in levels of 
liver enzymes between patients with simple steatosis and those with NASH. This is in 
agreement with the results from Sorrentino et al (Sorrentino et al., 2004) and Mofrad et 
al (Mofrad et al., 2003), but is in contrast with the findings of several other studies 
which showed differences in levels between the two groups (Abrams, Kunde, Lazenby, 
& Clements, 2004; Dixon, Bhathal, & O'Brien, 2001; Lima, Mourao, Diniz, & Leite, 
2005; Ong et al., 2005). The differences in these findings is probably due to the 
differences in the recruitment of subjects for the various studies, in which inclusion 
criteria ranges from morbid obese NAFLD to adults with NAFLD. Furthermore, a 
significantly higher triglycerides levels were observed in patients with NASH compared 
to those with simple steatosis. Triglyceride storage in hepatocytes marks the intensity of 
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exposure to potentially toxic fatty acids. As NAFLD progresses, excess free fatty acids 
are compensated with increase in triglycerides production (Jou et al., 2008). 
Analysis of interaction between PNPLA3 and AGTR1 gene, revealed a strong 
interaction between AGTR1 (rs3772627), AGTRI (rs3772630) and PNPLA3 (rs738409) 
SNPs on NAFLD susceptibility. Compared to the Malays and Chinese, the Indians 
presented with the greatest susceptibilty to NAFLD in the PNPLA3 study (Zain et al., 
2012a). Thus the PNPLA3 can possibly mask the effect of AGTR1 on NAFLD among 
the Indians. Although both genes encode different products (PNPLA3 encodes 
adiponutrin while AGTR1 encodes angiotensin II type 1 receptor), the strong interaction 
observed suggested a possible interaction as both genes are involved in lipid 
accumulation. The action of angiotensin II on angiotensin II type 1 receptor (AGTR1) 
promotes lipid accumulation in the liver while lack of AGTR1 reduces hepatic 
triglycerides (Nabeshima et al., 2009). PNPLA3 on the other hand is highly upregulated 
in response to feeding and downregulated in fasting state, displaying its role in lipid 
storage in the liver (Hoekstra et al., 2010). Of note, AGTR1 and PNPLA3 are 
correlatively upregulated in a state of excess lipid. 
This study further showed that the SNP rs3772622 was associated with 
occurence of fibrosis but not with the other histological parameters of NAFLD. The G 
allele of this SNP is associated with increased fibrosis score. The Japanese also found 
that SNP rs3772622 was associated with the presence of fibrosis (Yoneda et al., 2009b), 
but in contrast to our findings, the G allele was found to be associated with decreased 
fibrosis score. The difference is probably explained by a higher minor allele frequency 
in this study population than that of the Japanese. A greater systolic blood pressure 
mean value (136.00 mmHg) observed in the GG genotype compared to the AA 
genotype (128.65 mmHg) of the SNP rs3772633 could also contribute to the 
discrepancy. Data of the previous report showed that hypertensive patients have 
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significantly higher fibrosis score than that of non-hypertensive (Corey et al., 2009). 
The strong linkage disequilibrium observed between the five SNPs in the pooled 
subjects and even after ethnic stratification indicates a potential tagSNP selection based 
on the pairwise LD. This approach will be useful in future in order to minimize the 
genotyping cost yet presenting the information that could reflect the role of the other 
relevant SNPs within the gene. 
 
5.1.3     Single nucleotide polymorphism: LEPR 
 
This study showed significant association between both the LEPR rs1137100 and 
rs1137101 with susceptibility to NAFLD. Results suggest that in patients with NAFLD, 
the G allele of rs1137100 is associated with a less severe form of liver disease. To the 
best of knowledge, the current study is the first to report an interaction between LEPR 
and PNPLA3 genes with increased risk of NAFLD compared to either gene alone. 
The data to date, on the relationship between the LEPR gene variants, rs1137100 
and rs1137101, and obesity is conflicting. No significant association was found between 
rs1137100 with obesity (Furusawa et al., 2010; Yiannakouris et al., 2001). Although 
several studies have reported an association between rs1137101 with obesity (Mattevi, 
Zembrzuski, & Hutz, 2002; Yiannakouris et al., 2001), an equal number of negative 
studies have also been reported (Constantin et al., 2010; Pyrzak, Wisniewska, 
Kucharska, Wasik, & Demkow, 2009). A recent meta-analysis of the LEPR tagSNPs 
did not show an overall association with obesity (Bender et al., 2011). The discrepancy 
of these findings may be explained by the differences in allele frequency across ethnic 
groups. Ethnicity could act as a significant effect modifier thereby explaining the 
conflicting observations (Marchini, Cardon, Phillips, & Donnelly, 2004). 
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In the present study, polymorphisms on the LEPR, rs1137100 and rs1137101 
were shown to be associated with increased risk of NAFLD and NASH. The rs1137100 
was also shown to be associated with simple steatosis and NASH without significant 
fibrosis. The G allele frequency of rs1137100 in the control subjects was 0.78 for the 
Chinese and 0.19 for the Indian, which was almost the same as that reported in the 
International HapMap database (hapmap.ncbi.nlm.nih.gov/) but higher than that in other 
populations (such as European and African American). 
An interesting finding from this study is the association of the G allele with 
NASH without significant fibrosis but not with NASH with significant fibrosis, 
suggesting that the polymorphism of LEPR rs1137100 is associated with lower fibrosis 
score and patients with G allele are protected against higher stage of fibrosis ≥ 2. These 
findings suggest that rs1137100, specifically the G allele, is associated with a milder 
form of liver disease in patients with NAFLD. To date, there has been no published 
report of an association between LEPR rs1137100 G allele and liver fibrosis. The 
present study is the first to provide this association finding and the availability of 
histological profile of the liver samples made this possible, which is a major strength of 
this study. Hepatic fibrosis score was found to be higher in subjects with metabolic 
syndrome (Ryan et al., 2005). In a Taiwanese Han population, lower metabolic risk was 
reported in those bearing the GG genotype (C. W. Yang et al., 2013). A Japanese study 
in obese children showed a significantly lower total and LDL cholesterol in subjects 
with GG genotype (Okada, Ohzeki, Nakagawa, Sugihara, & Arisaka, 2010). Leptin 
level has been shown to correlate with metabolic syndrome profile such as adipocity 
and insulin resistance (Silha et al., 2003; Stylianou et al., 2007). It was reported that 
leptin level was significantly greater in subjects with AA genotype than G allele carriers 
(Wauters et al., 2001). Hence, these studies suggest that LEPR rs1137100 G allele is 
associated with a lower metabolic risk. 
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This study indicated nearly three-fold increased risk of NAFLD by the combined 
effect of the SNPs of LEPR with PNPLA3 compared to either gene alone. A common 
variant in the PNPLA3 gene (rs738409) was found to be associated with hepatic fat 
content and confers risk of NAFLD in the Dallas Heart Study of different ancestries; 
Hispanics, European-Americans and African Americans (Romeo et al., 2008). 
Subsequently, a number of  replicated studies on PNPLA3 in various populations have 
been carried out and interestingly, all yielded a positive association including that of 
this study population (Cox et al., 2011; Hotta et al., 2010; Kantartzis et al., 2009; Lin et 
al., 2011; Romeo et al., 2010a; Romeo et al., 2010b; Sookoian et al., 2009; Valenti et 
al., 2010; Zain et al., 2012a).
 
The effect size of NAFLD is increased with a single 
variant of LEPR or PNPLA3. The risk of NAFLD is however increased dramatically 
with the co-existence of both variants of LEPR and PNPLA3, suggesting a possible 
positive interaction between the two genes. Investigation of gene interaction between 
LEPR and PNPLA3 is therefore a good approach that allows us to understand the 
genetic interaction of the two genes that encode for products that are important in lipid 
regulation, and within same study population.  
Analysis of interaction between LEPR and PNPLA3 gene, revealed a strong 
interaction between LEPR (rs1137100) and PNPLA3 (rs738409) SNPs on NAFLD 
susceptibility. The pleiotropic actions of leptin via leptin receptor help suppress food 
intake, a mechanism involved in appetite control and body weight regulation (Zastrow 
et al., 2003). PNPLA3 exerts its effect in response to food intake, in which it is highly 
upregulated in response to feeding and downregulated in fasting state, displaying its role 
in lipid storage in the liver (Hoekstra et al., 2010). Both genes are correlatively 
upregulated in a state of excess lipid. 
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5.1.4     Single nucleotide polymorphism: GCKR 
 
The present study identified a common intronic SNP rs780094 and a loss of function 
SNP rs1260326 (C/T change results in a proline to leucine substitution in the amino 
sequence of the encoded protein) on GCKR that occur more frequently in patients with 
NAFLD compared to controls. These findings are thus in the same direction of that 
reported by a Genetics of Obesity-related Liver Disease (GOLD) consortium 
comprising of a meta-analysis of four genome-wide association studies (GWAS) 
(Speliotes et al., 2011). This study also report an association between rs1260326 T 
allele with increased grade of hepatic steatosis. 
Investigation of NAFLD-associated SNPs was performed in a Malaysian 
heterogeneous population comprised of three major ethnic groups, namely the Malay, 
Chinese and Indian. The pooled result indicates increased odds of NAFLD by 1.49 for 
rs1260326 and 1.51 for rs780094. This finding was supported by a GWAS consortium 
that exhibited 1.45 risk of NAFLD for GCKR rs780094. It has to be noted that both 
SNPs rs1260326 and rs780094 were in strong linkage disequilibrium (Speliotes et al., 
2011). Genetic origin of the Malaysian Chinese and Indians are evidenced from the 
immigration of these people into Malaysia from Southern China (Hock, 2007) and 
Southern India (Periasamy, 2007) in the late 18
th
 century and early 19
th
 century. 
However, only the Indian showed significant association with NAFLD. Despite 
relatively low sample size in the Indian subjects, this study was able to show the power 
ranges from 77% to 94%. This association can also be explained by the genetic 
admixture of this subpopulation with West Eurasian resulting in genetic affinity towards 
both Asian and European (Bamshad et al., 2001; Jorde & Wooding, 2004). The 
prevalence of NAFLD in European ancestral was reported higher than that of the Asian 
ancestral (Bellentani & Marino, 2009) thus supporting this finding. It is noteworthy that 
the minor allele frequency in the Indian controls is similar to that reported in the 
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International HapMap database (hapmap.ncbi.nlm.nih.gov/) for Gujarati Indians (19%). 
The pooled result is also in accordance to a report by Z. Yang et al. (2011), but failed to 
be replicated in the Chinese subjects. The difference in this finding could be due to 
difference in population structure. It was proposed that Shanghai subpopulation 
(Chinese subjects from Z. Yang et al., 2011 study) shares similar population structure 
with that of the Han Chinese from Beijing (CHB) reported in International HapMap 
database, however differs from Southeast Asia (Malaysian Chinese subjects) (J. Chen et 
al., 2009). This explains the difference in minor allele frequency in the control subjects 
between the Malaysian Chinese (44%) and Chinese subjects from Z. Yang et al. (2011) 
study (53%) and CHB (57%). Studies at a metapopulation level such as Chinese 
population therefore invite a better understanding of population structure that is an 
important part of evolutionary genetics. Of note, in the study by Z. Yang et al. (2011) 
the diagnosis of NAFLD was based on ultrasound but not definitively histological-
proven by liver biopsy. In a cohort of nine years, from 2000 to 2009, 1621 subjects who 
met the criteria participated in a consecutive health screening program in a day-care 
medical center−the Megah Medical Centre, Petaling Jaya, adjacent to the capital city of 
Kuala Lumpur, Malaysia (Goh, Ho, & Goh, 2012). The proportion of subjects in this 
study was 12.1% Malays, 78.3% Chinese and 9.6% Indians with a reported prevalence 
of NAFLD of 32.5%, 19.9% and 33.5%, respectively. This study indicates that the 
Indians, although being the minority has the highest prevalence of NAFLD, while 
Chinese the lowest. The data in this larger cohort therefore reflects the findings in the 
present study with regards to ethnic differences.    
The present study provide the first data on association between GCKR SNPs 
with NASH. The availability of histological profile of each patient contributes to the 
strength of this study. The GCKR rs1260326 and rs780094 T allele were found to be 
associated with susceptibility to NASH. Subsequently, association between the risk 
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allele with NASH with significant fibrosis was observed. Although it was first 
demonstrated to be associated with histologic NAFLD that could include NAFLD with 
inflammation and fibrosis in the recent GWAS (Speliotes et al., 2011), the authors do 
not identify how many patients with NAFLD are simple steatosis and how many are 
NASH. Prediction of steatohepatitis (which in most cases encompasses advanced 
fibrosis) in NAFLD is more important as it is potentially progressive (Wilson & 
Chalasani, 2007). Another interesting finding from this study is that GCKR rs1260326 T 
allele was significantly associated with higher grade steatosis. This finding was 
supported by Santoro et al (Santoro et al., 2012) in which GCKR rs1260326 was found 
to be associated with hepatic fat content in individuals of Caucasian, African American 
and Hispanic ancestry. The paradox of this finding may be because of the role of GCKR 
in insulin resistance (Shen et al., 2013), which is important in the “first hit” mechanism 
towards development of steatosis and triglycerides accumulation in the liver (Bugianesi 
et al., 2005). 
Concerning the importance of GCKR and PNPLA3 genes in the development of 
hepatic fat content (Romeo et al., 2008; Santoro et al., 2012), the present study reports 
an interaction between these two genes on susceptibility to NAFLD. The effect size 
contributed by the combined genes would result in a greater risk of NAFLD than either 
gene alone. Intriguingly, genes that share similar pathway or outcome as PNPLA3 have 
been shown to interact between each other (Zain et al., 2012b; Zain et al., 2013). These 
data therefore indicate the complex nature of NAFLD involving multiple gene 
interactions. More studies need to clarify the genetic underpinnings of NAFLD. 
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5.1.5     Single nucleotide polymorphism: Other candidate genes 
 
The present study also investigated a number of SNPs in various candidate genes that 
includes iNOS, TRAIL, SREBF1, CLOCK, COL13A1, FABP2, UCP3, PPARG, COX-2, 
NR1I2, KLF6, TFRC, PPARGC1A, FATP5, STAT3, APOA5, and PEMT and FDFT1. 
None of the SNPs in these genes were found to be associated with susceptibility to 
NAFLD in this study population except for SREBF1 rs2297508, which was found to be 
a risk for the Indian ethnic group. These genes and their related SNPs were chosen for 
analysis because during the time this study was conducted, they were among the recent 
SNPs and tagSNPs found to be associated with NAFLD in other populations. This study 
therefore intended to use these SNPs as a preliminary screening for NAFLD in 
Malaysian population. 
 
5.2 Copy number variation 
 
Genome wide CNV profiling was carried out using high-resolution aCGH to 
determine the genomic aberrations in a total of 40 NASH samples that were normalised 
against age-, gender- and ethnicity-matched controls. The response of the liver to stress 
during the second hit process and the progressive nature of NASH, contribute to the 
selectively chosen NASH patients in this CNV study. Apart from evaluation of 
biochemical parameters and ultrasonogaphy, magnetic resonance imaging (MRI) was 
carried out on all 40 controls for the genome wide profiling in order to rule out fatty 
liver. Given that the present study is first to investigate the genome wide profile of copy 
number in NAFLD, the total number, genomic positions, gene content, frequency 
spectrum and patterns of linkage disequilibrium (LD) of the genomic CNAs are 
challenging. The use of ultra-dense aCGH technology allows CNAs discovery at high 
resolution down to approximately 3 kb and hence provides great confidence in detection 
of CNVs. The use of 60mer probes provides high sensitivity and specificity to 
120 
 
accurately detect both known and de novo CNVs as compared to shorter oligonucleotide 
probes (Curtis et al., 2009).  
In this study, the most amplified 14q11.2 region is enriched with both T cell 
receptor family and olfactory receptor (OR) family genes, whereas an abundance of OR 
family genes were found in the most frequently deleted 11q11 region. Surprisingly, a 
search from database of Expressed Sequence Tags, NCBI dbEST, revelead many hits of 
OR gene expression not only in the olfactory system, but also in other tissues such as 
liver, lung, kidney, prostate, testis, brain and many others including tumor tissues. The 
families of these receptors play an important role during embryogenesis, and are 
expressed in various parts of the embryo suggesting that they are not only involved in 
the olfactory system but also throughout many other organs as these organs are 
assembled (Dreyer, 1998). In the early 2000s, a complete database on human olfactory 
subgenome was completed after comprehensive data mining using  highly automated 
data mining system (Glusman, Yanai, Rubin, & Lancet, 2001). Glusman et al. (2001) 
reported the presence of 906 potential coding regions for OR genes that cover almost all 
human chromosomes with the exception of chromosome 20 and Y, in which 2/3 of them 
have not been reported. Subsequently, a new set of database called the Olfactory 
Receptor Microarray Database (ORMD) that houses microarray gene expression data of 
the ORs was developed (N. Liu, Crasto, & Ma, 2007). These achievements clearly 
stated the importance of ORs not only in the olfactory sytem, but throughout organs that 
remain elusive. T cell receptors on the other hand, are essential to fight against cancer 
(Guitart et al., 2012) and viral infection (Pasetto et al., 2012). Region 14q11.2 also 
contained matrix metallopeptidase 14 gene (MMP14) in which expression was increased 
to 2-3 folds in fibrotic liver in comparison to normal liver (X. Zhou et al., 2004). The 
expression was also found higher in cancerous portion compared to non-concerous 
portion of hepatocellular carcinoma tissues (Harada et al., 1998). 
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Carboxylesterase 1 gene (CES1) which is important in the transportation of 
cholesterol was located in the chromosome 16q12.2. This region shared relatively 
similar high frequency of gain and loss events (37.5% gain, 32.5% loss) suggesting 
simultaneous involvement of multiple loci from this chromosome. In human study, 
expression of CES1 was higher in NAFLD-proven liver tissue compared to non-
NAFLD (Ashla et al., 2010). Positive correlation of CES1 was observed with 
triglyceride lipase activities and adiposity suggesting the lipolysis role of CES1 thereby 
contributing to hepatic steatosis (Nagashima et al., 2011). In animal study, CES1 
knockout mice exhibited gain in weight, hepatic steatosis and hyperinsulinemia, thus 
supporting the role of CES1 in the regulation of fatty acids (Quiroga et al., 2012). As 
can be predicted therefore, feeding with fatty acids and cholesterol-rich diet upregulates 
CES1 (Dolinsky et al., 2003). A recent mapping approach of 16q12.2 locus has found 
variants associated with BMI (Peters et al., 2013). Similar trend of gain and loss events 
was observed in the p-arm of chromosome 16p11.2 (20% gain, 20% loss). Among 
genes of interest that could be found was zinc finger protein 267 (ZNF267). Zinc finger 
proteins are among the most abundant proteins in the human genome with a diverse 
function including DNA recognition, transcriptional activation, protein folding and 
assembly, and lipid binding (Laity, Lee, & Wright, 2001). The expression of ZNF267 
was highly upregulated in HCC compared to non-cancerous tissue. Furthermore, the 
expression was found to be greater when induced by reactive oxygen species (Schnabl, 
Valletta, Kirovski, & Hellerbrand, 2011). 
Aberration in the region 14q32.33 (25% gain, 17.5 loss) was not found in the 
Database of Genomic Variants (DGV). This chromosomal region could serve as a 
potential copy number marker for NAFLD. This region is rich in immunoglobulin 
heavy chain gene (IGH) which is overexpressed in patients with NASH (Puri et al., 
2008). More importantly, v-akt murine thymoma viral oncogene homolog 1 (AKT1) and 
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metastasis associated 1 (MTA1) genes were concomitantly located in the same region. 
Deletion of AKT1 in animal model was shown to regulate hepatic metabolism by insulin 
(Lu et al., 2012), which is a contributing factor to NAFLD development. In a study 
consisting of 506 HCC patients who underwent hepatic resection, 17% of them were 
positive for MTA1. Those patients who were MTA-positive HCCs had poor survival 
rate (Ryu et al., 2008). It is also noteworthy to concentrate on the clear-cut gain on 
chromosome 16p12.2. At least 1/4 of the samples were amplified in this region, 
suggesting the importance of extended investigation such as chromosomal region 
mapping. 
Downstream studies to validate findings are to be pursued. Findings observed in 
genome wide analysis are basically in data output. Validation using quantitative Real-
Time PCR is necessary to provide the “real-time” picture of the events. But that is not 
the main concern here. Commonly, quantitative validation will ensure similar findings. 
What could be the next intriguing step to be taken is the downstream approach of copy 
number analysis. Current data are CNV-based, in which the genes of interest were 
“fished out” based on the high frequency of chromosomal aberrations found and is 
known to create bias. It will be a lot more interesting to investigate on the basis of gene. 
It is important to verify the CNV regions and their impact on NAFLD progression. In 
the context of exploring the biological link between these CNVs and NAFLD 
progression, functional annotation analysis using David Pathway 
(david.abcc.ncifcrf.gov/ ) should be performed between genes residing at the loci and 
NAFLD known genes, especially PNPLA3, in the search of similarity in terms of 
cellular components, biological processes and molecular functions. Principal component 
analysis that further emphasizes on annotations such as gender is another approach to be 
taken. 
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5.3 Limitations and strenghts of study 
 
5.3.1     Limitations 
 
There are several limitations to the present study. Most studies of NAFLD have been 
case-control association studies that only examined the association of NAFLD per se 
but not with the spectrum of NAFLD that comprises of simple steatosis, NASH without 
significant fibrosis and NASH with significant fibrosis. Studies on NAFLD spectrum 
have been limited since this requires valid ascertainment and scoring of the different 
NAFLD stages, for which liver biopsy is the gold standard in providing such accurate 
diagnosis. Such biopsies are limited to situations in which there are definite clinical 
indications for biopsy, and this reflects the relatively small sample size in this study. 
Unlike the diagnosis of NASH, diagnosis of fatty liver (steatosis) can be made based on 
clinical, radiological and laboratory findings, which therefore makes it slightly easier to 
carry out studies on NAFLD. Due to ethical considerations, no liver biopsies were 
performed for the controls leading to a possibility of misclassification of controls. 
However this likelihood was reduced by using the stated selection criteria for the 
controls. These criteria includes normality in BMI, fasting plasma glucose, lipid profile 
and liver enzymes. The difference in the distribution of these parameters between the 
two extremes of the NAFLD disease spectrum, provides confidence in the selection 
process of NAFLD cases and controls. Mild steatosis among the controls however 
cannot be ruled out and this may result in a bias towards the null. Some of the resulting 
associations between SNPs and NAFLD spectrum were smaller than hypothesized (OR 
less than 2.0) and would have resulted in a loss of power for the relevant analysis. The 
small sample size after stratification of the subjects into three ethnic groups, and 
NAFLD patients into simple steatosis and NASH contribute to this limitation. This 
yields an unmatched case-control study. However, the potential for confounding can be 
reduced by adjustment during the analysis. More importantly, the power after study was 
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provided and most of the analyses achieved the desired power of > 80%. The causal 
pathway between rs738409 and NASH has been postulated to be mediated through 
triglycerides. As this study conditions on BMI, the case control association of rs738409 
and NASH is vulnerable to confounding bias betweeen the pathway of triglycerides and 
NASH. Thus residual confounding from collider stratification bias due to conditioning 
of a downstream covariate might refute some of the association between rs738409 and 
NASH. However the associations between rs738409 and the different grades of NAFLD 
among the cases are not likely to be confounded and provide valid estimates. The 
limited knowledge on CNVs in NAFLD is another concern. Unlike SNPs where most of 
the frequencies have been determined in various populations, frequencies of CNVs are 
not well-defined. Considering the Malay subjects used in this CNVs study, CNAs 
identified in this study may be different from the future report from Western studies, or 
even another Asian studies.  
 
5.3.2     Strengths 
A major strength of this study was the ability to compare the genetic association among 
three asian ethnic groups in Malaysia, which are also the main ethnic groups in Asia 
(Crossette, 2011).  This study suggest that ethnicity modifies the relationship between 
genetic polymorphisms and NAFLD. It appears that the role of genetic polymorphisms 
on NAFLD is amplified among Indians compared to Chinese and Malays. The present 
study investigated the NAFLD spectrum that ranges from simple steatosis to NASH 
without significant fibrosis to NASH with significant fibrosis. This study is also the first 
to report the genetic interaction between the AGTR1, LEPR, and GCKR, and the much 
reported PNPLA3 gene on NAFLD susceptibility.  Reports on the copy number findings 
are novel and could serve as potential genetic marker for the identification of the 
potentially progressive form of NAFLD. It is also learnt that this is the first study on 
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NAFLD in Malaysia. Data from the present study could assist researchers and 
practitioners in downstream studies not limited to Malaysian population, but also to the 
other populations. 
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CHAPTER SIX 
CONCLUSION AND FUTURE STUDIES 
 
6.1 Conclusion 
 
Genetic association study of susceptibility to NAFLD indicates a positive association 
between the candidate genes PNPLA3, LEPR and GCKR with susceptibility to NAFLD 
in a Malaysian population comprising three major ethnic groups, namely, the Malays, 
Chinese and Indians. AGTR1 polymorphisms on the other hand, render a protection 
against NAFLD in the Indians. Contrary to reports in other populatuions, various other 
gene polymorphisms were not found to be associated with NAFLD susceptibility, 
suggesting variability in genetics across populations. This study also provides new 
finding on the association with NASH severity. While most of the studies have 
attempted to predict the risk or susceptibility to NAFLD, it is clinically more important 
to identify the predictor for the risk of NASH as it is potentially progressive. The G 
allele of the widely studied PNPLA3 rs738409 is associated with severity of NASH. 
The Malaysian Indians are genetically unique such that results differ between the 
Malays and Chinese. NAFLD is genetically a complex disease as delineated by multiple 
gene interactions, that may indirectly share similar pathway in cellular components, 
biological processes and molecular functions. There is a paucity in information with 
regard to CNV in NAFLD, and hence, current data provides some interestingly new 
information which points towards the complex nature of CNV in NAFLD. A larger 
sample size and more ethnically diverse samples are needed to replicate these findings. 
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6.2 Future studies 
 
A broad aspect of NAFLD covering not only genome but also proteome, remains a 
continuous plan for future studies. SNPs and CNVs are parts of genome that provide 
meaningful however static information. A functional study that offers more dynamic 
information such as proteomic study is one of the great aspects to look into. Although 
several studies on proteomics of NAFLD have been conducted, the novel approach can 
still be extracted out. The uniqueness of Biotin Carboxyl Carrier Protein (BCCP) tag 
technology ensures that only correctly folded, functional and full-length proteins are 
presented on the array. The tag also provides a single point of attachment which negates 
the problems of protein unfolding, random orientation and non-specific binding that can 
occur with other protein attachment methods. Another scope that can be explored is 
profiling of microRNA (miRNA). Reported miRNA in NAFLD are mostly coming 
from studies involving liver tissues. This however does not eliminate the use of biopsy, 
which is the main objective in most of the NAFLD studies−to predict NASH in the 
absence of liver biopsy. That is when a new technology called Locked Nucleic Acid 
(LNA) comes in handy. LNA technology can be used for a wide range of samples 
including biofluids such as serum. The first challenge of microRNAs studies is that 
miRNAs are made up of short sequences of approximately 22 nueclotides and hence, 
conventional DNA-based methods that have been commonly used are not sensitive 
enough to detect these sequences with any reliability. Secondly, closely-related miRNA 
family members differ by as short as one nucleotide, emphasizing the need for high 
specificity and sensitivity to discriminate between single nucleotide mismatches. LNA 
technology provides increased affinity and specificity of the probes, inhibitors and 
primers for their miRNA targets, thereby addressing both challenges described above. 
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I) Ethic approval form 
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II) Informed consent form 
A Clinical, Biochemical & Molecular Study of 
Multiethnic Metabolic Syndrome Subjects 
A. Personal Particulars: 
i. Name :En/ Puan/ Cik     
ii. Age   & Sex              yrs             months                       Male/Female 
iii. Local Address
  
   
 
 
iv. Permanent 
Address 
 
 
 
v. Occupation                
vi. IC number                                                       
       B. Informed consent 
I,                                                                                        (Full Name) have been explained about 
the Study of Metabolic Syndrome (MS) in my first language  
today on                              (Date) by Dr.                                                                       (Clinician). 
1. I have read the information sheet called Subject Information Sheet explaining 
this study and I have been given a copy for my reference.  
2. I agree to be clinically examined by a Clinician of Project and permit for my 
clinical data to be used as part of the project. 
3.  I am fully aware that being a study subject in this project does not involve or 
necessitate me undergoing any invasive methods or procedures other than 
during my blood/tissue collection. 
4. I agree to give a sample of my blood/biopsy tissue to this project for screening 
which will be collected as per the normal medical practice. My participation in 
this project is voluntary and I have not been induced with money or gift or 
coerced for doing the same.   
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5. I have been assured that being a study subject in this project will in no way cause 
interference in the regular treatment that I have to undergo for my existing 
medical condition at the hospital. 
 6. I am fully aware that being a study subject in this project does not involve or 
necessitate me to take any new or trial drug in the form of tablets, injections 
or syrups. 
7.  I give permission for the authorized staff from the Project team to look at my 
medical records to obtain necessary information. I have been assured that all 
my personal and health related information will be kept confidential and all 
data will be anonymised. 
8.  I understand that I will be informed if any of the results from the screening 
done using my blood/tissue sample as part of the project that is important to 
my health. 
9. I understand that I will not benefit financially if this project leads to the 
development of a new treatment or medical test. 
10.  I am free to withdraw my Consent for this study at any time of the project 
without giving a reason and without my medical treatment or legal rights being 
affected. 
11. I am aware and fully agree that the blood sample I have given and the clinical 
data about me can be stored for possible use to meet future project 
requirements. 
12.  I understand that the Project is a noble project that aims towards the study 
and better understanding of Metabolic Syndrome and for general betterment 
of the society.  
Name of Subject (Capitals)  
Signature & Date  
Name of Project staff obtaining 
Consent 
 
Signature & Date  
Independent Witness Name  
Signature & Date  
 
III) Patient information sheet 
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A Clinical Biochemical & Molecular Study of 
Multiethnic Metabolic Syndrome Subjects 
 
Please read the following information carefully, do not hesitate to 
discuss any question you may have with your Doctor. 
 
What is Metabolic Syndrome? 
Metabolic syndrome which is also known as metabolic syndrome X, syndrome X, 
insulin resistance syndrome or Reaven's syndrome is a combination of medical 
disorders that increase the risk of developing cardiovascular disease and diabetes.  
How do you identify Metabolic Syndrome? 
There are several guidelines available for identification of Metabolic Syndrome 
However, the one which is most accepted and followed in this study is the updated 
NCEP ATP III (National Cholesterol Education Program Adult Treatment Panel III) 
criteria for Metabolic Syndrome. The criteria are: 
 Men who have waist circumference above 90 cm/30.5 inches and 
women above 80 cm/31.4 inches 
 Blood pressure above 130/85 mm Hg or having normal BP but on 
medication. 
 Fasting glucose  above 110 mg/dl (> 6.1 mmol/l) 
 Serum Triglycerides  above 150 mg/dl  (1.69 mmol/l) 
 High Density Cholesterol less than 40mg/dl ( < 1.03 mmol/l) in men and 
less than  50mg/dl ( 1.29 mmol/l) in women. 
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How common is Metabolic Syndrome? 
With the presence of Metabolic Syndrome a person’s chances of developing 
cardiovascular disease and diabetes increases manifolds. It is a highly common yet 
silent condition which affects many people and has high prevalence rate. Some 
studies estimate the prevalence in the USA to be up to 25% of the population. 
Malaysia is a developing country with its people due to various life style and genetic 
factors are at a high risk of developing Metabolic Syndrome. The prevalence of 
metabolic syndrome among patients with premature vascular disease may be as 
high as 50%.With the changing lifestyle patterns it is estimated that the number of 
people afflicted with Metabolic Syndrome could be much higher than what has been 
anticipated. It is also associated with other diseases like increased uric acid levels 
in body, fatty liver (especially in concurrent obesity) which can progress to fatty liver 
disease, polycystic ovarian disease in women. Hence, identification, prevention and 
treatment of Metabolic Syndrome will help you to ensure a healthy and disease free 
life. Non alcoholic fatty liver disease (NAFLD) represent the hepatic manifestation of 
the metabolic syndrome which is characterized by obesity, Type 2 DM, 
dyslipidaemia, hypertension with insulin resistance. Liver enzymes (ALT, AST) are 
mildly elevated. Patients with NAFLD typically present in the fourth or fifth decade of 
life. NAFLD is characterized by excess fat in the liver of people who drink little or no 
alcohol and have no viral or autoimmune liver disease. In some people with NAFLD, 
fat accumulation is associated with liver cell injury and inflammation, a condition 
named nonalcoholic steatohepatitis (NASH) 
What is the purpose of this study? 
 To determine the possible causes of Metabolic syndrome in all the three 
ethnicities of Malaysian population namely the Malay, Chinese and Indian. 
 To obtain information to help develop methods to diagnose and treat 
Metabolic Syndrome. 
 
What are the procedures to be followed? 
 Please ask the clinical coordinator to explain about this study or project. After you 
clarify all the doubts, make sure that you have understood the purpose of the study 
and your role in this project.  Then sign the Informed Consent to participate in this 
study / project.   
 You would be asked routine questions about your lifestyle like diet, smoking, 
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exercise, family history etc. through a questionnaire. 
 A routine clinical examination by the clinician in the Out Patient Clinic 
 A routine blood sample from your arm vein will be collected only once using sterile, 
disposable syringe for the blood test. 
 Liver biopsy would be done wherein little part of liver tissue will be obtained. 
Note  : You are not required to take any medicines or come for repeated follow up 
Who should not enter the study? 
 There is no specific /general risk involved to the subjects as part of this 
project. Those persons who satisfy the laid down inclusive criteria for selection 
of subject can participate and be part of this project. 
 Those below the age of 18 years need to get informed consent form signed by 
their parents or guardians  
 
What are the benefits of the study? 
(a) To you as the subject 
 The result/report concerning yourself can be intimated to your treating Doctor 
who could use the specific information to treat you better. 
 Your family members can be screened at an early age which will help the 
Doctors to make early diagnosis, advice preventive measures and prevent 
early complications including death. 
(b) To the investigator 
This is a noble project that aims towards establishing a clinical, molecular and 
biochemical profile of Metabolic syndrome amongst Malaysian population. 
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Are there any possible drawbacks? 
 There are no drawbacks for the subjects who are part of the project 
 The project does not involve any invasive procedure or administration of any new 
trial drugs.  A control or study subject in this project does not necessitate you to take 
any new drugs such as tablets, injections or syrups for project purpose.  
 Your personal and health related information will be kept confidential and all 
data will be anonymised to prevent identification of your data in the project. 
 
Can I refuse to take part in the study? 
 Yes, you have complete freedom to refuse from taking part of this study.  
 Giving your blood sample for testing is voluntary on your part and you will not 
be induced with money or gift for doing the same.   
 You are free to withdraw your consent without giving a reason.  Your on-going 
medical treatment will be unaffected.  
How can I participate in the study? 
You have to ask the clinical coordinator who will explain the study procedure to 
you in detail. You will have to sign an informed consent form. After this it will be 
assessed if you fulfill the study criteria (both inclusion as well as exclusion 
criteria) and then the decision regarding your participation will be made. 
If you need further information please contact /call  
1. Prof.Rosmawati Mohamed.79492077 
2. Dr.Roma Choudhury Basu 79492886 
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APPENDIX B 
 
Detail methods of aCGH 
 
I) Labelling the target  
 
Reaction tubes were prepared as a mixture of 18 µL of genomic DNA sample (or 
reference), 10 µL of random primer and 10 µL of reaction buffer. The reactions were 
mixed and centrifuged for 15 s, followed by denaturation in a PCR block with a heated 
lid at 99C for 20 min. Immediately after, the tubes were placed on ice for 5 min. On 
ice, the followings were added to the tubes: 10 µL of dCTP labelling mix, 1 µL of Cy3-
dCTP (for sample) / 1 µL of Cy5-dCTP (for reference), and 1 µL of Klenow. The 
mixture was centrifuged for 15 s and incubated at 37C for 2 h. Following that, the 
mixture was incubated at 65C for 10 min, then placed on ice for 5 min. The mixture 
was centrifuged for 15 s. 
 
II) Purifying the labelled target 
 
Two purification columns were prepared by vortexing the resin briefly. The cap was 
loosened one-quarter turn and the bottom closure was snapped off. The column was 
placed in a collection tube and spun for 1 min at 2,000 x g. The spin column was 
removed from the tube and the eluate was discarded. The column was placed in a fresh 
tube. The lid was removed from the column and the sample was added to the centre of 
the resin and centrifuged at 2,000 x g for 1 min. The final volume was ~45 µl. The 
absorbance was measured and the amounts of target that should be obtained were as 
follows: minimum 6 µg of DNA and 250 pmol of dye (for Cy3) and minimum 5 µg of 
DNA and 200 pmol of dye (for Cy5). 
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III) Hybridisation of arrays with labelled target  
 
The 10x Blocking Agent was prepared by adding 1,350 µl of water to the 10x Blocking 
Agent tube. The Blocking Agent was left at room temperature for 60 min. The 
hybridisation was set up. Each sample was combined with its corresponding reference. 
A 1 x TE (pH 8.0) was added to give a final volume of 158 µl each. The following 
hybridisation mix: 158 µl of Cy3 and Cy5-labelled genomic DNA, 50 µl of Cot-1 (1 
mg/ml), 52 µl of Agilent 10x Blocking Agent, and 260 µl of Agilent 2x HiRPM 
Hybridization Buffer. The target was denatured at 94C for 3 min. The mixture was 
incubated at 37C for 30 min and centrifuged for 10 s. The Agilent SureHyb Gasket was 
placed into an Agilent Chamber base or MaiTai cassette. Immediately, 500 µl of the 
hybridisation mix was pipetted onto the gasket slide. OGT array was placed onto the 
Gasket slide. The hybridisation chamber was placed in the hybridisation oven and 
hybridised at 65C for 22 h in a light-tight container. The slides were fitted vertically 
and the chamber was rotated at a speed of 20 rpm.  
 
IV) Washing and scanning of arrays 
 
Wash 2 and one glass dish were pre-warmed to 37C. Wash 1 was placed in two glass 
dishes (one for disassemble and one for first wash). The slide was placed in the 
disassemble bath, the gasket slide was gently prised from the CytoSure array under the 
surface of the buffer. The slide was quickly transferred to the Wash 1 bath. A stirring 
flea was placed in the Wash 1 and stirred at room temperature for 5 min. The rack was 
removed and blotted on a paper towel. The set up was quickly placed into the pre-
warmed Wash 2 bath and stirred at 37C for exactly 1 min. The rack was removed, 
blotted and blow dried using air. The slide was scanned immediately. The data was then 
ready to be analysed.  
157 
 
APPENDIX C 
 
Gel picture of the extracted DNA products 
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APPENDIX D 
 
i) Allelic discrimination plot of the PNPLA3 rs738409 in controls 
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ii) Allelic discrimination plot of the PNPLA3 rs738409 in cases 
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APPENDIX E 
 
Hardy-Weinberg equilibrium of the SNPs in various candidate genes 
 Gene  SNP(s)  Ethnicity 
HWE 
Case Control 
PNPLA3 rs738409 Overall 0.17 0.36 
    Malay 0.33 0.13 
    Chinese 0.10 0.30 
    Indian 0.52 0.43 
AGTR1 rs3772633 Overall 0.34 0.70 
    Malay 0.37 0.86 
    Chinese 0.84 0.41 
    Indian 0.34 0.84 
  rs3772627 Overall 0.08 0.33 
    Malay 0.40 0.72 
    Chinese 0.25 0.33 
    Indian 0.11 0.82 
  rs2276736 Overall 0.06 0.44 
    Malay 0.40 0.92 
    Chinese 0.14 0.50 
    Indian 0.16 0.80 
  rs3772630 Overall 0.19 0.52 
    Malay 0.91 0.92 
    Chinese 0.25 0.67 
    Indian 0.11 0.80 
  rs3772622 Overall 0.84 0.23 
    Malay 0.56 0.52 
    Chinese 0.80 0.09 
    Indian 0.44 0.76 
LEPR rs1137100 Overall 0.50 0.12 
    Malay 0.07 0.06 
    Chinese 0.11 0.79 
    Indian 0.07 0.31 
  rs1137101 Overall 0.46 0.15 
    Malay 0.17 0.80 
    Chinese 0.65 0.09 
    Indian 0.39 0.37 
 
P > 0.05 indicates SNP in HWE 
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Hardy-Weinberg equilibrium of the SNPs in various candidate genes (cont.) 
 Gene  SNP(s)  Ethnicity 
HWE 
Case Control 
iNOS rs1060822 Overall < 0.05 < 0.05 
    Malay < 0.05 < 0.05 
    Chinese < 0.05 < 0.05 
    Indian 0.40    0.16 
TRAIL rs1131568 Overall 0.09 0.31 
    Malay 0.14 0.31 
    Chinese 0.68 0.61 
    Indian < 0.05    0.76 
 SREBF1 rs1186803 Overall 0.55 0.45 
    Malay 0.21 0.78 
    Chinese 0.16 0.16 
    Indian   < 0.05 0.70 
  rs2297508 Overall 0.14 0.09 
    Malay 0.21 < 0.05 
    Chinese 0.41 < 0.05 
    Indian 0.48 0.41 
 CLOCK rs1193259 Overall 0.61 0.08 
    Malay 0.42 0.99 
    Chinese 0.50 0.20 
    Indian 0.33 0.14 
  rs4864548 Overall 0.44 0.25 
    Malay 0.66 0.59 
    Chinese 0.65 0.22 
    Indian 0.12 0.08 
 
rs6843722 Overall 0.28 0.55 
    Malay 0.60 0.52 
    Chinese 0.92 0.38 
    Indian 0.11 0.21 
  rs6850524 Overall 0.46 0.97 
    Malay 0.36 0.45 
    Chinese 0.21 0.54 
    Indian 0.86 0.70 
 
P > 0.05 indicates SNP in HWE 
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Hardy-Weinberg equilibrium of the SNPs in various candidate genes (cont.) 
 Gene  SNP(s)  Ethnicity 
HWE 
Case Control 
COL13A1 rs1227756 Overall < 0.05   0.07 
    Malay 0.13 < 0.05 
    Chinese < 0.05 < 0.05 
    Indian 0.99    0.24 
FABP2 rs1799883 Overall 0.12    0.86 
    Malay 0.77    0.07 
    Chinese 0.32    0.76 
    Indian 0.15    0.25 
 UCP3 rs1800849 Overall 0.84    0.57 
    Malay 0.79    0.36 
    Chinese 0.47    0.57 
    Indian 0.82    0.14 
 PPARG rs1801282 Overall 0.48    0.74 
    Malay 0.68    0.77 
    Chinese 0.83    0.95 
    Indian 0.47    0.78 
 COX-2 rs20417 Overall < 0.05 < 0.05 
    Malay < 0.05 < 0.05 
    Chinese < 0.05 < 0.05 
    Indian < 0.05 < 0.05 
 NR1I2 rs2461823 Overall 0.16    0.86 
    Malay 0.67    0.32 
    Chinese 0.43    0.58 
    Indian 0.18    0.27 
 
rs7643645 Overall 0.38 < 0.05 
    Malay 0.85 < 0.05 
    Chinese 0.67    0.29 
    Indian 0.12    0.27 
KLF6  rs3750861 Overall 0.10    0.87 
    Malay < 0.05    0.55 
    Chinese 0.78    0.83 
    Indian 0.54    0.64 
 
P > 0.05 indicates SNP in HWE 
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Hardy-Weinberg equilibrium of the SNPs in various candidate genes (cont.) 
 Gene  SNP(s)  Ethnicity 
HWE 
Case Control 
TFRC rs3817672 Overall 0.69 0.64 
    Malay 0.79 0.65 
    Chinese 0.16 0.82 
    Indian 0.60 0.74 
PPARGC1A rs3755863 Overall 0.81 0.66 
    Malay 0.73 0.06 
    Chinese 0.89 0.87 
    Indian 0.79 0.25 
 FATP5 rs56225452 Overall 0.08 0.96 
    Malay 0.34 0.70 
    Chinese 0.83 0.95 
    Indian 0.23 0.37 
 STAT3 rs6503695 Overall 0.35 0.74 
    Malay 0.19 0.21 
    Chinese 0.68 0.38 
    Indian 0.72 0.89 
  rs9891119 Overall < 0.05 < 0.05 
    Malay < 0.05 < 0.05 
    Chinese < 0.05 < 0.05 
    Indian < 0.05 < 0.05 
 APOA5 rs662799 Overall 0.58 0.21 
    Malay 0.33 0.23 
    Chinese 0.82 0.61 
    Indian 0.40 0.07 
PEMT rs7946 Overall 0.70 0.12 
    Malay 0.40 0.33 
    Chinese 0.41 0.59 
    Indian 0.64 0.32 
GCKR rs1260326 Overall 0.77 0.66 
    Malay 0.50 0.96 
    Chinese 0.60 0.78 
    Indian 0.57 0.31 
 rs780094 Overall 0.26 0.85 
    Malay 0.22 0.64 
    Chinese 0.85 0.20 
    Indian 0.34 0.25 
 
P > 0.05 indicates SNP in HWE 
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APPENDIX F 
 
I) Comparison of various clinical and histological parameters between the SREBF1 
rs1186803 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  CC (n = 6) CG (n = 53) GG (n = 85) p value 
Age (years)  45.7 ± 10.6 51.1 ± 12.1 51.3 ± 11.9 0.538 
BMI (kg/m2)  30.3 ± 5.2 28.7 ± 4.8 28.5 ± 4.1 0.633 
HbA1c (%)*  6.1 ± 0.7 7.0 ± 2.1 6.4 ± 1.3 0.612 
Waist circumference (cm)  94.3 ± 11.6 94.8 ± 10.4 93.0 ± 11.1 0.641 
HDL cholesterol (mg/dl)  56.1 ± 20.6 46.8 ± 10.1 49.2 ± 13.3 0.189 
LDL cholesterol (mg/dl)  134.9 ± 61.8 120.3 ± 38.2 112.1 ± 37.1 0.233 
Total cholesterol (mg/dl)  224.6 ± 67.0 198.3 ± 45.4 192.2 ± 39.5 0.183 
Triglycerides (mg/dl)  158.3 ± 74.3 163.2 ± 68.2 149.5 ± 56.0 0.465 
AST (IU/L)*  57.2 ± 16.8 40.9 ± 26.2 43.4 ± 25.5 0.085 
ALT (IU/L)  121.5 ± 44.7 76.4 ± 50.4 84.5 ± 47.5 0.094 
GGT (IU/L)*  240.8 ± 164.7 86.8 ± 70.7 119.0 ± 129.5 0.039 
Systolic BP (mmHg)  142.5 ± 12.5 133.3 ± 16.0 129.2 ± 14.1 0.050 
Diastolic BP (mmHg)*  92.8 ± 6.9 82.3 ± 9.5 81.9 ± 10.0 0.031 
Steatosis grade*  1.5 ± 0.6 1.8 ± 0.8 1.8 ± 0.8 0.642 
Lobular inflammation*  1.3 ± 0.8 1.4 ± 0.6 1.3 ± 0.6 0.726 
Ballooning*  1.0 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 0.419 
Fibrosis*  1.7 ± 1.0 1.8 ±1.1 1.7 ± 0.9 0.967 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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II) Comparison of various clinical and histological parameters between the CLOCK 
rs1193259 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 96) AG (n = 42) GG (n = 6) p value 
Age (years)  51.6 ± 12.0 50.7 ± 12.1 45.0 ± 11.3 0.548 
BMI (kg/m2)  28.6 ± 4.8 28.8 ± 3.5 28.8 ± 1.7 0.949 
HbA1c (%)*  6.5 ± 1.4 6.8 ± 2.1 6.6 ± 2.5 0.634 
Waist circumference (cm)  93.8 ± 11.7 94.0 ± 9.2 93.5 ± 8.4 0.991 
HDL cholesterol (mg/dl)  49.6 ± 12.7 46.5 ± 13.1 43.2 ± 6.4 0.287 
LDL cholesterol (mg/dl)  115.7 ± 39.6 119.9 ± 40.8 123.0 ± 48.4 0.812 
Total cholesterol (mg/dl)  194.4 ± 42.6 201.7 ± 46.4 200.8 ± 49.3 0.661 
Triglycerides (mg/dl)  150.0 ± 58.0 167.4 ± 74.7 149.3 ± 21.7 0.323 
AST (IU/L)*  41.9 ± 23.5 44.8 ± 29.7 48.3 ± 25.5 0.846 
ALT (IU/L)  80.3 ± 45.5 88.1 ± 53.6 97.8 ± 71.1 0.570 
GGT (IU/L)*  115.7 ± 39.7 201.7 ± 46.9 200.8 ± 49.3 0.198 
Systolic BP (mmHg)  131.4 ± 15.8 132.5 ± 12.5 126.2 ± 21.8 0.728 
Diastolic BP (mmHg)*  81.7 ± 10.2 84.1 ± 9.2 82.5 ± 5.0 0.386 
Steatosis grade*  1.8 ± 0.8 1.9 ± 0.8 1.5 ± 0.6 0.613 
Lobular inflammation*  1.3 ± 0.5 1.3 ± 0.7 1.3 ± 0.5 0.964 
Ballooning*  1.2 ± 0.6 1.2 ± 0.5 1.5 ± 0.6 0.601 
Fibrosis*  1.6 ± 1.0 1.9 ± 0.9 2.0 ± 1.4 0.181 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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III) Comparison of various clinical and histological parameters between the CLOCK 
rs4864548 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  GG (n = 26) GA (n = 64) AA (n = 54) p value 
Age (years)  50.0 ± 13.0 51.6 ± 11.8 51.2 ± 12.0 0.843 
BMI (kg/m2)  28.5 ± 3.8 28.4 ± 4.3 29.1 ± 4.8 0.617 
HbA1c (%)*  6.1 ± 1.2 6.8 ± 1.9 6.5 ± 1.5 0.358 
Waist circumference (cm)  92.1 ± 10.3 94.0 ± 10.7 94.5 ± 11.4 0.613 
HDL cholesterol (mg/dl)  50.6 ± 17.7 48.2 ± 11.1 47.9 ± 11.4 0.698 
LDL cholesterol (mg/dl)  125.0 ± 41.8 114.4 ± 41.0 116.0 ± 38.0 0.499 
Total cholesterol (mg/dl)  204.9 ± 45.4 193.9 ± 47.2 195.8 ± 38.9 0.538 
Triglycerides (mg/dl)  151.6 ± 48.9 158.4 ± 74.2 152.3 ± 53.7 0.821 
AST (IU/L)*  45.5 ± 26.5 40.8 ± 21.7 44.1 ± 28.8 0.829 
ALT (IU/L)  93.3 ± 58.1 80.3 ± 44.2 80.8 ± 48.2 0.448 
GGT (IU/L)*  137.7 ± 133.5 119.7 ± 122.9 87.8 ± 90.4 0.282 
Systolic BP (mmHg)  129.8 ± 12.5 130.5 ± 13.7 133.9 ± 17.7 0.384 
Diastolic BP (mmHg)*  82.3 ± 8.9 82.1 ± 9.2 83.5 ± 11.1 0.886 
Steatosis grade*  1.8 ± 0.8 1.8 ± 0.8 1.9 ± 0.8 0.728 
Lobular inflammation*  1.3 ± 0.5 1.3 ± 0.6 1.3 ± 0.5 0.859 
Ballooning*  1.1 ± 0.6 1.2 ± 0.6 1.3 ± 0.6 0.204 
Fibrosis*  1.6 ± 1.0 1.7 ± 1.0 1.8 ± 1.0 0.741 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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IV) Comparison of various clinical and histological parameters between the CLOCK 
rs6843722 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 30) AC (n = 62) CC (n = 52) p value 
Age (years)  50.8 ± 12.8 50.9 ± 12.0 51.5 ± 11.8 0.954 
BMI (kg/m2)  28.4 ± 3.7 28.3 ± 4.4 29.2 ± 4.8 0.523 
HbA1c (%)*  6.3 ± 1.5 6.7 ± 1.8 6.5 ± 1.5 0.328 
Waist circumference (cm)  92.0 ± 9.9 94.1 ± 10.8 94.7 ± 11.6 0.552 
HDL cholesterol (mg/dl)  49.4 ± 17.3 48.7 ± 11.1 47.6 ± 11.4 0.828 
LDL cholesterol (mg/dl)  127.5 ± 42.8 112.4 ± 39.7 116.7 ± 38.3 0.228 
Total cholesterol (mg/dl)  206.2 ± 46.2 192.3 ± 46.2 196.5 ± 39.0 0.351 
Triglycerides (mg/dl)  151.4 ± 46.5 158.0 ± 75.2 153.6 ± 53.4 0.876 
AST (IU/L)*  45.4 ± 26.1 40.7 ± 21.8 44.2 ± 29.1 0.757 
ALT (IU/L)  91.8 ± 56.1 81.3 ± 44.7 80.0 ± 48.3 0.521 
GGT (IU/L)*  133.3 ± 127.3 119.7 ± 124.8 88.1 ± 91.4 0.277 
Systolic BP (mmHg)  130.8 ± 12.5 130.3 ± 13.7 133.9 ± 17.9 0.418 
Diastolic BP (mmHg)*  82.4 ± 8.6 81.8 ± 9.4 83.6 ± 11.2 0.773 
Steatosis grade*  1.8 ± 0.8 1.8 ± 0.8 1.9 ± 0.8 0.742 
Lobular inflammation*  1.3 ± 0.5 1.3 ± 0.6 1.3 ± 0.5 0.961 
Ballooning*  1.2 ± 0.6 1.1 ± 0.6 1.3 ± 0.6 0.174 
Fibrosis*  1.7 ± 0.9 1.7 ± 1.0 1.8 ± 1.0 0.867 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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V) Comparison of various clinical and histological parameters between the NR1I2 
rs7643645 genotypes among NAFLD patients 
Characteristics  NAFLD, n = 144 (mean ± SD) 
  AA (n = 50) AG (n = 62) GG (n = 32) p value 
Age (years)  52.0 ± 12.6 49.5 ± 12.4 52.8 ± 10.4 0.352 
BMI (kg/m2)  27.9 ± 3.7 29.1 ± 4.6 29.0 ± 4.8 0.343 
HbA1c (%)*  6.6 ± 1.9 6.5 ± 1.6 6.6 ± 1.5 0.688 
Waist circumference (cm)  93.3 ± 10.3 93.9 ± 11.5 94.6 ± 10.7 0.869 
HDL cholesterol (mg/dl)  48.0 ± 12.6 48.1 ± 13.5 50.1 ± 11.5 0.718 
LDL cholesterol (mg/dl)  120.5 ± 41.1 118.8 ± 40.4 108.8 ± 37.8 0.399 
Total cholesterol (mg/dl)  198.9 ± 45.3 199.0 ± 44.7 188.8 ± 40.8 0.518 
Triglycerides (mg/dl)  148.8 ± 55.1 162.4 ± 69.6 150.4 ± 60.0 0.466 
AST (IU/L)*  44.2 ± 27.9 44.2 ± 24.3 38.3 ± 23.4 0.452 
ALT (IU/L)  85.7 ± 50.8 88.0 ± 52.7 69.2 ± 32.7 0.183 
GGT (IU/L)*  87.4 ± 74.3 129.3 ± 138.8 115.1 ± 115.6 0.659 
Systolic BP (mmHg)  131.5 ± 15.8 130.2 ± 14.3 134.5 ± 15.6 0.452 
Diastolic BP (mmHg)*  82.4 ± 10.5 82.0 ± 9.5 83.8 ± 9.9 0.803 
Steatosis grade*  1.9 ± 0.8 1.9 ± 0.8 1.7 ± 0.7 0.472 
Lobular inflammation*  1.3 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 0.651 
Ballooning*  1.2 ± 0.6 1.3 ± 0.6 1.2 ± 0.6 0.387 
Fibrosis*  1.7 ± 1.0 1.7 ± 0.9 1.86 ± 1.1 0.784 
 
*P values obtained using Kruskal-Wallis test, all other comparisons used ANOVA 
 
ALT alanine transferase, AST aspartate aminotransferase, BMI body mass index, GGT gamma glutamyl transpeptidase, HbA1c 
haemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, NAFLD non-alcoholic fatty liver disease 
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APPENDIX G 
I) Amplified chromosome 14q32.33 region encompassing AKT1 gene 
 
II) Amplified chromosome 14q32.33 region encompassing MTA1 gene 
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